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ABSTRACT
Cleft lip and/or cleft palate are a heterogeneous group of disorders that rank among
the commonest birth defects known, affecting 1 in 700 births worldwide. The
underlying cause is poorly understood, with a complex interaction of genes and
environmental factors being implicated. Nevertheless, several important genetic
causes have been identified, including that of X-linked cleft palate and
ankyloglossia (CPX). CPX is a semi-dominant condition caused by mutations in
TBX22 which encodes a T-box containing transcription factor. TBX22/Tbx22 is
highly conserved and expressed in the developing palatal shelves as well as at the
base of the tongue, medial and lateral nasal prominences and periocular
mesenchyme in both human and mouse embryos.
This project set out to better understand the functional role of TBX22 using Tbx22
null mouse model that is characterised by overt or submucous cleft palate,
ankyloglossia and choanal atresia. Microarray analysis of E13.5 palatal shelves
dissected from wild type and Tbx22 null mice revealed a global upregulation of
muscle genes such as myosin and muscle actin in the null palatal shelves. Key
myogenic regulatory factors MyoD and myogenin were moderately upregulated.
Increased expression was independently confirmed using real-time PCR. In vitro
analysis in a mammalian cell line using luciferase reporter assays and chromatin
immunoprecipitation showed that TBX22 could repress the MyoD promoter and
was capable of interacting with its promoter regions. This may provide a link
between lack of Tbx22 and upregulation of muscle markers. These results support a
hypothesis that MyoD is a possible direct target gene of TBX22. In addition,
decreased cell proliferation in the Tbx22 null palatal shelves was observed, along
with reduced expression of Cyclin D2. This indicates that TBX22 has a role in the
regulation of cell proliferation during palate development as well as a previously
identified role in osteoblast differentiation and maturation.
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CHAPTER 1: INTRODUCTION
16
1 INTRODUCTION
1.1 Overview of craniofacial development
The craniofacial structures of the mammalian embryo are composed of cells derived
from all three germ layers which are endoderm, mesoderm and ectoderm (Sperber
et al., 2001). By the middle of the third week of development, each of these layers
starts to follow specific developmental instruction to form the five craniofacial
primordia or prominences. These are the frontonasal prominence, a pair of
maxillary and a pair of mandibular prominences, which become distinct structures
during early in the fourth week of development (Figure 1.1). The maxillary and
mandibular prominences are both derived from the first branchial arch, a structure
that is populated with cranial neural crest (CNC) cells that migrate from the anterior
neural folds. The first branchial arch and particularly the CNC population is
especially important in the morphogenesis of the face as the developing maxillary
and mandibular prominences will go on to form the upper and lower jaw.
Meanwhile, the frontonasal prominence forms the forehead and the horseshoe-
shaped medial and lateral nasal processes surrounding the nasal pits, which are the
future nares.
The midline fusion of the mandibular prominences occurs first to form the lower lip
and lower jaw (mandible) as well as the chin and the lower cheeks. The upper lip
and upper jaw (maxilla), nose and primary palate are then formed during fusion of
the medial and lateral nasal and maxillary prominences, which also separate the
nasal pits from the stomodeum. The maxillary prominences eventually form the
maxilla, zygomatic bone and the secondary palate. The maxillary and mandibular
prominences also merge laterally to form the corners of the mouth. As embryonic
development continues, the cells of CNC origin eventually give rise to the bone,
cartilage and ligaments while mesenchymal cells of mesodermal origin give rise to
the muscles and vascular endothelia.
17
Figure 1.1 Schematic depiction of facial morphogenesis
Schematic depiction of facial morphogenesis at the fourth, fifth, sixth and seventh
weeks of human development (Sperber et al., 2001). The figure is not shown due to
copyright issues.
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1.2 Origin of the cranial neural crest
The CNC cells are an important cellular component of the developing head. The
CNC arises as a transient ectodermal component that is formed during anterior
neurulation. It contains a population of pluripotent cells that migrate into the
branchial arches and the frontonasal process (Figure 1.2), some of which
differentiate into ectomesenchyme and eventually give rise to the craniofacial
skeletal and connective tissues (Weston et al., 2004; Smith and Schoenwolf, 1997;
Hall, 1999; LaBonne and Bronner-Fraser, 1999).
CNC migration follows stereotypical directional routes which are regulated by
various cues of both intrinsic genetic factors and extrinsic signals which in turn
establish unique positional identity of the CNC subpopulations (Minoux and Rijli,
2010). The migration process itself is facilitated by chemoattractant and repellent
factors. The most important intrinsic factors for establishing positional identity are
homeobox (Hox) genes and distal-less homeobox (Dlx) genes. Specific patterns of
Hox gene expression in each branchial arch gives inter-arch rostro-caudal identity
(Hunt et al., 1991). Dlx genes, on the other hand, are involved in specification of
intra-arch dorso-ventral identity (Depew et al., 2005). External signals such as
endothelin 1, FGF, BMP and SHH are as important in establishing and maintaining
the CNC (reviewed in Minoux and Riji, 2010).
The appropriate positioning and segregation of the CNC into each branchial arch
combined with intrinsic and extrinsic signals are then translated into differentiation
of cells to distinct cell types later on, including bone, cartilage, cranial ganglia and
the connective tissue of the head and neck. For example, the palatal shelves are
mainly composed of mesenchymal cells derived from the ectomesenchymal CNC
cells, which eventually differentiate into osteoblasts and form palatal bones (Figure
1.3) (Ito et al., 2003). Thus normal palatogenesis is reliant on appropriate CNC
migration, proliferation and differentiation. The importance of neural crest
development is highlighted by a mouse model for Treacher-Collins syndrome,
where haploinsufficiency for Tcof1 results in altered CNC cell formation and
proliferation causing craniofacial malformations including cleft palate (Dixon et al.,
19
2006). Another study reports that A/WySn mouse strain is cleft-liable (CL/P) as a
result of a defect in CNC migration and lower mitotic activity (Young et al., 2007).
20
Figure 1.2 Migration of cranial neural crest cells during early development
Neural crest cells are labelled with enhanced green fluorescent protein (EGFP) in
Wnt1-Cre/Z-EG transgenic mouse embryo at E9.5. EGFP expression is observed in
the first and second branchial arches (BA1 and BA2) and in the frontonasal region
(FN) (Greene and Pisano, 2010). Permission to reproduce this material has been
granted by John Wiley & Sons.
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Figure 1.3 Contribution of CNC cells during palate development
CNC-derived palatal mesenchymal cells are marked by β-galactosidase (blue) in
Wnt1-Cre;R26R mice. B, D, F, H, J and L are magnified pictures of A, C, E, G, I
and K. CNC-derived cells contribute significantly to the palatal mesenchymal cells
along the anterior to posterior regions. There are few non-CNC-derived cells (pink)
within the developing palate (arrowhead). Arrows in E, F and H indicate the
midline epithelium at E14.5. Arrows in I and J indicate remaining of the midline
epithelium and double arrows in K and L indicate aggregated CNC cells at E15.5.
The palatal epithelium is non-CNC-derived, indicating a distinct embryonic origin.
MX, maxilla; PS, palatal shelf; T, tongue; *, the forming palatal bone (Ito et al.,
2003). Permission to reproduce this material has been granted by The Company of
Biologists.
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1.3 Palate development
In mouse, palate development starts at around embryonic day (E) 10.5 and is
completed by E16.5, which roughly corresponds to the end of the fifth week until
the twelfth week of gestation in human.
The mammalian palate consists of the primary and the secondary palate; the former
is derived from the intermaxillary segment and contributes to an anterior small part
of the hard palate, whereas the latter is formed from the maxillary prominences and
represents the majority of the hard and soft palates (Sadler, 2004). In embryology,
the secondary palate is a primordium of the future hard and soft palates which
separates the oral cavity from the nasal cavity in many adult vertebrates.
Development of the palate in the embryonic stage involves several steps including
the development and migration of CNC, the formation of the secondary palate and
ossification in the anterior to midposterior palate to form the palatal bones as well
as the formation of soft palate, as described below.
1.3.1 Formation of the primary palate
Development of the primary palate starts at around E10.5 in mouse (Diewert and
Wang, 1992). It is formed from a mesenchymal mass called the intermaxillary
segment derived from merging of medial nasal prominences. The intermaxillary
segment contributes to the central upper lip as well as the primary palate which are
initially continuous. The intermaxillary segment then grows into the stomodeum to
form the primary palate which later fuses with the secondary palate (Hinrichsen,
1985). The primary palate consists of a premaxillary part of the maxilla anterior to
the incisive foramen and represents a small part of adult hard palate.
1.3.2 Formation of the secondary palate
The development of the secondary palate starts at around E11.0. It involves the
budding and vertical growth of a pair of palatal shelves from the maxillary
prominences that elevate horizontally above the tongue and fuse to form a
continuous palate (Figure 1.4). The three fundamental steps required for normal
23
palate development are described in this section, along with the gene pathways
known to be involved in the process that have been greatly informed and facilitated
by the use of many transgenic animal models.
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Figure 1.4 Development of the secondary palate
The palatal shelves appear from the maxillary prominences at E11.0 (the sixth week
in human development) (A). The shelves grow laterally either side of the tongue
from E12.0 to E14.0 (the seventh to eighth weeks in human development) (B, C).
The shelves elevate above the tongue at around E14.5 to E15.0 (the ninth week in
human development) (D). The shelves initially grow horizontally towards each
other close to the midpoint (yellow arrows) and fuse anteriorly and posteriorly (blue
arrows) between E15.0 to E16.5 (the ninth to tenth weeks in human development)
(E, F). These images are used with permission from Professor Kathy Sulilk from
http://www.med.unc.edu/embryo_images/unit-hednk/hednk_htms/.
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1.3.2.1 Palatal shelf growth
Two palatal shelf outgrowths appear from the maxillary prominences at E11.0 and
extend downward on each side of the tongue between E12.0 to E14.0. At this stage,
the tongue sterically limits the lateral movement of the palatal shelves. The palatal
mesenchymal cells are rapidly proliferating in the growing shelves, and many
signalling pathways are implicated in the shelf growth.
In fact, defects in the growth of the palatal shelves are the most common causes of
cleft palate in transgenic animal models. Examples include Msx1, Fgf10, Fgfr2b,
Tgfβr2, Pdgfc, Sim2 and Lhx8 mutant mice (Satokata and Maas, 1994; Rice et al.,
2004; Ito et al., 2003; Ding et al., 2004; Shamblott et al., 2002; Zhao et al., 1999).
Msx1 mutant mice exhibit a cleft palate caused by a reduced proliferation of the
palatal mesenchyme (Satokata and Maas, 1994; Zhang et al., 2002). The cleft palate
phenotype can be rescued by Bmp4 which is thought to act downstream of Msx1
(Zhang et al., 2002). Null mutations in Fgf10 and its receptor Fgfr2b result in cleft
palate due to reduced cell proliferation in both the palatal epithelium and
mesenchyme, which is caused by altered SHH signalling downstream of
Fgf10/Fgfr2b (Rice et al., 2004). In fact, a loss of either the ligand or receptor
results in loss of Shh and Ptc expression. In addition to the altered cell proliferation,
apoptosis is elevated in the mutant epithelium which may also contribute to the
growth defects. Also, a loss of Fgf10 in epithelia causes inappropriate fusion of the
shelves to the surfaces of the tongue and mandible (Rice et al., 2004; Alappat et al.,
2005). The palatal shelves of Tgfβr2, Pdgfc, Sim2 and Lhx8 mutant mice grow
vertically and elevate normally but the shelves fail to contact in the midline as a
result of retarded horizontal growth (Ito et al., 2003; Ding et al., 2004; Shamblott et
al., 2002; Zhao et al., 1999). Cleft palate as well as calvaria defects are caused by
conditional inactivation of Tgfβr2 in neural crest cells (Ito et al., 2003). Pdgfc
mutant mice have a complete cleft of the secondary palate which results in perinatal
death (Ding et al., 2004). In this case, the defect may have been caused by
disruption of CNC cell migration into the palatal shelves as Pdgf signalling is
important for this process (Eberhart et al., 2008). Disruption of Sim2 results in
craniofacial malformations including a cleft of the secondary palate (Shamblott et
al., 2002). The mutant mice are postnatal lethal due to aerophagia which is
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characterised by accumulation of air in the gastrointestinal tract. Lhx8 mutant mice
develop an isolated cleft of the secondary palate without other craniofacial defects,
indicating that the cleft palate is caused by an intrinsic factor (Zhao et al., 1999).
Interestingly, deletion of TGF-β type I receptor Alk5 in the ectoderm and neural
crest cells results in an increased apoptosis in the branchial arch and palatal
mesenchyme as well as over proliferation in the shelves, leading to cleft palate and
severe craniofacial defects (Dudas et al., 2006).
Taken together, normal shelf growth can often be affected by altered cell
proliferation and/or apoptosis in the palatal mesenchyme which results in
hypoplastic or retarded palatal shelves. As a consequence, they fail to fuse at the
midline simply by not making contact and thereby result in a cleft palate.
1.3.2.2 Palatal shelf elevation
Palatal shelf elevation is a rapid process. The anterior region flips first, followed by
the posterior region (Ferguson, 1988). The exact mechanism of elevation is
unknown but some possibilities have been suggested. One of them is an intrinsic
force generated within the palatal shelf. There is an accumulation of the extra
cellular matrix (ECM) prior to and during the shelf elevation (Larsson, 1960) as
well as increased hyaluronic acid which forms hydrated gels that expands the ECM
(Ferguson, 1988). The highest concentration of hyaluronic acid is observed in the
posterior two third of palatal shelves (Brinkley and Vickerman, 1982; Brinkley and
Morris-Wiman, 1984). This causes the ECM to swell and the resultant intrinsic
force moves the palatal shelves into the horizontal position (Ferguson, 1988). It is
also suggested that alignment of type I collagen and mesenchymal cells within the
shelves facilitate shelf elevation (Brinkley and Morris-Wiman, 1984; Greene and
Pratt, 1976). Apart from intrinsic factors required for shelf elevation to occur
normally, the tongue needs to descend first in order to provide space for the
horizontal apposition of the palatal shelves. In Hoxa2-/- and Foxf2-/- animals, the
shelves fail to elevate due to mechanical obstruction by the tongue (Wang et al.,
2003; Rijli et al., 1993; Barrow and Capecchi, 1999). In the case of Hoxa2-/- mice,
the tongue anomaly is caused by the failure in the insertion of the hyoglossus
muscle into the hyoid bone which in turn sterically limits the shelf movement,
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resulting in a cleft. Interestingly, this phenotype is actually rescued by an additional
mutation in Hoxa1 because of its further effect on the hyoid bone, although the
overall phenotype is more severe (Barrow and Capecchi, 1999). Similarly,
mechanical obstruction by the tongue also causes a cleft phenotype in Foxf2-/-
(Wang et al., 2003). There are no obvious defects in these mice other than the
tongue which does not descend. In addition, the shelves also fail to elevate when
they fuse with the tongue or the mandible instead of each other as shown by loss of
function mutations in Jagged2 (Jiang et al., 1998) and Fgf10 (Alappat et al., 2005).
In Jagged2-/- mice, the elevation defect is caused because the palatal epithelial cells
aberrantly fuse to the tongue and mandible rather than a mechanical obstruction by
the tongue. Interestingly, down regulation of Jagged2 throughout the palatal
epithelium, as well as ectopic expression of Tgfβ3 in the oral epithelium of the
palate, have been observed in Fgf10-/- mice in which shelf elevation was physically
prevented due to adhesion of the shelves to the tongue and mandible (Alappat et al.,
2005). Similarly, Irf6 loss of function mutations in mice results in cleft palate due to
epithelial adhesion in the oral cavity which prevents the palatal shelves from
elevation (Ingraham et al., 2006; Richardson et al., 2006; Stottmann et al., 2010).
Lastly, mutations in Osr2 (Lan et al., 2004) and Pdgfc (Ding et al., 2004) cause
cleft palate due to delayed elevation that is caused by abnormal mesenchymal cell
proliferation.
Taken together, in terms of defective shelf elevation observed in vivo, it is often
caused either by mechanical obstruction by the tongue or inappropriate fusion of
shelves to the oral surface.
1.3.2.3 Palatal shelf fusion
Following elevation of the palatal shelves, they continue to grow horizontally
towards each other until eventually the medial edge epithelial (MEE) cells contact
and fuse between E14.5 to E15.0. This palatal fusion occurs in a zip-like manner
toward anterior and posterior directions starting from the point of first contact
which is between the third and the fourth rugae (Biddle, 1980; Sakamoto et al.,
1989). The contact of MEE cells forms a midline epithelial seam (MES), which
disappears by E15.5 to allow mesenchymal confluence to be achieved. However, in
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some transgenic mouse models of cleft palate, the palatal shelves elevate and
contact but the MES fails to disappear during the fusion process and thus
mesenchymal continuity is not achieved, leading to an increased incidence of cleft
palate. The exact mechanism of MES disappearance is controversial and three
major hypotheses have been proposed as follows:
i) Apoptosis of MES has been indicated by various studies based on
morphological and molecular analyses such as the TUNEL assay
(Cuervo and Covarrubias, 2004; Martinez-Alvarez et al., 2000). In vitro
experiments using cultured palatal shelves however resulted in
somewhat different conclusions. In one study, palatal shelves failed to
fuse in the presence of apoptosis inhibitors (Cuervo and Covarrubias,
2004) suggesting apoptosis was required, while in another study palatal
shelf fusion occured in the presence of the inhibitors suggesting that
apoptosis is not a prerequisite for fusion (Takahara et al., 2004). These
contradictory results from different laboratories indicated that the in
vitro systems used may not accurately reflect the in vivo situation. A
more recent study used conditional transgenics (Cre-LoxP) to mark
epithelial cells with β-galactosidase allowing in vivo genetic fate-
mapping of the MEE (Vaziri et al., 2005). Analysis of these transgenic
mice revealed that the β-galactosidase positive cells in the MES
eventually aggregated and disappeared from the fusing palate. In
addition, the cells in the seam were also positive for the apoptotic
marker activated Caspase-3, underscoring the importance of apoptosis in
the disappearance of MES. In terms of defective shelf fusion, Tgfβ3
deficient mice are probably investigated most. The palate develops
normally in the mutant up to the point where the shelves make contact at
the midline (Kaartinen et al., 1995; Proetzel et al., 1995). However, the
MES persists after fusion and fails to degenerate. Apoptosis clearly
seems to be important in the seam degeneration as it is reduced in this
mutant mouse model (Martinez-Alvarez et al., 2000) which also exhibits
an excess proliferation in the MES (Cui et al., 2003).
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ii) Epithelial to mesenchymal transformation (EMT) refers to a
transdifferentiation of epithelial cells into mesenchymal cells. EMT has
originally been proposed following observations in ultrastructural and
lipophilic dye cell labelling studies in vitro (Shuler et al., 1992; Fitchett
and Hay, 1989; Griffith and Hay, 1992). The disadvantages of using
lipophilic markers included an inefficient uptake of dye by the MEE
cells as well as nonspecific uptake by non-epithelial cells. As an in vivo
approach, the Cre-LoxP system was used to label and fate map MEE
cells (Jin and Ding, 2006). In their system, the cells positive for β-
galactosidase were detected even after palatal fusion and some cells had
typical morphology of mesenchymal cell, demonstrating the occurrence
of EMT which contradicts the finding by Vaziri et al. (2005). Jin and
Ding (2006) suggested that this might be because of the different Cre
transgenic lines used in the two studies.
iii) Migration of the MEE cells along the midline to the nasal and oral
epithelia has also been supported by lipophilic dye cell labelling (Carette
and Ferguson, 1992) and in vivo fate mapping studies (Jin and Ding,
2006). However, it is not clear whether the thinning of the MES was
caused by the movement of epithelial cells into the periphery or rather
the epithelial cells are driven by the proliferating mesenchymal cells in
the fusing palate.
In summary, the fate of MEE cells is still not conclusive but it is likely that a
combination of the three mechanisms detailed above may be involved in the
disappearance of the MES during the fusion process.
1.3.3 Formation of the hard and soft palates
The craniofacial bones are formed by two different processes called
intramembranous and endochondral ossifications (Miloro et al., 2004). Both
processes are essential during the embryonic development of bone tissue. In
particular, the maxillary and palatine bones in the hard palate undergo
intramembranous ossification, which does not involve a cartilaginous intermediate
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as it does in endochondral ossification. In essence, intramembranous ossification
starts with the condensation of mesenchyme followed by the differentiation of
immature cells into osteoblasts that deposit mineralised extracellular matrix to form
bone tissues. This process is regulated by a complex network of transcription
factors and extracellular growth factors.
The ossification process is initiated at around E15.0 in the mouse palate after shelf
fusion is complete. At this point, the undifferentiated mesenchymal cells start to
condense to form dense aggregate known as intramembranous ossification centre.
Once the ossification centre is formed, the mesenchymal cells stop proliferating and
start to differentiate into osteoprogenitor cells, a precursor of osteoblasts.
Osteoprogenitor cells express Runx2, also known as Cbfa1, which is a master
regulatory transcription factor for the differentiation of the osteoblast lineage (Ducy
et al., 1997; Komori et al., 1997; Ducy et al., 2000). Apart from its role during
differentiation, RUNX2 also regulates the expression of osteoblast specific proteins
such as Osteocalcin in terminally differentiated osteoblasts (Ducy and Karsenty,
1995), and its binding sites are present in the regulatory regions of genes involved
in the synthesis of bone extracellular matrix (Ducy et al., 2000). Osterix is another
key controller of osteoblast differentiation which acts downstream of Runx2
(Nakashima et al., 2002). In fact, bone formation fails to take place without these
factors as demonstrated by Runx2 and Osterix deficient mice (Komori et al., 1997;
Otto et al., 1997; Nakashima et al., 2002). Growth factors such as bone
morphogenetic proteins (BMPs) and fibroblast growth factors (FGFs) are also
essential in the differentiation of osteoprogenitor cells into mature osteoblasts
(Chen et al., 2004; Agata et al., 2007). For instance, BMP2 is a strong inducer of
osteoblastic differentiation in mesenchymal cells (Ryoo et al., 2006), while FGF2 is
known to be important in the induction of osteoblast proliferation, although its role
in differentiation seems to be stage-specific (Fakhry et al., 2005; Kalajzic et al.,
2003). During differentiation and maturation processes, osteoblasts express
characteristic markers including Osterix, type I collagen, bone sialoprotein, alkaline
phosphatase, osteopontin, osteocalcin and osteonectin. Mature osteoblasts are bone
forming cells entirely responsible for the deposition of bone extracellular matrix
called osteoid which is mainly composed of type I collagen, and for the regulation
of osteoclasts involved in bone resorption. During the mineralisation process, active
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osteoblasts line the periphery of the ossification centre and continue to secrete
osteoid as well as calcium, magnesium and phosphate ions. Eventually, these
inorganic chemicals are combined within the osteoid and mineralised to become
bone tissue. Some osteoblasts are trapped and incorporated within the osteoid
during the process. These cells are called osteocytes. In the mouse palate,
mineralisation within the ossification centre is observed from E15.5 onwards
(Pauws et al., 2009a). Intramembranous ossification in the maxilla occurs anteriorly
and posteriorly to the infraorbital foramen region, then ossification spreads through
the secondary palate. This process results in the formation of the palatine process of
the maxilla and the palatine bone accounting for the anterior three fourths and the
posterior fourth of the bony hard palate, respectively (Figure 1.5).
Figure 1.5 Schematic diagram of the hard and soft palates in human
Schematic diagram showing the hard and soft palates in human. Adopted from
Instant anatomy, RH Whitaker, NR Borley, 4th edition, Wiley-Blackwell 2010.
Permission to reproduce this material has been granted by John Wiley & Sons.
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The posterior third of the secondary palate lacks ossification and consists mainly of
muscle fibres covered in mucous membrane thereby developing into the soft palate.
It mainly serves as a mobile flap to close off nasal cavity during swallowing as well
as to direct the airflow during speech and breathing (Stal and Lindman, 2000).
The majority of craniofacial muscles including the muscles of the soft palate are
derived from the branchial arch cells of cranial paraxial mesodermal origin (Zhang
et al., 1999). In addition, progenitors of other cell lineages including endothelial
cells, smooth muscles and connective tissues have been identified in this
mesenchymal population (Noden and Francis-West, 2006). In humans, five types of
muscles (tensor veli palatini, levator veli palatini, palatopharyngeus, palatoglossus
and uvula) are found within the soft palate and attach to nearby hard tissue
structures (Figure 1.6). Of these, tensor veli palatini and levator veli palatini insert
onto, and palatopharyngeus, palatoglossus and uvula originate from the palatine
aponeurosis which is a fibrous lamella found at the posterior border of the hard
palate. The same muscles compose the soft palate in mouse but the uvula at the
posterior end is absent (Zhang et al., 1999). During the soft palate development,
muscles first emerge as mesenchymal condensations both in mouse and human
(Cohen et al., 1993; Trotman et al., 1995). The condensation in the mouse palatal
shelves starts at E13.5 for the tensor veli palatini followed by levator veli palatini,
palatoglossus and palatopharyngeus at around E14.5 (Zhang et al., 1999). Next,
they form myoblast fields and then differentiate into myocytes followed by the
formation of muscle fibers. The morphology of the palatal muscles in mouse
become evident by E15.5 and muscle fibers start to appear at E18.5 (Zhang et al.,
1999). The development of muscle is controlled by the network of myogenic
regulatory factors such as MyoD and myogenin, both are well known markers of
myogenic lineage that promote differentiation (Arnold and Braun, 1996).
Expression of these factors in the head muscles are controlled by specific
combinations of transcription factors involving capsulin, MyoR, Tbx1, Pitx2, Isl1,
and Nkx2.5 in different craniofacial muscles (Tzahor, 2009), although the myogenic
regulation specific to the soft palate muscle has not been investigated.
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Figure 1.6 Schematic diagram of the soft palate muscle structures in human
In humans, five types of muscles (tensor veli palatini, levator veli palatini,
palatopharyngeus, palatoglossus and uvula) are found within the soft palate, while
the uvula is absent in mouse. Image is adopted from
http://www.neuroanatomy.wisc.edu/virtualbrain/BrainStem/09NA.html. The figure
is not shown due to copyright issues.
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1.4 Orofacial clefting in humans
Orofacial clefts, particularly clefts of the lip and palate (Figure 1.7), are among the
commonest birth defects with an incidence of about 1 in 700 births worldwide but
with variability depending on geographic origin and ethnicity (Wyszynski et al.,
1996; Vanderas, 1987). Cleft lip and palate are frequently described as
multifactorial involving both genetic and environmental risk factors (Murray, 2002).
Children born with clefts often suffer from difficulties with feeding, hearing and
speech problems which require surgical intervention as well as issues with
psychological development and social integration (Schutte and Murray, 1999;
Stanier and Moore, 2004). The gold standard treatment for clefts of the lip and
palate is plastic surgery, within the care of a multidisciplinary team consisting of
surgeons, speech therapists, orthodontists, geneticists, specialist nurses and
psychologists. It essentially involves repositioning of tissue and muscles in order to
bring the lip muscle (orbicularis oris) into its correct anatomic orientation and
rebuild the continuous palate (Millard, Jr. and Latham, 1990; Randall, 1965;
Tollefson et al., 2008).
Figure 1.7 Clefts of the lip and palate
Unilateral cleft lip only (A), cleft lip with cleft palate (B), and isolated cleft palate
(C) (Jugessur et al., 2009). Permission to reproduce this material has been granted
by John Wiley & Sons.
A B C
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1.4.1 Cleft lip and palate
Orofacial clefts including clefts of the lip and palate are a heterogeneous group of
disorders. Clefts of the lip and palate are subdivided into clefts of the lip and/or
cleft palate (CL/P) and clefts of the secondary palate only (CP). In addition, CL/P
and CP can also be divided into either syndromic or non-syndromic forms
depending on whether affected individuals exhibit other phenotypic anomalies. CP
is thought to be more frequently associated with other congenital anomalies than
CL/P (Mossey and Little, 2002). For CL/P, about 70% of cases are non-syndromic
and the rest are associated with other anomalies (Calzolari et al., 2007). For CP, the
ratio of non-syndromic to syndromic cases is about 1 to 1 (Calzolari et al., 2004).
Some of the better known examples of human congenital syndromes that are
associated with CL/P and CP are described in 1.4.3.
The prevalence for CL/P varies related to geographic origin and socioeconomic
status (Murray et al., 1997; Vanderas, 1987), but overall, the frequency is about 1 in
700 births worldwide (Murray, 2002; Stanier and Moore, 2004). Geographically,
the occurrence of CL/P has been found to be higher in parts of Asia and Latin
America than in South Africa, Israel and southern Europe, whereas the rates of CP
are higher in parts of northern Europe and Canada than in parts of Latin America
and South Africa (Mossey et al., 2009). Ethnicity is clearly an important factor for
the variable occurrence of clefts as shown by several studies where the prevalence
of orofacial clefts in certain ethnic groups matches to the prevalence of their ethnic
origins rather than that observed in the area they have migrated (Croen et al., 1998).
Interestingly, CL/P is more frequent in males than in females and varies with
different ethnic origins. In white populations for example, the ratio for CL/P is
about 2 to 1 (male to female) (Mossey and Little, 2002). On the other hand, CP is
slightly more common in females than in males and does not vary with ethnicity. In
terms of etiology, CL/P and CP are generally considered to be distinct because
families at high risk for CL/P are not at increased risk for CP and vice versa
(Jugessur and Murray, 2005). However, the occurrence of both CL/P and CP within
the same family are occasionally observed especially in syndromes such as Van der
Woude syndrome caused by IRF6 mutations (Kondo et al., 2002) and CL/P with
hypodontia caused by MSX1 mutations (van den Boogaard et al., 2000).
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Anatomically, CL/P involves cleft of the upper lip and anterior part of the maxilla
which is either unilateral (one sided) or bilateral (two sided), possibly accompanied
by cleft of the secondary palate (Figure 1.8). In the case of CL/P, cleft of the
secondary palate is thought to be secondary to disruption of the primary palate. The
clinical phenotypes of CP are categorised as follows; complete cleft of the
secondary palate in which both the hard and soft palate are affected, cleft of the soft
palate in which only the soft palate is split, bifid uvula where the uvula at the
posterior end of the soft palate is split, and submucous cleft palate.
Figure 1.8 Cleft lip and/or palate phenotypes
Normal lip and palate (top panel). Unilateral cleft of the soft palate (a). Unilateral
cleft lip (b). Unilateral cleft lip and palate involving the hard palate (c). Unilateral
cleft lip and palate involving both the hard and soft palates (d). Bilateral cleft of the
soft palate (e). Bilateral cleft lip (f). Bilateral cleft lip and palate involving the hard
palate (g). Bilateral cleft lip and palate involving both the hard and soft palate (h)
(Muenke, 2002). Permission to reproduce this material has been granted by Nature
Publishing Group.
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Submucous cleft palate is sometimes considered a clinical subcategory of cleft
palate and is certainly part of the spectrum of developmental defects affecting the
palate. It is also thought to be the most common type of cleft found in the posterior
palate in human (Moss et al., 1988). It is called ‘submucous’ because the cleft is
found within the mucous membrane which makes the diagnosis difficult because it
is not as visually obvious as overt cleft palate. A submucous cleft palate can be
further classified into a submucous cleft of the hard palate which is characterised by
a bony defect within the hard palate, and a submucous cleft of the soft palate which
is characterised by a lack of muscular tissue and abnormal positioning of the
muscles within the soft palate. Classic submucous cleft palate, usually diagnosed
during a thorough physical examination, is characterised by having a bifid uvula,
palatal muscle diastasis, and a notch in the posterior surface of the hard palate
(Figure 1.9), whereas occult submucous cleft palate lacks one or more of these overt
anatomical findings with muscle malposition and hypernasal speech may be the
only features (Stal and Hicks, 1998; Gosain et al., 1996). One of the functional
findings found in classic submucous cleft palate and in some occult submucous
cleft palate cases is velopharyngeal insufficiency (VPI) which is caused by an
incorrect insertion of the palatine muscle onto the hard palate (Kaplan, 1975). VPI
is associated with speech problems such as hypernasal resonance, feeding
difficulties and otitis media (Gosain et al., 1996). There are few, if any, mouse
models reported with classical features of submucous cleft palate apart from Tbx22
null mouse featured in this thesis (Pauws et al., 2009a). Others include Tgfβr2 (Xu
et al., 2006) and Tshz1 (core et al., 2007) mutant mice, although they feature cleft or
premature truncation of the soft palate and could also be classified as partial clefts
of the soft palate rather than a true submucous cleft. However, we strongly suspect
that many cases of submucous clefts in mouse models may have gone unnoticed.
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Figure 1.9 Physical features found in classic submucous cleft palate
Classic submucous cleft palate is characterised by a bifid uvula, palatal muscle
diastasis, and a notch in the posterior surface of the hard palate (Stal and Hicks,
1998). Permission to reproduce this material has been granted by Allen Press
Publishing Services.
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1.4.2 Environmental factors
Cleft lip and palate are multifactorial disorders that involve environmental factors in
the occurrence of cleft cases as well as genetic factors. Various studies have
suggested environmental risk factors such as maternal smoking, alcohol
consumption, poor diet, viral infection, drugs and teratogens, many of which have
been associated with increased risks of orofacial clefts (Prescott et al., 2001). Other
studies suggest that the occurrence of birth defects recur in families partly due to
shared environment (Hayes, 2002).
Cigarette smoking during pregnancy has been almost uniformly associated with
increased risks of both CL/P and CP possibly due to hypoxia, with the population
attributable risk can be as high as 20% (Munger et al., 1996; Shaw and Lammer,
1999; Little et al., 2004; Honein et al., 2007). Alcohol consumption during
pregnancy however, has been associated in some studies (Romitti et al., 1999;
Chevrier et al., 2005) but not others (Meyer et al., 2003), making it uncertain. The
risk increases when smoking or alcohol consumption are combined with certain
allelic variants of cleft susceptible genes such as TGFβ3 and MSX1 (Romitti et al.,
1999) indicating interaction or cumulative effects of environmental and genetic
factors. In terms of nutrition, low intake of B-complex vitamins and deficient or
excessive vitamin A are suggested to increase the risks of clefts (Finnell et al.,
2004; Munger, 2002). In fact, supplementation of multivitamins in early pregnancy
has been associated with a reduced prevalence of orofacial clefts (Krapels et al.,
2004b; Krapels et al., 2004c). Similarly, folic acid antagonists are linked to the risk
of orofacial clefts in human (Hernandez-Diaz et al., 2000). However, it has not been
clearly established if folate supplementation reduces the risk of clefts. For instance,
a reduced prevalence of orofacial clefts has been reported following folate
fortification of grain in the U.S.A. (Yazdy et al., 2007) but this was not consistent in
some other countries (Botto et al., 2006). Other nutrients such as zinc could also
affect the occurrence of orofacial clefts (Krapels et al., 2004a; Tamura et al., 2005).
The use of chemotherapeutic drugs during pregnancy is also associated with
orofacial clefts. These include cholesterol-lowering drugs such as statins (Edison
and Muenke, 2004) and a range of anti-epileptic drugs (Wide et al., 2004; Goldman,
1984). In terms of viral infection, having influenza during first couple of months of
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pregnancy has been associated with a higher prevalence of CL/P (Acs et al., 2005).
In this case, fever seemed to be blamed since the risk was reduced when antifever
drugs were used. Still, it is interesting to note that genes such as PVRL1 and IRF6,
both involved in immune response, are associated with orofacial clefts in CLPED1
(Suzuki et al., 2000) and Van der Woude syndrome (Kondo et al., 2002)
respectively (detailed in 1.4.3).
1.4.3 Genetic factors
The importance of genetic factors in the occurrence of human orofacial clefts has
been illustrated in various ways from sibling and twin studies, to mapping of
orofacial cleft susceptibility loci as well as identification of causative genes.
Familial clustering of orofacial clefts is well known and reflected in a high
recurrence risk within families and between siblings (Lie et al., 1994; Wyszynski et
al., 1998; Sivertsen et al., 2008). In twin studies, the concordance rate in
monozygotic twins (40-60%) is much higher than that has been observed for
dizygotic twins (3-5%), indicating a strong genetic involvement in orofacial clefts,
but also implying a role of other factors such as environmental risks which are
discussed above.
The identification of genetic loci and genes associated with CL/P has been an area
of intense research. Linkage studies have suggested several loci susceptible to CL/P
in regions on chromosomes 1, 2, 4, 6, 14, 17, 19 and X (Schliekelman and Slatkin,
2002; Prescott et al., 2000; Zeiger et al., 2003), although the number of loci
suggested varies among studies. More recently, genome-wide association study, a
powerful method to examine almost all the genes in individuals, has been used to
identify a susceptibility locus on 8q24 for nonsysndromic CL/P (Birnbaum et al.,
2009). The number of genes associated with human orofacial clefts is remarkably
less than those identified in animal models for clefts but the list is expanding. These
include IRF6, TGFβ3, MSX1, MSX2, FGFR1, FGFR2, FGF8, FOXE1, p63,
PDGFC, PVRL1, GABRB3, TBX10, TBX22, SATB2, GLI2, JAG2, SPRY2, LHX8,
SK1, MTHFR and RARA (reviewed in Jugessur et al., 2009). Those that have been
identified in human are mostly the result of mapping and sequencing genes
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responsible for monogenic and syndromic forms of clefts. In addition, exome
sequencing has identified genes linked to Kabuki and Miller syndromes in which
cleft palate is one of a clinical components (Ng et al., 2010b; Ng et al., 2010a).
Exome sequencing is a relatively new technique to efficiently sequence the coding
regions to discover novel genes. Powerful techniques such as this exome
sequencing and whole-genome association studies are expected to play important
roles in identification of genes for orofacial clefts in the future. Some of the most
investigated cases in which genetic factors play an important role in human cleft
phenotypes are detailed below.
1.4.3.1 Van der Woude syndrome (VDWS) and popliteal pterygium
syndrome (PPS)
The two allelic autosomal dominant disorders VDWS (OMIM 119300) and PPS
(OMIM 119500) are caused by mutations in the interferon regulatory factor 6
(IRF6) gene (Kondo et al., 2002). VDWS is a good model for isolated CL/P
because the majority of patients exhibit only minor additional phenotypes such as
lip pits and hypodontia while about 15% of patients do have isolated CL/P. PPS is
clinically similar to VDWS but include additional phenotypes of popliteal
pterygium, syngnathia, syndactyly, toe/nail abnormalities and genitor-urinary
malformations. Mice deficient for Irf6 have cleft palate along with abnormal skin
and limb development (Kondo et al., 2002; Ingraham et al., 2006) which resemble
clinical features of VDWS and PPS. It has been demonstrated that there is a
genotype-phenotype correlation in that missense mutations that affect DNA binding
cause PPS while the majority of missense mutations that do not affect DNA binding
result in VDWS (Kondo et al., 2002). Later, the involvement of IRF6 as a risk
factor in the occurrence of isolated CL/P was demonstrated (Zucchero et al., 2004).
More recently, a common SNP was identified in a highly conserved enhancer
element of IRF6 which essentially disrupted the binding site for AP-2α (Rahimov et
al., 2008). AP-2α is known to be involved in craniofacial development (Schorle et
al., 1996) and AP-2α chimeric mice show facial dysmorphology (Nottoli et al.,
1998). Along with the finding that mutations in TFAP2A, a gene encodes for AP-2α,
cause branchio-oculo-facial (BOF) syndrome in human which is a cleft palate-
craniofacial disorder (Milunsky et al., 2008; Stoetzel et al., 2009), it is likely that
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IRF6 and AP2-α are placed in the same pathway during craniofacial development in
human as well as in mouse.
1.4.3.2 Malformation syndromes caused by mutations in p63
CL/P is a major feature in four of the five developmental disorders caused by
mutations in the tumour protein P63 that are characterised by orofacial clefts, limb
abnormalities and ectodermal dysplasia (van Bokhoven and Brunner, 2002). There
is a clear genotype-phenotype correlation depending on the position of mutations
(Celli et al., 1999; Celli et al., 1999; Rinne et al., 2007). In mice, p63 is expressed in
the branchial arch ectoderm and has a role in craniofacial and limb development
(Yang et al., 1999). A heterozygous mutation in this gene has also been associated
with non-syndromic CL/P (Leoyklang et al., 2006). Recently, P63 and IRF6 have
been reported to cooperatively regulate epithelial proliferation and differentiation
during palate development (Thomason et al., 2010; Moretti et al., 2010), linking the
pathogenesis of syndromes caused by these two genes.
1.4.3.3 Orofacial clefting and tooth agenesis
MSX1 was found to be associated with orofacial clefting and tooth agenesis (OMIM
106600) in a family carrying a missense mutation following its original description
in a null mouse with a similar phenotype (van den Boogaard et al., 2000; van den
Boogaard, 2004; Satokata and Maas, 1994). Subsequently, a screen of 917 non-
syndromic CL/P cases identified mutations in 2% of patients (Jezewski et al., 2003),
although functional testing was not used to confirm that these were causative
mutations. Msx1 is known to be required for expression of Bmp4, Bmp2 and Shh,
which are all implicated in craniofacial development (Zhang et al., 2002) and
suggest their genetic interaction in the craniofacial structure. BMP4 has recently
been associated with cleft lip as well as microform and subepithelial lip defects that
are considered to be part of the CL/P spectrum (Suzuki et al., 2009). The mouse
homolog of this gene appears to play important roles in lip and palate fusion also
(Liu et al., 2005).
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1.4.3.4 Kallman syndrome and Apert syndrome
A number of FGF signalling molecules and their receptors are expressed in the
craniofacial region during development (Bachler and Neubuser, 2001) and are
interesting candidates for orofacial clefts. A comprehensive sequencing study in
individuals with non-syndromic CL/P involving members of the FGF signalling
pathway identified a small number of nonsense and missense mutations in FGFR1,
FGFR2, FGFR3 and FGF8 (Riley et al., 2007). Kallman syndrome (OMIM
147950) is an autosomal dominant disorder with hypogonadism and anosmia,
caused by mutations in FGFR1. 5-10% of these patients have craniofacial
malformations including CL/P (Dode et al., 2003). Apert syndrome (OMIM
101200) which is caused by mutations in FGFR2, includes about 75% of patients
with CP or bifid uvula (Kreiborg and Cohen, Jr., 1992).
1.4.3.5 Cleft lip and palate-ectodermal dysplasia syndrome (CLPED1)
An autosomal recessive disorder CLPED1 (OMIM 225060) also known as
Margarita Island syndrome is caused by homozygosity for a common mutation
W185X in poliovirus receptor-related 1 (PVRL1) (Suzuki et al., 2000). It encodes a
cell-cell adhesion molecule nectin-1 which is expressed in the medial edge epithelia
of the palatal shelves as well as in the olfactory and skin surface epithelia and in the
ectodermal component of tooth buds in mice (Suzuki et al., 2000). Heterozygosity
for this common mutation and some other variants in PVRL1 were later associated
with isolated CL/P (Sozen et al., 2001; Avila et al., 2006), indicating a contribution
of PVRL1 in the occurrence of non-syndromic CL/P.
1.4.3.6 X-linked cleft palate and ankyloglossia (CPX)
The causative gene for CPX (OMIM 303400) was located in Xq21 region by
linkage analyses in Icelandic, Native North American Indian and Manitoba
Menonite kindreds (Gorski et al., 1992; Gorski et al., 1994; Stanier et al., 1993;
Moore et al., 1987). Later, sequence analysis of CPX patients from the same
families and two previously unreported Brazilian families identified TBX22 as the
causative gene (Braybrook et al., 2001). Patients were found to have frame shift,
splice site, nonsense and missense mutations, which essentially result in a complete
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loss of function of the gene in affected males (Braybrook et al., 2001; Braybrook et
al., 2002). Mutations in TBX22 were also found to account for 4-8% of all non-
syndromic cases of isolated cleft palate (Marcano et al., 2004).
The cleft phenotype varies between patients and even within family members
ranging from a submucous cleft palate (50%), complete cleft of the secondary
palate (20%), cleft of the soft palate, bifid uvula or absent tonsils, all frequently but
not always accompanied by ankyloglossia (tongue-tie) (Figure 1.10) (Stanier and
Moore, 2004). Family members who share an identical mutation can have either
cleft palate or ankyloglossia, or both, indicating that these defects are caused
independent of each other and partially penetrant. In males, cleft palate phenotype
is highly penetrant and often present with ankyloglossia (78%) (Marcano et al.,
2004). In addition to the males being affected, CPX is inherited in a semi-dominant
manner where female carriers can also display a range of phenotypes from complete
cleft of the secondary palate and ankyloglossia to unaffected (Bjornsson et al.,
1989). Among one third of carrier females affected by CPX, 16% present with cleft
palate regardless of ankyloglossia, while many carriers only have ankyloglossia
without cleft palate (Marcano et al., 2004). The reason for the difference in
penetrance between males and females are not known but may be due to variable
non-random X-inactivation.
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Figure 1.10 Physical features found in CPX patients
Isolated cleft palate (A), a less severe partial cleft with ankyloglossia (not shown)
(B), a partial cleft in the process of repair (C), a complete cleft of the secondary
palate (D), ankyloglossia (E), ankyloglossia in a patient with bifid uvula (not
shown) (F) (Stanier and Moore, 2004). Permission to reproduce this material has
been granted by Oxford University Press.
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TBX22 is composed of eight coding exons and an alternative non-coding exon
which is located about 10kb upstream of the first coding exon (Andreou et al.,
2007). The gene encodes a 520 amino acid protein which contains a highly
conserved T-box DNA binding domain of about 180 amino acids in its N-terminal
half. In vitro experiments have demonstrated that the protein acts as a
transcriptional repressor and is capable of autoregulation via the distal promoter P0
located immediately upstream of the non-coding exon (Andreou et al., 2007). Also,
the protein was shown to undergo post-translational modification with the small
ubiquitin-like modifier (SUMO-1) at the lysine 63 (K63) residue (Andreou et al.,
2007). SUMO modification is known to have diverse effects on target protein
activity but SUMOylation of transcriptional factors are often associated with
inhibition of transcription (Gill, 2005). In this case, SUMOylation of TBX22 is
required for its repressor activity (Andreou et al., 2007).
Previous data reporting the expression of TBX22 indicated that it was found by in
situ hybridisation in the tongue and mandible during the time of palatogenesis
(eighth to twelfth weeks), as might be expected from the patient’s phenotypes, and
to a lesser extent also in brain, heart, limb, kidney, stomach, eye and intestine, as
detected by RT-PCR (Braybrook et al., 2001). To date, no defects have been
associated with these organs in CPX patients. Detailed temporal and spatial
analyses of TBX22/Tbx22/tbx22 expression in human, mouse, chick and zebrafish
revealed a general agreement between species (Braybrook et al., 2002; Bush et al.,
2002; Haenig et al., 2002; Herr et al., 2003; Jezewski et al., 2009). In the human
embryo, the gene is expressed in the developing facial mesenchyme by the end of
sixth week of development. The highest expression is observed in the palatal
shelves, the nasal septum and at the base of the tongue prior to palatal shelf
elevation (Figure 1.11) (Braybrook et al., 2002). The expression is stronger
medially than laterally in the growing palatal shelves. It continues through to week
eight but is significantly reduced by week nine at which time the palatal shelves
have elevated, and made contact to fuse to form the palate (Braybrook et al., 2002).
Similarly in mouse embryos, craniofacial Tbx22 expression is detected anteriorly at
the base of the tongue in the vicinity of the frenulum region, which corresponds to
the ankyloglossia phenotype in CPX. It is also present in the medial and lateral
nasal prominences and in the periocular mesenchyme around the eyes. Most
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significantly, its expression is detected medially and posteriorly in the palatal
shelves before palatal fusion at E13.5 (Braybrook et al., 2002; Bush et al., 2002;
Herr et al., 2003). Mice deficient for Tbx22 predominantly exhibit a closed but
submucous cleft palate (94%) or more occasionally an overt cleft palate (6%). The
mice also have a detectable ankyloglossia (100%) but with the additional feature of
unilateral or bilateral choanal atresia (75%), which is not currently a recognised
feature of CPX (Pauws et al., 2009a). Submucous cleft palate is very well known to
the cleft surgeon but is less well documented in the literature, nevertheless it is a
frequent and possibly predominant feature in CPX families, suggesting that Tbx22
null mouse will be a good model to study mechanisms underlying the CPX
phenotype.
Figure 1.11 TBX22 expression pattern in human embryo
TBX22 in situ hybridisation of Carnegie stage 19 (A and B) and Carnegie stage 20
(C) human embryo transverse sections (Braybrook et al., 2002). Strong expression
is detected in the developing palatal shelves, the nasal septum/oronasal membrane
and at the base of the tongue. Permission to reproduce this material has been
granted by Oxford University Press.
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1.5 Tongue development
In this section, development of the tongue with particular relevance to the
ankyloglossia malformation associated with the CPX phenotype is discussed.
1.5.1 Embryonic development of the tongue
The tongue starts to develop as the tuberculum impar and the two lateral lingual
swellings at around E11, followed by the elevation of the hypobranchial eminence.
By E13, under normal circumstances, a selective degeneration occurs at the tip of
the tongue which is facilitated by programmed cell death or apoptosis and
resorption of the developing skeletal muscle in the anterior region of the tongue,
leaving a thin lingual frenulum as the only attachment (Paulson et al., 1985; Morita
et al., 2004). This effectively frees the distal end of the tongue from the mandible.
1.5.2 Ankyloglossia
Ankyloglossia, also known as tongue-tie, is a congenital anomaly caused by a short,
thick lingual frenulum. The severity varies from a mild form with a slight
impairment of tongue mobility, to a severe form where the tongue is closely
attached to the floor of the mouth (Suter and Bornstein, 2009). The reported
prevalence of ankyloglossia varies between 0.1% to 10.7 % and males in general
are more affected than females but no ethnic predispositions have been found (Suter
and Bornstein, 2009).
The pathogenesis of ankyloglossia is unclear. In most cases, ankyloglossia presents
in isolation of other congenital anormalies. However, it is also found in several
human syndromes including CPX (Bjornsson et al., 1989; Gorski et al., 1994;
Braybrook et al., 2001), Van der Woude syndrome (Kantaputra et al., 2002;
Burdick et al., 1987), Kindler syndrome (Hacham-Zadeh and Garfunkel, 1985) and
Opitz syndrome (Brooks et al., 1992), suggesting an involvement of genetic
components in its manifestation. Maternal cocaine use during pregnancy has been
associated with higher occurrence (3.5 times increase) of ankyloglossia in neonates,
indicating an involvement of environmental components (Harris et al., 1992).
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Ankyloglossia can cause difficulties in feeding and speech as well as affecting
mechanical aspects of oral hygiene. Surgical treatment like frenectomy is a routine
for this condition which involves a division of the frenulum by cutting its thinnest
portion. In some cases, an observation approach is taken as the frenulum recedes
naturally while children grow during the first six months to six years of life (Ruffoli
et al., 2005).
To date, only two mouse models have been described that exhibit ankyloglossia.
One is the Lgr5 null mice that exhibit aerophagia characterised by a gastrointestinal
tract dilation with air and an absence of milk in the stomach, which are neonatal
lethal (Morita et al., 2004). They revealed, by histological examination, that the null
mice had a severe form of ankyloglossia where the tongue was fused to the floor of
the oral cavity and concluded that this could account for the neonatal lethality
(Morita et al., 2004). The other is Tbx22 null mouse that shows a milder form of
ankyloglossia compared to Lgr5 null mice (Pauws et al., 2009a) and is further
detailed in 1.8.2.
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1.6 Choanae development
This section discusses specific development of the nasal choanae with particular
relevance to the developmental disorder choanal atresia, present in Tbx22 null mice
(Pauws et al., 2009a).
1.6.1 Embryonic development of nasal cavity and choanae
In the mouse embryo, development of the nasal cavity starts at around E9.5. At this
stage the frontonasal process develops at the rostral side of the stomodeum which
consists largely of mesenchyme derived from fore and midbrain neural crest (Jiang
et al., 2006). At around E10.0, the surface ectoderm on the ventrolateral part of the
frontonasal process starts to thicken and gives rise to the nasal placodes, while the
frontonasal process grows and bulges around them. As a result, the nasal placodes
invaginate to form nasal pits surrounded by the swelling medial and lateral nasal
processes (Hinrichsen, 1985). By E10.5, the shape of the nasal pits convert from
round depressions into slits due to rapid growth of the medial nasal processes and
the maxillary processes. The epithelial cells of medial and lateral nasal processes
start to fuse at E10.5, followed by fusion between the medial nasal and maxillary
processes, resulting in the formation of nasal fins. Posteriorly, the fins coalesce to
form oronasal membranes that eventually degrade by E12.5 resulting in the
formation of choanae, also called the posterior nasal aperture (Jiang et al., 2006;
Dupe et al., 2003). The process of oronasal membrane degeneration during choanae
development in mouse is depicted in Figure 1.12. Choanae is defined as the opening
between the nasal cavity and the nasopharynx therefore permitting air flow between
these structures. Though the choanae in human is located more posteriorly than the
choanae in mouse, initial formation during embryonic development is similar
between the two (Moore and Persaud, 2003). It was shown that the fusing epithelial
cells between the medial and lateral nasal processes expressed activated Caspase-3
suggesting that apoptosis plays an important role at least in lip fusion process (Jiang
et al., 2006).
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Figure 1.12 Development of the choanae in mouse
At E11.0, choanal pit is unperforated (A and B). At E11.5, interstitial gaps appear in
the oronasal membrane (C and D) that enlarge and rupture by E12.5 (E and F).
Complete opening of choanae is established by E13.5 (G and H). Arrows in A, C, G
and H indicate choanae and rugae are numbered (H). Double arrows in E indicate
oronasal grooves. l, lip; ln, lateral nasal process; md, mandibular process; mn,
medial nasal process; mx, maxillary process; n, nasal canal; p, primary palate; r,
roof of the stomodeum; s, secondary palate; tr, tectal ridge (Tamarin, 1982). The
figure is not shown due to copyright issues.
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1.6.2 Choanal atresia
Choanal atresia is a congenital craniofacial disorder characterised by narrowing or
blockage of the posterior nasal aperture by bony or soft membranous tissue that can
manifest unilaterally or bilaterally, which impairs or blocks air passage through the
nasal cavity (Feuerstein et al., 1980; Rizzo et al., 1989; Ramsden et al., 2009).
Computed tomography scan of the paranasal sinuses and skull base have
demonstrated narrowing of posterior nasal cavity, an enlargement of the posterior
portion of the vomer and occurrence of stenosis in the anterior nasal cavity
associated with choanal atresia (Slovis et al., 1985; Cheung and Prince, 2001; Aslan
et al., 2009). It affects one in 5,000-8,000 live births (Ramsden et al., 2009; Krespi
et al., 1987; Nemechek and Amedee, 1994). Bilateral choanal atresia can be life
threatening after birth because babies are obligate nasal breathers, requiring airway
maintenance by oral airway or intubation. About half of the patients with choanal
atresia also have associated anomalies (i.e. syndromic form) as in CHARGE
syndrome (Coloboma, Heart defects, Atresia of the nasal choanae, Retardation of
growth, Genital urinary abnormalities, Ear abnormalities and deafness) where
mutations in CHD7 gene account for most cases (Vissers et al., 2004; Hall, 1979),
and craniosynostosis syndromes associated with FGFR2 mutations including
Crouzon, Apert, Pfeiffer, and Antley-Bixler syndromes (Freng, 1978; Burrow et al.,
2009). Normally, the disorder is surgically treated by perforating the atresia to
establish a nasopharyngeal passage.
The four classical theories that explain the etiology of choanal atresia are:
persistence of the buccopharyngeal membrane from the foregut, abnormal
persistence or location of mesoderm forming adhesions in the nasochoanal region,
abnormal persistence of the nasobuccal membrane of Hochstetter, misdirection of
neural crest cell migration and subsequent mesodermal flow (Flake and Ferguson,
1964; Hengerer and Strome, 1982). Although the pathogenesis remains largely
unknown, recent molecular and genetic studies have advanced our understanding of
the disorder as well as shed light to its pathogenesis. For example, the Chd7 mutant
mice are a good model for CHARGE syndrome (Bosman et al., 2005). Choanal
atresia is found along with other congenital anomalies including inner ear
malformations, eye and genital abnormalities, cardiovascular defects and cleft
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palate that mimic the features of CHARGE syndrome. Raldh3 null mice also
develop choanal atresia (Dupe et al., 2003). Retinoic acid synthesis is suppressed in
this mouse line but maternal administration of retinoic acid prevented the phenotype.
They observed persistence of Fgf8 expression in the nasal fins in the null mice
which may have accounted for the occurrence of choanal atresia (Dupe et al., 2003).
We have also observed choanal atresia in Tbx22 null mice, which is
morphologically very similar to that seen in Chd7 and Raldh3 null mice, and is
further detailed in 1.8.2.
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1.7 T-box family of transcription factors
Brachyury (or T, for short tail) mouse mutant was first described in 1927
(Dobrovolskaia-Zavadskaia, 1927). Homozygous mutant mice exhibited embryonic
lethality while heterozygous had truncated tails. About 60 years later, the T gene
was eventually cloned and found to encode a protein of 436 amino acids that was
localised into the nucleus (Herrmann et al., 1990; Schulte-Merker et al., 1992). This
was accompanied by the finding that the T gene was in fact expressed in early
mesoderm which became restricted to the notochord, the tissues most affected by
the T mutation in mice (Wilkinson et al., 1990). Since then, more than 50 members
of the same protein family, that all share a highly conserved DNA binding domain
called the T-box domain, have been identified throughout metazoan species. In
mammals, 17 T-box genes are present, which can be categorised into 5 subfamilies;
Brachyury/T, Tbx1, Tbx2, Tbx6 and T-brain 1 (Tbr1) (Figure 1.13) (Naiche et al.,
2005). Genes in each subfamily are thought to have arisen as a result of
chromosomal duplication and cluster dispersion of a common ancestral gene during
evolution (Agulnik et al., 1996; Minguillon and Logan, 2003). For that reason,
some genes are expressed in overlapping regions and in some cases they are
functionally redundant. Recent advances in molecular biology techniques and the
use of spontaneous and targeted mutations in model organisms have suggested
important roles of T-box genes in early development, which is further underscored
by the association of specific human disorders with most of the T-box genes as
described in 1.7.2.
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Figure 1.13 Phylogenetic tree of the T-box gene family of transcription factors
Schematic diagram showing a phylogenetic tree of the T-box family members
found in vertebrates. All are present in mammals except the zebrafish Drtbx6 and
Drtbx16 (Naiche et al., 2005). The figure is not shown due to copyright issues.
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1.7.1 Properties of T-box transcription factors
1.7.1.1 T-box proteins and DNA binding specificity
T-box proteins are known to act as transcription factors, with the conserved ~180
amino acid T-box DNA binding domain being involved in DNA binding and
dimerisation. The T-box binding element (TBE) to which they preferentially bind
was first demonstrated by the high affinity of Brachyury to a 20 base pair
palindromic sequence T(G/C)ACACCTAGGTGTGAAATT (Kispert and Herrmann,
1993). Brachyury binds as a dimer to this palindromic sequence, with each
Brachyury monomer binding to a T-half site (5’-AGGTGTGAAATT-3’)
(Papapetrou et al., 1997). X-ray crystallography demonstrated an interaction
between T-box domain and DNA where a dimer of T proteins appeared to bind to
the T-palindrome (Muller and Herrmann, 1997). The T-box domain required for
DNA binding is conserved in Brachyury homologues of other species such as
Xenopus and zebrafish. All of the other T-box proteins are thought to be capable of
binding to the T-palindrome with slightly different optimal DNA sequences or half
of the sequence, the T-half site as monomers (Ghosh et al., 2001; Lingbeek et al.,
2002; Tada and Smith, 2001). Sometimes the preference in vivo is for varying
numbers of T-half sites arranged in different spacing and orientations (Conlon et al.,
2001; Sinha et al., 2000).
1.7.1.2 Transcriptional regulation
Sequences in the N- and C-terminal domains flanking the T-box domain are more
divergent among family members. The N-terminus may interact with cofactors and
the C-terminus may act as transcriptional activator and/or repressor domain. For
example, activation domains are found in C-terminal domains of some T-box
proteins such as T and TBX5 (Zaragoza et al., 2004; Kispert et al., 1995). T has two
activation and two repression domains in its C-terminal domain. Reporter gene
expression experiments demonstrated that the protein worked as a transcriptional
activator and the two activation domains acted additively (Kispert et al., 1995).
TBX2 and TBX3 are known to repress transcription (Carreira et al., 1998; Habets et
al., 2002; Lingbeek et al., 2002). However, depending on context, TBX2 is shown
to be capable of both activating and repressing transcription (Paxton et al., 2002).
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Some target genes are regulated by T-box proteins without cofactors (Kusch et al.,
2002) but as with other transcription factors, many T-box proteins probably control
transcriptional regulation in concert with other factors including homeodomain
proteins (Bruneau et al., 2001; Hiroi et al., 2001; Lamolet et al., 2001), GATA zinc
finger proteins (Stennard et al., 2003) and LIM domain proteins (Krause et al.,
2004). For instance, T and TBX19 interact with the Pitx homeodomain proteins
(Lamolet et al., 2001), and TBX5 has been shown to interact with the homeodomain
protein NKX2-5 (Bruneau et al., 2001; Hiroi et al., 2001). TBX20 specifically and
directly interacts with GATA4 and GATA5 in the developing heart (Stennard et al.,
2003), and TBX4 and TBX5 interact with PDZ-LIM protein but they do so via
different LIM domain repeat (Krause et al., 2004). As there is little sequence
conservation outside the common T-box domain, interaction with these factors may
define target gene promoter specificity, and whether activation or repression is
induced.
1.7.2 T-box genes in development
Since the discovery of Brachyury, many other T-box family members have been
cloned and their spatiotemporal expression patterns examined. T-box genes are
expressed throughout embryonic development where they have biologically
important roles in the specification of primary germ layers to the cell fate
determination during organogenesis. Here, some of their functional roles in
embryonic development and associated human disorders are detailed.
1.7.2.1 The role of T-box genes in extraembryonic tissue development
and gastrulation
i) Some T-box genes are involved in extraembryonic tissue development
as well as germ layer specification during early embryonic development.
The role of T-box genes starts in trophectoderm which subsequently
forms placental structures. In normal mouse trophoblast development,
the expression of Eomesodermin is upregulated but the cells show
defects in proliferation and uterine implantation in the absence of
Eomesodermin (Russ et al., 2000). Brachyury and Tbx4 are also known
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to have roles in extraembryonic tissue development. Brachyury
expression in the caudal primitive streak extends into an extraembryonic
outgrowth, the future umbilical cord, whose growth is stunted by a
deletion of Brachyury, although this may be a secondary effect to the
defective mesodermal proliferation (Beddington et al., 1992). Tbx4 is
also required for extraembryonic mesodermal outgrowth, causing
allantois defects such as disruption of vasculogenesis and failure to
undergo morphological changes when mutated (Naiche and Papaioannou,
2003).
ii) During gastrulation, the primary germ layers are arranged through the
gradual movement of presumptive mesoderm and endoderm cells. This
creates a primitive streak from which mesodermal cells migrate and
subsequently form structures such as notochord and somites
(Beddington, 1982; Tam and Beddington, 1992). Many T-box genes are
known to be involved in the process of mesoderm specification and
patterning. Brachyury and Eomesodermin in mouse, Xbra,
Xeomesodermin and XvegT in Xenopus, no tail, spadetail, eomesodermin
and Tbx6 in zebrafish are important in induction, formation and
patterning of mesoderm (Reviewed in Showell et al., 2004). Brachyury
homozygous mutant mice display loss of the posterior mesoderm
(Gluecksohn-Schoenheimer, 1944; Gluecksohn-Schoenheimer, 1938).
The importance of Eomesodermin in mesoderm patterning come from
chimeric embryos whose extraembryonic tissues are predominantly wild
type but embryo itself is composed of Eomesodermin mutant cells (Russ
et al., 2000). These chimeric embryos thereby bypass embryonic death
after implantation but die shortly after due to a failure in the formation
of mesodermal layer (Russ et al., 2000). In terms of gene hierarchy,
expression of Eomesodemin is known to precede that of Brachyury.
Tbx6 is required for somite formation as well as patterning as shown by
the targeted disruption of the gene which resulted in a replacement of
caudal somites with ectopic neural tubes (Chapman and Papaioannou,
1998).
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1.7.2.2 The role of T-box genes in organogenesis and human
disorders
The involvement of T-box genes in organogenesis is demonstrated by targeted
mutagenesis in mice; Tbx1, Tbx2, Tbx5 and Tbx20 for cardiac development, Tbx4
and Tbx5 for limb development, Tbx19/Tpit for pituitary development and Tbx1 and
Tbx22 for craniofacial development. In fact, some of the T-box genes are also
linked to several human disorders including DiGeorge syndrome, Ulnar-mammary
syndrome, Holt-Oram syndrome, ACTH deficiency, and orofacial clefts. Here, the
role of T-box genes in organogenesis and the key features of human disorders
caused by mutations in certain T-box genes are detailed.
i) In the developing heart, Tbx1, Tbx2, Tbx3, Tbx5, Tbx18 and Tbx20 are
expressed in specific regions with some overlap (Papaioannou, 2001).
Among these genes, null mutations in Tbx1, Tbx2, Tbx5, and Tbx20
cause cardiac defects whereas mutations in Tbx3 and Tbx18 do not result
in heart defects in mice. A role of Tbx1 in cardiogenesis is suggested in
proliferation of cardiac progenitor cells and the null mice have defects in
anterior cardiac development (Jerome and Papaioannou, 2001; Lindsay
et al., 2001). Homozygous mutant mice are neonatal lethal and also
display craniofacial, glandular and vascular defects phenocopying
virtually all features of the DiGeorge syndrome (OMIM 188400). The
phenotype is less penetrant in the viable Tbx1 heterozygous mice which
display thymus and vascular abnormalities (Jerome and Papaioannou,
2001; Lindsay et al., 2001). In human, DiGeorge syndrome is associated
with translocations and deletions of 22q11 region among which, TBX1 is
identified as a major contributor (Baldini, 2003). It affects about 1 in
4,000 live births and the phenotype can be highly variable between
patients. The main clinical features include a congenital heart defect,
hypoplastic or aplastic thymus and parathyroids, craniofacial defects
including cleft palate, ear and mandible development, and in most cases
learning difficulties and behavioural problems (Ryan et al., 1997;
Wilson et al., 1993; Scambler, 2000). The penetrance may be affected by
variation in genetic backgrounds including specific modifier genes along
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with non-genetic effects mediated by environmental factors. Tbx5 null
mice show developmental defects in the posterior heart structure
(Bruneau et al., 2001). Homozygous mutant mice are embryonic lethal
due to severe heart malformations and heterozygotes also show heart
abnormalities and forelimb defects with reduced viability (Bruneau et al.,
1999; Bruneau et al., 2001). The human Holt-Oram syndrome (OMIM
142900) is caused by mutations in TBX5 and is characterised by clinical
features that include congenital heart and limb abnormalities (Basson et
al., 1997; Li et al., 1997). It is a rare syndrome affecting about 1 in
100,000 live births. TBX20 mutations are also associated with congenital
heart disease (Kirk et al., 2007; Posch et al., 2010). Similarly, loss of
Tbx20 results in heart abnormalities in mice (Stennard et al., 2005).
There are no known syndromes associated with TBX2 in human
although a microdeletion at 17q23.1q23.2, which includes TBX2 and
TBX4 has been associated with individuals who have clinical features
such as heart and limb abnormalities (Ballif et al., 2010). Recent
association studies such as this, further underscore the importance of T-
box genes in the pathology of human birth defects. It has also been
demonstrated that mouse mutants for Tbx2 develop heart abnormalities,
implying biological importance of this gene in cardiogenesis (Harrelson
et al., 2004; Stennard et al., 2005). Conversely, although both Tbx3 and
Tbx18 are expressed in the mouse heart during development, mutations
for either gene do not result in heart defects in mice. In fact, Tbx3 null
mice rather phenocopy human Ulnar-mammary syndrome (Davenport et
al., 2003), and Tbx18 null mice exhibit vertebral malformations (Bussen
et al., 2004) but no human disorder has been linked to TBX18.
ii) Tbx2, Tbx3, Tbx4, Tbx5 and Tbx15 are all expressed during limb
development (Agulnik et al., 1998; Gibson-Brown et al., 1996). Tbx2
and Tbx3 are expressed in the limb mesenchyme along the anterior and
posterior margins of both developing forelimbs and hindlimbs. Tbx4 and
Tbx5 are expressed in the mesenchyme of hindlimbs and forelimbs
(Gibson-Brown et al., 1996). Homozygous mutant mice for Tbx3 exhibit
limb, mammary gland and yolk sac defects and embryonic lethal, and
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heterozygous mice have hypoplastic mammary glands and abnormal
external genitalia, phenocopying the Ulnar-mammary syndrome (OMIM
181450) (Davenport et al., 2003; Jerome-Majewska et al., 2005). Ulnar-
mammary syndrome in human is caused by mutations in TBX3
(Bamshad et al., 1997). The clinical features include limb abnormalities
ranging from hypoplasia of the terminal phalanxof the fifth digit to the
absence of forearm and hand, hypoplastic mammary glands and
abnormal external genitalia (Bamshad et al., 1996). Mutations in TBX4
cause small patella syndrome in human (OMIM 147891) (Bongers et al.,
2004) and the null mice also exhibit hindlimb defects (Naiche and
Papaioannou, 2003). Mutations in TBX5 are linked to Holt-Oram
syndrome which is characterised by heart and hand defects as mentioned
above (Basson et al., 1997). The null mice exhibit lack of forelimb bud
formation as well as heart defects (Agarwal et al., 2003). Tbx15 null
mice have defects in limb skeletal elements as well as the skeleton of the
vertebral column and head due to reduced proliferation and smaller
mesenchymal condensations (Singh et al., 2005). Recently, mutations in
TBX15 are identified in individuals with Cousin syndrome (OMIM
260660) which is a complex cranial, cervical, auricular and skeletal
malformation syndrome with scapular and pelvic hypoplasia
recapitulating the mouse dysmorphic phenotype (Lausch et al., 2008).
Homozygous Tbx2 null mice develop heart and limb defects (Harrelson
et al., 2004) but no mutations have been reported for TBX2 that cause
human disorders other than a link to 17q23.1q23.2 microdeletion (Ballif
et al., 2010) as mentioned above.
iii) In pituitary gland, Tbx19/Tpit is expressed in the corticotrophs and
melanotrophs of the anterior and intermediate lobes which express pro-
opiomelanocortin (POMC). It is required for the differentiation of
corticotrophs and melanotrophs, and with the homeodomain protein
Pitx1 it activates POMC expression (Lamolet et al., 2001). In human and
mouse, loss of function mutations in TPIT/Tpit result in early onset of
adrenocorticotrophic hormone (ACTH) deficiency (OMIM 201400) due
to an absence of POMC (Pulichino et al., 2003).
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iv) Tbx1 is expressed in the anterior mesoderm and pharyngeal endoderm
during craniofacial development (Chapman et al., 1996). Tbx1 is known
to regulate and be regulated by Fgf8, Fgf10, Foxa2 and Shh, and both
human and mouse lacking functional TBX1/Tbx1 develop multiple
craniofacial defects in addition to heart defects (Jerome and
Papaioannou, 2001). Craniofacial defects caused by mutations in
TBX22/Tbx22 are detailed in 1.4.3.6 and 1.8.2.
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1.8 The role of TBX22 in craniofacial development
1.8.1 Using mutant mice to model human disease
Model organisms are non-human animal species that are widely used in research to
model human disease in order to better understand potential causes and treatments.
Model organisms for biomedical research defined by National Institutes of Health
(NIH) include several animal species of which genomic data are extensively studied.
They are mouse (Mus musculus) and rat (Rattus norvegicus) for mammalian models
as well as non-mammalian models such as zebrafish (Danio rerio), frog (Xenopus
laevi) and chicken (Gallus gallus).
Among these, mouse has become an essential tool in medical and biological
research. They are small in size; adult mice weigh 25-40g on average so that they
can be housed efficiently. They have a short generation time; a gestation period of
about 3 weeks, and they reach sexual maturity at 6-8 weeks. The litter size is
relatively large; ranging from 6 to 12 or even more depending on strains. Also,
pregnancy can be timed accurately by observing deposition of a copulatory plug
upon mating.
Mouse and human diverged from a common ancestor about 65 million years ago,
yet approximately 80% of mouse genes have at least one ortholog in the human
genome, often with high degree of sequence similarity between them (Waterston et
al., 2002; Lander et al., 2001). Most importantly, the technology of genetic
manipulation is well established for mouse embryonic stem cells. This makes the
mouse one of the most popular model organisms in terms of modelling human
disease and studying human gene function in vivo.
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1.8.2 Tbx22 null mice
Mice deficient for Tbx22 were recently generated using standard gene targeting
techniques (Pauws et al., 2009a). The Cre-lox recombination system was employed
in this study principally to avoid postnatal lethality, which usually occurs with the
cleft palate phenotype. Constitutive knockout of a gene resulting in cleft palate may
therefore not allow for future generation and maintenance of the transgenic line.
Since the aim was to provide a model to allow a more detailed investigation of the
pathogenesis that might underpin human CPX, a floxed line was first created by
introducing loxP sites flanking the first three exons of Tbx22. By then breeding to a
β-actin-Cre deleter strain (or other tissue specific Cre), the first three coding exons,
which include the start codon, nuclear localisation signal and a part of the T-box
domain, can be removed as desired. This essentially created a conditional Tbx22
null allele. In the floxed Tbx22 strain, the Neo cassette, which was used for
selection in the ES cells, was located outside of the two LoxP sites. Therefore on
recombination, it was still retained in the Tbx22null genome. In later studies, it was
determined that many male null animals not only survived but were fertile and
tended to be used for the majority of the breeding startegies. This allowed greater
efficiency in numbers of embryos with the desired genotype.
Following birth, about half of all homozygous null mice die post-natally. Those that
were found dying at P0 struggled to breathe and were unable to suckle milk,
resulting in their stomach and intestine being filled with air (Pauws et al., 2009a).
Although this is a classic symptom of cleft palate in mice, only a small proportion
of null mice (6%) were found to have an overt cleft palate, while the majority of
mutants had palatal shelves fused normally, along the entire length. A detailed
examination of E18.5 embryos was performed by various methods including
hematoxylin and eosin staining, skeletal preparations and computed tomography
(CT) scanning (Figure 1.14). This revealed that palatine bone formation was
severely reduced in the posterior hard palate of the null mice. In addition, the vomer,
which supports the nasal cartilage and the secondary palate, was also reduced in
size in the null mice. According to the computed tomography scan measurements,
the palatine bone was reduced by 68% and the vomer by 74% in size. The under-
developed palatal bone caused a semi translucent region in the mid palate region
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which appeared as a notch, similar to that often described in human babies with
submucous cleft palate. These mice therefore exhibit the entire spectrum of both the
overt and submucous cleft palate phenotypes observed in human CPX patients.
Preliminary analysis of bone formation showed that alkaline phosphatase activity
was lower in the null palate compared to the wild type at E15.5. This stage is after
the completion of the fusion process and at the onset of ossification within the
presumptive future hard palate. In the null palate, mesenchymal condensation was
observed but osteoblast activity was reduced, indicating a significant delay in
differentiation and/or maturation of osteoblasts leading to impaired
intramembranous ossification in the absence of TBX22.
As described above, ankyloglossia is frequently observed in CPX patients. In the
case of Tbx22 null mice, the tongue was attached to the mandible more anteriorly
but did not extend to the tip of the tongue, indicating a mild form of ankyloglossia
(Figure 1.15). In addition, the null mice were found to have a persistent oronasal
membrane at the site of the medial nasal prominence (Figure 1.15), which is
equivalent to choanal atresia in humans. The oronasal membrane is a transient
structure which disappears during development resulting in the formation of
choanae. It was suggested that choanal atresia may have been the main cause of
postnasal lethality because this phenotype was present in the null mice that died but
absent in those that survived. This has not been reported as a feature of CPX but is
well known in other syndromic conditions involving clefts such as CHARGE
syndrome (Vissers et al., 2004).
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Figure 1.14 Posterior palatal bone is reduced in Tbx22 null mice
Skeletal preparations with Alizarin Red (bone) and Alcian Blue (cartilage) (a1-3,
a5-7) showed reduced palatine bones (brack arrowhead, a2) and the vomer (asterisk,
a7) but not the maxillary palatal bones (white arrowhead, a2) in Tbx22 null mice at
E18.5. Reduced posterior palatal bones in the null mice compared to the wt were
also detected by hematoxylin and eosin staining (arrows, a4 and a8) and computed
tomography scan (b1-6). BS, basisphenoid; BO, basoccipital; Ma, mandible; PS,
presphenoid; T, tongue; A, anterior; P, posterior (Pauws et al., 2009a).
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Figure 1.15 Ankyloglossia and choanal atresia in Tbx22 null mice
In the null mice, the tongue is attached more anteriorly than in the wt indicating
ankyloglossia (arrowheads, a2, a3, a5 and a6). The oronasal membrane persisted in
the null mice indicating choanal atresia (arrows, b3, b5 and b6). Some had more
severe atresia where the entire length of choanae was blocked by oronasal
membrane (b3 and b6) at E15.5. Asterisks in b3 and b6 indicate overt cleft palate.
M, Meckel’s cartilage; NS, nasal septum; Pa, palate; PP, primary palate; T, tongue;
A, anterior; P, posterior (Pauws et al., 2009a).
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1.8.3 The role of TBX22 in craniofacial development
TBX22 was identified as a causative gene for CPX by positional cloning (Braybrook
et al., 2001), a method which provides no insight into understanding of the
regulation and function of the gene. Since its discovery, further clues have been
revealed regarding its role in craniofacial development.
There are only a couple of studies reported in which the expression of Tbx22 has
been altered as a consequence of knocking down other craniofacial expressed genes
in mice. In 36 Pub mutant mouse palatal shelves, the expression of Tbx22 was
downregulated posteriorly at E14.5 (Welsh et al., 2007). The mutant mice
essentially lacked the FGF signalling antagonist Spry2 and as a consequence they
developed overt cleft palate. This study indicates the importance of Tbx22
expression for posterior palatal growth. The fact that its expression was reduced due
to the lack of Spry2 also implies that FGF signalling somehow affects the
expression of Tbx22. However, it is not clear from this study if the reduced Tbx22
expression was a direct consequence of an increased FGF signalling or if its
expression was affected by elevated FGF responsive transcription factors such as
Etv5, Msx1, Barx1 and Shh.
Meningioma 1 (Mn1) null mice also develop cleft palate (Meester-Smoor et al.,
2005) and are informative for Tbx22 but for different reasons. MN1 was originally
identified as a gene disrupted in a benign brain tumor called meningioma (Lekanne
Deprez et al., 1995). However, instead of having higher incidence of tumor
formation, Mn1 null mice develop severe defects of craniofacial bones including
cleft palate (Meester-Smoor et al., 2005). Further investigation revealed no
significant differences in cleft susceptible genes including Fgf10, Fgfr2, Osr2, Shh,
Ptch, Pax9, Shox2 and Tgfβ3, although a downregulation of Tbx22 in the mutant
E13.5 palatal shelves was noted (Liu et al., 2008). The regulation of Tbx22 by Mn1
was then confirmed by an in vitro reporter assay. In the case of Mn1 null mice, the
cell proliferation rate was reduced in the growing palatal shelves, which is probably
what caused the cleft phenotype at the cellular level. Interestingly, Mn1 is reported
to have an important regulatory role in proliferation, differentiation and maturation
of osteoblasts, both in vitro and in vivo (Zhang et al., 2009). These recent findings,
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as well as a role in the bone differentiation and/or maturation defects observed in
Tbx22 null mice (Pauws et al., 2009a), strongly suggest that TBX22 is an essential
component in the osteogenesis pathway in palatal shelves. However, this idea fails
to explain other pathological phenotypes (i.e. ankyloglossia and choanal atresia) in
Tbx22 null mice since oronasal membrane and frenulum are not osteoblastic cells,
making it difficult to speculate on other aspects of its function during development.
More recently, two independent groups reported the regulation of Tbx22 by FGF
and BMP signalling in chick (Higashihori et al., 2010; Fuchs et al., 2010) and
mouse (Fuchs et al., 2010) embryos. Both groups used FGF and BMP soaked beads
as well as the FGF antagonist SU5402 and the BMP anatagonist Noggin to
investigate how expression of Tbx22 is altered in the facial region. Higashihori et al.
(2010) demonstrated that Tbx22 failed to upregulate or was reduced in the chick
frontonasal mass at stages 15 and 24 respectively, when injected with SU5402.
Implantation of FGF2 and FGF8 soaked beads at stage 24 led to upregulation of
Tbx22. They also showed that implantation of BMP4 and BMP7 soaked beads in
the chick frontonasal mass at stage 24 repressed Tbx22 while treatment with Noggin
beads strongly induced its expression. In addition, overexpression of human TBX22
using a viral expression construct resulted in reduced cell proliferation in the chick
frontonasal mass and went on to induce a cleft of the lip. This suggested a
potentially down-regulatory role for TBX22 in cell proliferation. As a consequence,
the size of the frontonasal mass, maxillary and mandibular bones were all reduced
with smaller ossification centres. Moreover, Dlx5 and Msx2 levels were reduced in
the chick frontonasal mass following overexpression with human TBX22. This
suggested that TBX22 may act as a repressor of these genes. A very similar study
was also reported by Fuchs et al. (2010). Here they extended the analysis of Tbx22
regulation by FGF and BMP signalling in the facial mesenchyme by looking in
mouse embryos as well as the chick. The results were remarkably similar to those
reported by Higashihori et al. (2010). Interestingly, Fuchs et al. (2010) also showed
that although expression of Tbx22 was altered by addition of SU5402 or FGF8 in
the chick and mouse maxillary explants at stage 23 and E10.5 respectively, its
expression became independent of FGF signalling later at stage 26 and E12.5 in the
palatal explants. Taken together, these studies demonstrated a positive regulation of
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Tbx22 by FGF signalling during early facial development and a negative regulation
by BMP signalling later on.
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1.9 Aims of the study
It has previously been shown that mutations in TBX22 are a frequent cause of X-
linked cleft palate and ankyloglossia (CPX) (Braybrook et al., 2001; Braybrook et
al., 2002; Chaabouni et al., 2005; Marcano et al., 2004). In vitro analysis has shown
that TBX22 can function as a transcriptional repressor, which requires post-
transcriptional modification by a small ubiquitin-like modifier (SUMO-1) for its
action (Andreou et al., 2007). Thus far, little is known about the cellular and
biochemical mechanisms involving TBX22 that lead to the disease phenotype.
Identification of candidate genes that function in the same molecular pathway as
TBX22 will provide important insights into the occurrence of CPX as well as
normal craniofacial development. Thus, this project aims to better understand the
molecular and cellular role of TBX22 and the downstream effects of its loss of
function.
As a starting point it is decided to perform whole mount and/or section in situ
hybridisation for Tbx22 on wt mouse embryos ranging between E9.5 to E15.5.
Previously there has only been limited data covering the entire period of
palatogenesis or craniofacial morphogenesis and this data would provide a
comprehensive reference for the following experiments.
The next aim of this study is to identify genes that are differentially expressed in the
presence and absence of Tbx22. This would help to elucidate the transcriptional
events and regulatory networks involved, as well as reveal potential new candidate
genes for cleft palate in humans. For this purpose, it was intended to perform a
comparative gene expression analysis using a microarray between wild type and
Tbx22 null mice. Tbx22 null mice display overt or submucous cleft palate and
ankyloglossia with an additional feature of choanal atresia (Pauws et al., 2009a).
These pathological phenotypes essentially recapitulate human CPX, thus they serve
as a good model to investigate the effects caused by a loss of Tbx22. Based on the
microarray results, genes of interest will be selected for independent verification by
real-time PCR. These candidate gene(s) whose expression is altered due to a lack of
Tbx22 are considered to be downstream targets and will be further investigated by
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functional analysis such as luciferase reporter assays and chromatin
immunoprecipitation.
In addition, it is intended to investigate the molecular networks and mechanisms
underlying pathogenic phenotypes and especially the submucous cleft palate
observed in Tbx22 null mice. In the developing palate of null animals, a deficiency
or delay in palatine bone formation was observed. This was suggested to result from
defective differentiation and/or maturation of osteoblasts. However, recent studies
in different experimental systems have demonstrated a role for TBX22 in cell
proliferation (Higashihori et al., 2010). In the null palate, although there is a bone
deficiency, at least some osteoblasts do mature to become bone forming cells
followed by mineralisation. Thus, it is possible that cell proliferation may also be
down regulated in Tbx22 null mice. In addition, the choanal atresia phenotype will
be examined during early choanae development by histological staining and in situ
hybridisation. These studies will contribute towards a better understanding of
TBX22 function in craniofacial development.
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CHAPTER 2: MATERIALS AND METHODS
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2 MATERIALS AND METHODS
2.1 Materials
Chemicals and Solvents
Acetic anhydride BDH
Agarose Invitrogen
Ammonium persulphate Sigma-Aldrich
Ampicillin Sigma-Aldrich
BCIP Roche Applied Science
Bovine serum albumin Sigma-Aldrich
Bradford reagent Sigma-Aldrich
Bromophenol blue Sigma-Aldrich
Chloroform BDH
Denhardt's solution 50× concentrate for molecular biology,
liquid
Sigma-Aldrich
Deoxyribonucleic acid, low molecular weight, from salmon
sperm
Sigma-Aldrich
Dextran sulfate Sodium salt from Leuconostoc spp. Sigma-Aldrich
Dietylpyrocarbonate Sigma-Aldrich
Dried skimmed milk Marvel
DTT Sigma-Aldrich
EDTA Sigma-Aldrich
Ethanol Hayman Ltd
Formaldehyde Sigma-Aldrich
Formamide Sigma-Aldrich
Glutaraldehyde Sigma-Aldrich
Glycerol BDH
Heparin Sigma-Aldrich
Hydrochloric acid Fisher Scientific
Hydrogen peroxide Sigma-Aldrich
Isopropanol BDH
LB Agar Invitrogen
LB base Invitrogen
Levamisole Sigma-Aldrich
Magnesium chloride Fisher Scientific
Methanol Hayman Ltd
NBT Roche Applied Science
Paraformaldehyde Sigma-Aldrich
PBS tablets Oxoid
Phenol chroloform isoamyl alcohol Fisher Scientific
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Polyvinyl alcohol VWR
Potassium chloride Sigma-Aldrich
RNaseA Invitrogen
Sodium acetate Sigma-Aldrich
Sodium bicarbonate Sigma-Aldrich
Sodium chloride Fisher Scientific
Sodium citrate Sigma-Aldrich
Sodium deoxycholate BDH
Sodium dodecyl sulfate Sigma-Aldrich
TEMED Sigma-Aldrich
TRI Reagent Sigma-Aldrich
Triethanolamine Sigma-Aldrich
Tris Sigma-Aldrich
Triton X-100 Sigma-Aldrich
Tween-20 Sigma-Aldrich
β-mercaptoethanol Sigma-Aldrich
Enzymes
Antarctic phosphatase New England Biolabs
GoTaq® Hot Start Polymerase Promega
M-MLV Reverse Transcriptase Promega
Protease inhibitors Roche Diagnostics
Proteinase K Roche Diagnostics
Recombinant RNasin® Ribonuclease Inhibitor Promega
Restriction endonucleases Promega, New England Biolabs
RQ1 RNase-Free DNase Promega
T4 DNA ligase BIOLINE
TaqMan® Fast Universal Master Mix (2X), No
AmpErase® UNG
Applied Biosystems
Bacterial strains
Fusion-BlueTM competent cells Clontech
XL1-Blue supercompetent cells Stratagene
Cell culture materials
Dimethyl sufoxide Sigma-Aldrich
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Dulbecco’s Modified Eagle’s Medium - high glucose Sigma-Aldrich
Fetal bovine serum Clontech
FuGENE 6 Transfection Reagent Roche Applied Science
L-glutamine Gibco
MEM Non Essential Amino Acids (100X), liquid Gibco
Penicillin-Streptomycin, liquid Gibco
Phosphate buffered saline Gibco
Tissue culture plastic ware Corning
Trypan blue Sigma-Aldrich
Trypsin, 0.5% (10x) with EDTA 4Na, liquid Gibco
Antibodies
Anti-digoxygenin, Fab fragments Roche Applied Science
Anti-phospho-Histone H3 (Ser10) Upstate
Anti-V5 Invitrogen
Cleaved caspase-3 Cell Signaling
Polyclonal goat anti-rabbit immunoglobulins
biotinylated
DAKO
Rabbit anti-mouse HRP DAKO
Streptavidin, Alexa Fluor® 555 conjugate Invitrogen
Histology
Cover slips BDH
Embedding molds Thermo Scientific
Histoclear National Diagnostics
Paraffin wax Raymond A Lamb
SuperFrost Plus glass slides VWR
Vectamount H-5000 Vector
VECTASHIELD mounting medium with DAPI Vector Laboratories
Miscellaneous
30% Acrylamide/Bis solution BIO-RAD
Amersham ECL Plus Western Blotting Detection
System
GE Healthcare Life Sciences
BigDye® Terminator v3.1 Cycle Sequencing RR-100 Applied Biosystems
BioMax Light Film Kodak
Bioruptor Diagenode
CHROMA SPIN-100 DEPC-H2O column Clontech
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Coelenterazin Invitrogen
DIG RNA Labeling Kit (SP6/T7) Roche Applied Science
dNTPs Promega
GeneChip® Mouse Gene 1.0 ST Array Affymetrix
Goat serum Sigma-Aldrich
HiSpeed Plasmid Maxi Kit QIAGEN
HiSpeed Plasmid Midi Kit QIAGEN
HyperLadders BIOLONE
PCR Nucleotide Mix Promega
Precision Plus Protein Standards BIO-RAD
Protein G Thermo Fisher Scientific
PVDF membrane Millipore
QIAprep Spin Miniprep Kit QIAGEN
QIAquick Gel Extraction Kit QIAGEN
QIAquick PCR Purification Kit QIAGEN
QuikChange site-directed mutagenesis kit Stratagene
Random primers Promega
Ribonucleic acid, transfer from Baker's yeast (S.
cerevisiae) buffered aqueous solution
Sigma-Aldrich
Sheep serum Sigma-Aldrich
Steady Lite Plus PerkinElmer
Trans-Blot SD Semi-Dry Transfer Cell BIO-RAD
Plamids
pcDNA3.1.V5/His Invitrogen
pcDNA3.1.TBX22.V5/His A. Andreou, our laboratory
pcDNA3.1.TBX22(N264Y).V5/His A. Andreou, our laboratory
pEGFP-N2 Clontech
pGEM®-T Easy Promega
pGL3-Basic Promega
pRL-CMV Promega
In situ probes
Bmp4 B. Hogan, Duke University, USA
Msx1 P. Sharpe, University of Minnesota Duluth, USA
Msx2 P. Sharpe, University of Minnesota Duluth, USA
Pax9 A. Neubuser, University of Freiburg, Germany
Snail M. Sefton and A. Nieto, Instituto Cajal, Spain
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Tgfβ3 R. Akhurst, University of California, San Francisco, USA
Osr1 A. Andreou, our laboratory
Tbx22 E. Pauws, our laboratory
Cyclin D2 R. Jiang, University of Rochester, USA
Fgf10 R. Jiang, University of Rochester, USA
Fgfr2 R. Jiang, University of Rochester, USA
TaqMan® Gene Expression Assays and
TaqMan® Endogenous Controls Assay ID or Part Number
Acta1 Mm00808218_g1
Casq2 Mm00486742_m1
Cdkn1a (p21) Mm00432448_m1
Ctsk Mm00484039_m1
Myf5 Mm00435125_m1
Myh3 Mm01332463_m1
MyoD Mm00440387_m1
Myog Mm00446194_m1
Osterix Mm00504574_m1
Runx2 Mm01269515_mH
Eukaryotic 18S rRNA Endogenous Control 4352930E
Mouse GAPD (GAPDH) Endogenous Control 4352932E
Oligonucleotides Sequence 5’ to 3’
Tbx22_F CAGCTTCCAAAACAGTGGAG
Tbx22_R CTTCTAGGGACAGTCAACAG
Tbx22_R2 CAATAGCAGCCAGTCCCTTC
Smc_F TGAAGCTTTTGGCTTTGAG
Smc_R CCGCTGCCAAATTCTTTGG
MyoD_F_-683 ATTCTCGAGACCCGGAGTTTGAGCAGAAT
MyoD_R_+115 ATTCTCGAGACAAAGGTTCTGTGGGTTGG
FseqpGL3_RVprimer3 CTAGCAAAATAGGCTGTCCC
RseqpGL3_GLprimer2 CTTTATGTTTTTGGCGTCTTCCA
sMyoD_C-511A/C-509A ATTTGTGCCAGGCTTGCTAA
ACTAGACCTTCTGAGTCTC
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asMyoD_C-511A/C-509A GAGACTCAGAAGGTCTAGTT
TAGCAAGCCTGGCACAAAT
MyoD_ChIP_F ATTCTCGAGTCCGAGTTTGGAGAGATTGG
MyoD_ChIP_R TGAGGAGTGAGACCGTGAAA
MyoD_insitu_F AGCACGCACACTTCCCTACT
MyoD_insitu_R AGGGCTCCAGAAAGTGACAA
Bmp2_insitu_F AGGCTGCCACAAAAGACACT
Bmp2_insitu_R GCCTGCGGTACAGATCTAGC
Bmp3_insitu_F ACAGCAGGACTTCGCTATGG
Bmp3_insitu_R GGGACCCTTTCCTCTGTTTC
Spry2_insitu_F ACATCGCTGGAAGAAGAGGA
Spry2_insitu_R CCTCTCACTGCAAACCACAA
Solutions
0.5 M EDTA 186.1 g EDTA dissolved in 800 ml H2O, bring the
pH to 8.0 with NaOH pellets, adjust the volume to 1
L with H2O
0.5 M HEPES 119.2 g HEPES dissolved in 800 ml H2O, adjust the
pH to 7.8 with NaOH peletts, adjust the volume to 1
L with H2O
1x PBS 10 PBS tablets dissolved in 1 L H2O
1 M Tris-HCl 121.1 g Tris base dissolved in 800 ml H2O, adjust to
desired pH with HCl, adjust the volume to 1 L with
H2O
1x TAE 40 mM Tris, 20 mM acetic acid, 1 mM EDTA
20% SDS 200 g SDS dissolved in 800 ml H2O, adjust the
volume to 1 L with H2O
20x SSC 175.3 g NaCl, 88.2 g sodium citrate in 800 ml H2O,
adjust the volume to 1 L with H2O
4% paraformaldehyde in PBS 20 g PFA dissolved in 400 ml DEPC water and 50 ml
10X PBS at 60ºC, adjust the volume to 500 ml with
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DEPC water
DEPC treated water 1 ml diethylpyrocarbonate in 1 L H2O, autoclaved
LB-agar 32 g LB agar dissolved in 1 L H2O, autoclaved
LB-broth 25 g LB base dissolved in 1 L H2O, autoclaved
Renilla buffer 5 ml 0.5 M HEPES pH 7.8, 400 µl 0.5 M EDTA
Renilla reagent 10 ng/µl coelenterazin in Renilla buffer
TE buffer 40 mM Tris-HCl pH 8.0, 1 mM EDTA pH 8.0
Water used in all experimental procedures was purified using a Millipore reverse
osmosis and MilliQ system. Water used for RNA analysis was treated with DEPC.
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2.2 Methods
2.2.1 General molecular biology techniques
2.2.1.1 Restriction digestion
DNA was digested with chosen restriction enzyme(s) and appropriate buffer at the
recommended optimal temperature for 1-2 hours, typically in a total volume of 20
µl. 10X BSA was also added to the reaction to facilitate digestion.
2.2.1.2 Gel extraction of DNA
QIAquick Gel Extraction Kit (QIAGEN) was used to extract DNA from agarose gel
slices according to the manufacturer’s instruction. Briefly, DNA bands were
excised under UV light following electrophoresis in a 0.8% agarose gel and
dissolved in three volumes of Buffer QG at 50ºC for 10 min. The sample was mixed
with one volume of isopropanol, applied to a QIAquick spin column and
centrifuged for 1 min at 13,000 rpm followed by washing with Buffer PE. The
DNA was eluted in 30 µl of Buffer EB and stored at -20ºC.
2.2.1.3 Ligation
Linearised vector and insert were combined at 1:1 to 3:1 molar ratio in a 10 µl
reaction mixture containing ligase buffer and T4 DNA ligase (BIOLINE) and
incubated overnight at 4ºC.
2.2.1.4 Transformation of chemically competent bacteria
Transformation by heat shock was performed using Fusion-BlueTM Competent Cells
(Clontech) according to the manufacturer’s instruction. 25 µl of cells were removed
from -80ºC freezer and thawed on ice. 1 µl of DNA solution was added and
incubated on ice for 5 min followed by heat shock for 30 sec at 42ºC, then
immediately placed on ice for 2 min. 250 µl of LB medium was added and
incubated at 37ºC for 1 hour while shaking at 180 rpm. Typically, 50-100 µl of
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transformed cells was spread on an LB agar plate containing appropriate selective
antibiotics (e.g. 100 µg/ml of Ampicillin) and incubated overnight at 37ºC. The next
day, single colonies were picked and expanded in LB in the presence of selective
antibiotics.
2.2.1.5 Mini, Midi and Maxiprep of DNA
Plasmid DNA from overnight cultures was purified using either QIAprep Spin
Miniprep Kit, HiSpeed Plasmid Midi or Maxi kit (QIAGEN), depending on the
amount of DNA required. The DNA purification procedure is based on alkaline
lysis of bacterial cells followed by adsorption of DNA onto silica membrane.
Briefly, appropriate amount of overnight cultures (1.5 ml for Mini, 50 ml for Midi
or 150 ml for Maxi) were centrifuged, resuspended in Buffer P1 containing 1 mg/ml
RNase A (250 µl for Mini, 6 ml for Midi or 10 ml for Maxi), lysed in Buffer P2
(250 µl for Mini, 6 ml for Midi or 10 ml for Maxi) and cell debris was precipitated
by adding chilled Buffer P3 (350 µl for Mini, 6 ml for Midi or 10 ml for Maxi).
Then for Miniprep, the supernatants were applied to the QIAprep spin column after
centrifuging for 10 min at 13,000 rpm and the column was washed twice, first by
adding 0.5 ml and then 0.75 ml of Buffer PB. The DNA was eluted in 50 µl Buffer
EB and stored at -20ºC. For Midi and Maxi, the lysate was filtered through the
QIAfilter Catridge and the supernatants were applied to the equilibrated HiSpeed
Midi or HiSpeed Maxi Tip, washed with Buffer QC (20 ml for Midi or 60 ml for
Maxi), and the DNA was eluted with Buffer QF (5 ml for Midi or 15 ml for Maxi).
After precipitation with isopropanol (3.5 ml for Midi or 10.5 ml for Maxi), the
DNA elute was filtered through QIAprecipitator Midi or Maxi Modules, washed
with 2 ml of 70% ethanol, eluted in 0.5 ml of Buffer TE and stored at -20ºC.
2.2.1.6 Extraction of total RNA from cells and tissues
Total RNA was extracted from cells and tissues using TRI Reagent (Sigma-Aldrich).
For cultured cells, semi-confluent cells in 6 well plates were harvested,
homogenised in 1 ml of TRI Reagent. For tissues, a pair of palatal shelves dissected
from individual mouse embryos was immediately homogenised in 0.5 ml of TRI
Reagent. Samples were incubated for 5 min at room temperature to ensure complete
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dissociation of nucleoprotein complexes. 0.2 ml of chloroform was added per ml of
Tri Reagent used and samples were shaken vigorously for 15 sec which were left at
room temperature for 10 min before centrifuging at 12,000 g for 15 min at 4ºC to
separate the mixture into 3 phases. A colourless upper phase contained RNA, and a
red organic phase and an interphase contained protein and DNA, respectively. For
RNA extraction, a colourless upper phase was carefully transferred and was
precipitated by adding 0.5 ml isopropanol per ml of TRI Reagent used, left for 5
min at room temperature and centrifuged at 12,000 g for 10 min at 4ºC. The RNA
pellet was washed with 1 ml of 75% ethanol by inversion, centrifuged at 8,000 g for
5 min at 4ºC and air-dried before being dissolved in appropriate volume of DEPC
treated water. RNA samples were then ethanol precipitated to remove residual
phenol which may interfere with down stream applications.
2.2.1.7 Ethanol precipitation of DNA and RNA
Ethanol precipitation was carried out by adding a one tenth volume of 3M NaOAc
pH 5.2 and three volumes of ice-cold 100% ethanol to DNA, or 5 µl of 3M NaOAc
pH 5.2 and 450 µl of ice-cold 100% ethanol to ~50 µl of RNA. The samples were
left overnight at -20ºC and centrifuged for 20 min at 14,000 rpm at 4ºC the
following day. The pellet was washed with 1 ml of ice-cold 70% ethanol,
centrifuged for 5 min at 14,000 rpm at 4ºC to remove supernatant and dissolved in
appropriate amount of TE buffer or DEPC treated water. The DNA and RNA were
stored at -20ºC and -80ºC, respectively.
2.2.1.8 Phenol chloroform extraction of DNA
Phenol chloroform extraction of DNA was carried out by adding an equal volume
of pH 7.9 phenol chloroform isoamyl alcohol mixture. After centrifuging the
sample for 2 min at 13,000 rpm, a top aqueous layer which contained DNA was
collected and ethanol precipitated.
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2.2.1.9 Determining nucleic acid concentration
Concentrations of DNA and RNA samples were determined spectrophotometrically
using the NanoDrop ND-1000 (Themo Scientific). Typically, 1 µl of DNA or RNA
was loaded onto the optical pedestal and absorbance at 260 nm was measured. The
purity of nucleic acids was assessed by the absorbance ratio at 260/280 nm and
260/230 nm. A 260/280 ratio of ~1.8 for DNA and ~2.0 for RNA are considered to
be pure and lower ratio indicates presence of substances such as proteins and phenol.
A 260/230 ratio was used as a secondary measure. In this case, values between 2.0-
2.2 are considered to be pure and lower ratio indicates presence of substances such
as EDTA, carbohydrates and phenol which all absorb at around 230 nm.
2.2.1.10DNA sequencing
DNA sequencing was performed by mixing 4 µl of miniprep plasmid DNA, 1.5 µl
of BigDye® Terminator v3.1 Cycle Sequencing RR-100 (Applied Biosystems), 2.25
µl of BigDye® Terminator v1.1, v3.1 5x Sequencing Buffer (Applied Biosystems),
1 µl of sequencing primer (20ng/µl) and 0.75 µl of H2O in 96 well plates and then
subjected to the following thermal cycle conditions: 98ºC for 5 min followed by 30
cycles of 96ºC for 30 sec, 55ºC for 15 sec and 60ºC for 4 min using a DNA Engine
Dyad Peltier Thermal Cycler (Bio-Rad Life Sciences). PCR sequencing products
were ethanol precipitated and dissolved in 10 µl of deionised formamide to denature
dsDNA. The sequencing plates were heated at 90ºC for 2 min before subjecting to
capillary electrophoresis with a 3730xl DNA Analyzer (Applied Biosystems). The
sequence outputs were analysed with Sequencher 4.8 (Gene Codes Corporation).
2.2.2 Cell culture
2.2.2.1 HEK 293T and C2C12 cell lines
HEK 293T cell line was originally derived from human embryonic kidney cells of a
healthy aborted fetus. The transformation was brought by adenovirus that made the
cells immortal (Graham et al., 1977; Louis et al., 1997). C2C12 is a mouse
myoblast cell line, originally obtained through serial passage of myoblasts from the
C3H mouse thigh muscle after a crush injury (Yaffe and Saxel, 1977). Both cell
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lines were grown in Dulbecco’s Modified Eagle’s Medium - high glucose (Sigma-
Aldrich) supplemented with 10% v/v FBS (Clontech), 2 mM L-glutamine (Gibco),
0.1 mM MEM Non Essential Amino Acids (100X), liquid (Gibco) and 50 units/ml
Penicillin-Streptomycin, liquid (Gibco) in a humidified incubator at 37ºC with 5%
CO2. Cells were seeded at 1/10 dilutions and passaged every 3-4 days.
2.2.2.2 Trypsinising cells
Cells were trypsinised and passaged when semi-confluence was reached. For
trypsinisation, the growth media was aspirated and cells were rinsed with 1X PBS
(5 ml per 25 cm3 flask area). Then Trypsin/EDTA solution (1 ml per 25 cm3 flask
area) was added to the cells and incubated in a 37ºC incubator until they detached
from the flasks, normally within 5 min. A proportion of the trypsinised cells were
seeded to a new flask.
2.2.2.3 Counting cells using a haemocytometer
For counting, cells were first trypsinised, centrifuged at 1000 rpm for 5 min and
then resuspended in appropriate amount of media. 10 µl of the cell suspension was
diluted in appropriate amount of 0.4% trypan blue (Sigma-Aldrich) and counted in
eight squares (0.1 µl) of haemocytometer under the inverted microscope. The total
number was averaged, multiplied by dilution factor and by 1 X 104 to determine the
number of cells per ml. Those cells stained with trypan blue were dead and were
excluded from counting.
2.2.2.4 Freezing cells for long term storage
The semi-confluent cells in a T-75 flask were trypsinised, centrifuged at 1000 rpm
for 5 min and resuspended in 3 ml of complete growth media with 10% DMSO. 1
ml aliquots were transferred to cryogenic vials and stored at -80ºC overnight. Vials
were placed in liquid nitrogen (-180ºC) the next day for long term storage.
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2.2.2.5 Thawing cells for culture
Cells were taken from the liquid nitrogen tank and rapidly thawed in a 37ºC water
bath and immediately diluted in 13 ml of complete growth media as DMSO is
cytotoxic to cells. Then the cells were centrifuged at 1000 rpm for 5 min to remove
DMSO containing media and plated to a T25 flask.
2.2.3 Western blot
2.2.3.1 Protein extraction
For western blot, HEK 293T cells in 6 well plate were transfected with 1 µg of
mock (pcDNA3.1.V5/His), the full-length wild type TBX22
(pcDNA3.1.TBX22.V5/His) or the previously described N264Y pathogenic mutant
(pcDNA3.1.TBX22(N264Y).V5/His) using FuGENE 6 according to the
manufacturer’s instruction. After 48 hours incubation, the cells were harvested and
lysed in lysis buffer (150 mM NaCl, 25 mM Tris pH 7.5, 1% Triton X-100, 1%
SDS, 0.5% sodium deoxycholate, 1x protease inhibitor) for 40 min at 4ºC with
rotation. The lysate was centrifuged for 20 min at 3,000 g at 4ºC and the
supernatant was collected and stored at -20ºC. Also, 10 µl of the supernatant was
collected in a separate tube to estimate concentration using the Bradford assay.
2.2.3.2 Bradford assay to determine protein concentration
The Bradford reagent was gently mixed and brought to room temperature. Bovine
serum albumin (BSA) protein standards were prepared at concentrations of 0 mg/ml,
0.125 mg/ml, 0.25 mg/ml, 0.5 mg/ml, 1 mg/ml in lysis buffer. 10 µl of the standards
or 1:10 diluted samples were mixed with 250 µl of the Bradford reagent in 96 well
plate and incubated for 5 min at room temperature before assayed on plate reader at
595 nm (DYNEX REVELATION 4.21). Each standard or sample was measured in
triplicate. The read out from the BSA standards less the background was used to
plot a standard curve (i.e. OD at 595 nm against BSA protein concentration) from
which the concentration of the samples were calculated.
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2.2.3.3 SDS-PAGE and immunoblotting
The protein samples were made up to a concentration of 20 µg/10 µl using lysis
buffer and mixed with 5 µl of loading buffer (0.3 ml 0.5 M Tris pH 6.8, 2.5 ml
glycerol, 2 ml 10% SDS, 0.1% bromophenol blue, 10% β-mercaptoethanol) and 1
µl of 0.5 M DTT, then boiled for 5 min at 95ºC. Samples and protein standards
were loaded and gels (10% resolving gel: 2.5 ml 1.5 M Tris pH 8.8, 3.33 ml 30%
acrylamide, 0.1 ml 10% SDS, 3.983 ml H2O, 0.075 ml 10% APS, 0.012 ml
TEMED; 5% stacking gel: 1.25 ml 1 M Tris pH 6.8, 0.66 ml 30% acrylamide, 0.05
ml 10% SDS, 3 ml H2O, 0.05 ml 10% APS, 0.006 ml TEMED ) were run at 150 V
for 1 hour in 1X running buffer (3.02 g Tris, 14.4 g glycine, 0.1% SDS, H2O to 1 L).
Proteins were then immunoblotted onto PVDF membranes using Trans-Blot SD
Semi-Dry Transfer Cell (BIO-RAD) in the following order; 3X filter papers, PVDF
membrane, SDS-PAGE gel, 3X filter paper immersed in blot butter (1X running
buffer, 20% methanol), and transferred at 400 mA for 30 min. The membranes were
then incubated in blocking solution (5% milk in PBS-0.05% tween-20) overnight at
4ºC to reduce background. The next day, the membrane was incubated with primary
antibody (anti-V5 antibody 1:5,000; anti-β-actin antibody 1:1,5000) in blocking
solution for 1 hour at room temperature, washed three times in PBS-0.05% tween-
20, incubated with secondary antibody (rabbit anti-mouse HRP 1:5,000) for 40 min
at room temperature, washed three times in PBS-0.05% tween-20, followed by
detection using ECL Plus Western Blotting Detection System (GE Healthcare Life
Sciences). The membrane was incubated with 1 ml of 1:40 solution A:solution B
for 5 min at room temperature and exposed to autoradiography film for different
lengths of time.
2.2.4 Luciferase assay
2.2.4.1 PCR amplification of the MyoD putative promoter
Primers to amplify the MyoD putative promoter region contained XhoI site at 5’
ends. For PCR reaction, 4 µl of mouse genomic DNA template was mixed with 20
µl of 5X Green GoTaq® Flexi Buffer, 4 µl of 10 mM dNTPs, 20 µl of 25 mM
MgCl2, 20 µl of 5 M Betaine, 0.8 µl of GoTaq® Hot Start Polymerase (Promega),
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3.2 µl of MyoD_F_-683 and 3.2 µl of MyoD_R_+115 primers. The total reaction
volume was made up to 100 µl with H2O. PCR reactions were performed in 96 well
plates using DNA Engine Dyad Peltier Thermal Cycler (Bio-Rad Life Sciences)
with the following thermal cycle conditions: 94ºC for 5 min followed by 35 cycles
of 94ºC for 30 sec, 65ºC for 1 min 30 sec and 74ºC for 1 min 30 sec. The PCR
products were visualised on a 1% agarose gel under UV light.
2.2.4.2 Cloning the MyoD putative promoter into pGL3-Basic vector
The PCR products were first ligated into 50 ng of pGEM®-T Easy at 1:1 to 1:3
vector:insert molar ratios using T4 DNA ligase in a 10 µl reaction volume. After
transformation of competent cells by heat shock, the PCR products were released
from the pGEM®-T Easy vector by XhoI digestion and gel extracted using
QIAquick Gel Extraction Kit (QIAGEN). 1 µg of the pGL3-Basic vector was also
digested with XhoI, treated with 1 µl of 5 u/µl Antarctic phosphatase (NEB) for 15
min at 37ºC and gel extracted using QIAquick Gel Extraction Kit (QIAGEN).
Concentrations of the insert and vector were estimated on a gel and the insert was
ligated into 50 ng of the pGL3-Basic vector at 1:1 to 1:3 vector:insert molar ratios
using T4 DNA ligase in a 10 µl reaction volume. After transformation of competent
cells by heat shock, plasmid DNA was purified from isolated colonies and analysed
by restriction digestion. For pGL3-MyoD-683/+115, SmaI digest of positive clones
with correct orientation produced bands at 5112 bp and 636 bp.
2.2.4.3 Site-directed mutagenesis
The QuikChange site-directed mutagenesis kit (Stratagene) was used to substitute
two bases in the TBE of pGL3-MyoD. Predicted TBE sequence in the MyoD
promoter region was TGCTCACCTAG that was located between -515 bp to -505
bp relative to the transcription start site (TSS). Two complimentary
oligonucleotides containing the mutations that resulted in substitutions of a base C
to a base A at -511 bp relative to TSS and a base C to a base A at -509 bp relative to
TSS, flanked by unmodified nucleotides were synthesized (Sense:
5’ATTTGTGCCAGGCTTGCTAAACTAGACCTTCTGAGTCTC3’; antisense: 5’-
GAGACTCAGAAGGTCTAGTTTAGCAAGCCTGGCACAAAT-3’). 2 µl (10 ng)
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of pGL3-MyoD was mixed with 5 µl of 10X reaction buffer, 1.25 µl (125 ng) of
sense and antisense oligonucleotide primers, 1 µl of 10 mM dNTPs and 1 µl of
PfuTurbo DNA polymerase (2.5 U/µl). The total reaction volume was made up to 5
µl with H2O. Then, thermal cycling reaction was performed using DNA Engine
Dyad Peltier Thermal Cycler (Bio-Rad Life Sciences) with the following thermal
cycle conditions: 95ºC for 30sec followed by 16 cycles of 95ºC for 30 sec, 55ºC for
1 min and 68ºC for 6 min. The reaction was cooled on ice for 2 min, and then
incubated with 1 µl of Dpn I restriction enzyme (10 U/µl) at 37ºC for 1 hour to
digest the parental non-mutated dsDNA. After digestion, 1 µl of the Dpn I-treated
DNA was added to 50 µl of XL1-Blue supercompetent cells, incubated on ice for
30 min followed by heat shock for 45 sec at 42ºC, then immediately placed on ice
for 2 min. 0.5 ml of LB medium was added and incubated at 37ºC for 1 hour while
shaking at 180 rpm. Transformed cells was spread on LB agar plate containing 100
µg/ml of ampicillin and incubated overnight at 37ºC. The next day, isolated
colonies were picked and expanded accordingly in LB in the presence of 100 µg/ml
of ampicillin, and the base substitutions in the insert was verified by DNA
sequencing.
2.2.4.4 Measuring luciferase activity in cells transfected with pGL3-
MyoD promoter
HEK 293T cells, which lack endogenous TBX22 expression, were used in luciferase
assay. One day before transfection, 1.2 x 104 cells/well were seeded in a 96 well
plate. The following day, sub-confluent cells were transiently co-transfected with
0.15 µl of FuGENE 6 (Roche) containing 50 ng of luciferase reporter construct
(pGL3-MyoD), 2.5 ng or 10 ng of wtTBX22 or N264Y and 5 ng of Renilla
luciferase construct (pRL-CMV) and left incubated for 48 hours. Luciferase activity
was measured as follows. 50 µl of medium was removed and 50 µl of Steady Lite
Plus (Perkin Elmer) in reconstitution buffer was added to each well. Cells were left
at room temperature for 10 min, transferred to a 96 well MICROLITE plate
(Dynex) and read by FLUOstar OPTIMA (BMG LABTECH). Then 25 µl of
coelenterazin (10 ng/µl) in Renilla buffer was added to the same samples, incubated
for 10 min and Renilla luciferase activity was read. Firefly luciferase reading was
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normalised to Renilla luciferase reading. Each set of experiment was done in
quadruplicate wells and repeated three times.
2.2.5 Chromatin immunoprecipitation
The direct interaction of TBX22 with the MyoD promoter was analysed by
chromatin immunoprecipitation in transfected HEK 293T cells. One day before
transfection, 3.84 x 105 cells were seeded in a 6 well plate. The following day,
subconfluent cells were transiently transfected with 3 µl of FuGENE 6 containing 1
µg of mock, wtTBX22 or N264Y. After incubating for 48 hours, the cells were
cross linked with 0.8% formaldehyde at room temperature for 10 min, and stopped
by addition of glycine to a final concentration of 0.125 M, followed by 5 min
incubation at room temperature. The fixed cells were washed twice with PBS and
harvested by scraping. Then, the cells were pelleted by centrifugation for 3 min at
1,000 rpm and resuspended in lysis buffer (150 mM NaCl, 25 mM Tris pH 7.5, 1%
Triton X-100, 1% SDS, 2 mM EDTA, 0.5% sodium deoxycholate, protease
inhibitors) at a concentration of 1.5 x 106 cells/300 µl. Followed by 5 min
incubation on ice, 1.5 x 106 cells were sonicated for 15 min at high power setting
(320 W) with a 30 sec on 30 sec off cycle by water-based sonicator Bioruptor
(Diagenode) to fragment the DNA to a size of 100-500 bp. After sonication, cell
debris was pelleted by centrifugation for 30 sec at 8,000 g and supernatant was
transferred to a new tube. 50 µl of sonicated sample was removed as the total input
which served as a control in the PCR. For immunoprecipitation, 150 µl of sonicated
chromatin preparation was diluted 1:10 with RIPA buffer (0.01% SDS. 1.1% Triton
X-100, 1.2 mM EDTA, 16.7 mM Tris pH 7.5, 167 mM NaCl, protease inhibitors)
and incubated overnight with rotation at 4Cº with 1 µg of anti-V5 antibody
(invitrogen) and 20 µl of protein G agarose beads (Pierce) which was preadsorbed
with 75 ng/µl salmon sperm DNA and 0.1 µg/µl BSA. The next day, the protein G
agarose beads were washed three times with 1 ml wash buffer (0.1% SDS, 1%
Triton X-100, 2 mM EDTA pH 8.0, 150 mM NaCl, 20 mM Tris pH 8.0) followed
by a wash with 1 ml final wash buffer (0.1% SDS, 1% Triton X-100, 2 mM EDTA
pH 8.0, 500 mM NaCl, 20 mM Tris pH 8.0) for 15 min at room temperature. Then,
bound DNA was eluted by adding 120 µl of elution buffer (1% SDS, 100 mM
NaHCO3) and rotated for 15 min at room temperature. 100 µl of the sample was
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incubated with 2 µl of RNaseA (20 mg/ml) and 140 µl of elution buffer at 65Cº
overnight to reverse cross link. For input samples, 1 µl of RNaseA (20 mg/ml) and
70 µl of elution buffer were added. The DNA was purified using the QIAquick PCR
purification kit (QIAGEN) according to the manufacturer’s instruction before
subjected to PCR amplification. Primer pairs used for PCR amplification were
MyoD_ChIP_F and MyoD_ChIP_R which produced a 310 bp fragment.
2.2.6 Mouse techniques
2.2.6.1 Animal husbandry
Mice were treated in accordance with the UK Animals (Scientific Procedures) Act,
1986 and all procedures were approved by the British Home Office Inspectorate.
The original Tbx22 null mouse strain was generated by Dr. Erwin Pauws. Briefly,
exon 1 and exon 3 of Tbx22 were flanked by loxP sites and then removed by
crossing with a β-actin-Cre deleter strain (Pauws et al., 2009a).
2.2.6.2 Embryo collection
Mice were kept on a 12 hour light-dark cycle. Male null (Tbx22Neo/Y) and female
heterozygote (Tbx22+/Neo) pairs were set up in a breeding cage to obtain four
possible genotype embryos Tbx22+/Y, Tbx22Neo/Y, Tbx22+/Neo and Tbx22Neo/Neo. On
the following day, female mice were examined for a copulatory plug. Noon of the
day a plug was observed was referred to as embryonic day 0.5 (E0.5), assuming
mating took place around midnight. Pregnant female mice were sacrificed by
cervical dislocation at different embryonic time points and embryos were dissected
from the uterus in cold PBS, then either fixed overnight at 4ºC in 4%
paraformaldehyde in PBS, or homogenised in TRI Reagent (Sigma-Aldrich) and
stored at -80ºC.
2.2.6.3 Genotyping
To obtain embryo specific DNA for genotyping, the yolk sac was collected and
digested overnight at 55ºC in 100 µl PBS with 2 µl of proteinase K (10 mg/ml), and
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boiled for 5 min before being subjected to PCR. 0.2 µl of proteinase K digested
DNA template was mixed with 1 µl of 5X Green GoTaq® Flexi Buffer, 0.2 µl of 10
mM dNTPs, 1 µl of 25 mM MgCl2, 1 µl of 5 M Betaine, 0.04 µl of GoTaq® Hot
Start Polymerase (Promega), and 0.16 µl of 10 µM Tbx22_F, Tbx22_R and
Tbx22_R2 primers for genotyping PCR or 0.16 µl of 10 µM Smc_F and Smc_R
primes for sexing PCR. The total reaction volume was made up to 5 µl with H2O.
PCR reactions were performed in 96 well plates using DNA Engine Dyad Peltier
Thermal Cycler (Bio-Rad Life Sciences) with the following thermal cycle
conditions: 94ºC for 5 min followed by 35 cycles of 94ºC for 30 sec, 65ºC for 1 min
30 sec and 74ºC for 1 min 30 sec. The PCR products were visualised on a 1%
agarose gel under UV light.
2.2.7 Expression microarray analysis
2.2.7.1 Extraction of total RNA from tissues
Mouse embryos were dissected from the uterus and pairs of palatal shelves were cut
out under a dissecting microscope. Tissue samples were immediately homogenised
in TRI Reagent (Sigma-Aldrich) and total RNA was extracted. The samples were
then ethanol precipitated.
2.2.7.2 Microarray hybridisation
Quality control of the RNA samples and microarray analysis were performed by the
ICH Microarray Centre which is now part of UCL Genomics. The yield and quality
of the RNA samples were determined by spectrophotometry measurements using a
NanoDrop (Thermo Scientific), and RNA integrity was checked by ribosomal
18S/28S ratio using the Agilent 2100 Bioanalyzer (Agilent Technologies).
RNA samples collected from Tbx22+/Y and Tbx22Neo/Y were appropriately processed
and hybridised to GeneChip® Mouse Gene 1.0 ST Array (Affymetrix). Briefly,
double-stranded cDNA was synthesised form 100 ng of total RNA with random
hexamers tagged with a T7 promoter sequence which was subsequently amplified
by T7 RNA polymerase to produce antisense cRNA. Then the cRNA was reverse
transcribed with random hexamers to produce single-stranded cDNA which was
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fragmented and labelled with Affymetrix® proprietary DNA Labeling Reagent. The
labelled cDNA was hybridised to the array, washed and stained using the
GeneChip® Hybridization, Wash and Stain Kit. The array was then scanned by the
GeneChip® Scanner 3000 7G.
2.2.8 Quantitative real-time PCR
2.2.8.1 Extraction of total RNA
Total RNA was extracted from cells and tissues using TRI Reagent (Sigma-Aldrich)
and samples were ethanol precipitated.
2.2.8.2 First strand cDNA synthesis
500 ng of total RNA was treated with 1 µl of RQ1 RNase-Free DNase (1 u/1 µl)
(Promega) for 30 min at 37ºC to remove possible genomic DNA contamination.
The reaction was terminated by incubating with 1 µl of RQ1 DNase Stop Solution
(Promega) for 10 min at 65ºC. Prior to first strand cDNA synthesis, 9 µl of the
DNase treated RNA sample was mixed with 1 µl of random primers (Promega) and
incubated for 10 min at 70ºC, followed by cooling on ice for 5 min. First strand
cDNA synthesis was performed by adding 4 µl of M-MLV 5X Reaction Buffer
(Promega), 2 µl of 10 mM dNTPs, 0.5 µl of Recombinant RNasin® Ribonuclease
Inhibitor (Promega), 1 µl of M-MLV Reverse Transcriptase (Promega) and 2.5 µl
of DEPC treated water. The reaction mixture was incubated at 37ºC for 1 hour
followed by incubation at 95ºC for 10 min to denature M-MLV Reverse
Transcriptase.
2.2.8.3 Taqman quantitative real-time PCR
Quantitative real-time PCR technique enables either absolute or relative
quantification of target DNA samples based on the fact that there is a quantitative
relationship between the starting amount of DNA and the amount of PCR product
made. In this study, TaqMan® Gene Expression Assays (Applied Biosystems) were
used to perform relative quantification of gene expression. Its chemistry is based on
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the 5’ exonuclease activity of AmpliTaq Gold® DNA polymerase which cleaves and
releases a fluorescent reporter dye (6-FAMTM dye) linked to the TaqMan® probes
resulting in an increase in fluorescence during PCR amplification. Real-time PCR
reaction mixture was composed of 1 µl of cDNA, 5 µl of TaqMan® Fast Universal
Master Mix (2X), No AmpErase® UNG (Applied Biosystems), 0.5 µl of TaqMan®
Gene Expression Assay or Endogenous Control (20X) (Applied Biosystems) and
3.5 µl of DEPC treated water. The fluorescent signals were detected with 7500
FAST Real-Time PCR system (Applied Biosystems) using the following thermal
cycle conditions: 95ºC for 20 sec followed by 40 cycles of 95ºC for 3 sec, 60ºC for
30 sec. All samples were tested in triplicate wells for both target and endogenous
control genes and repeated at least three times. For data analysis, comparative CT
method for relative quantification was carried out using SDS 3.1 (Applied
Biosystems).
2.2.9 Section in situ hybridisation
2.2.9.1 Embryo fixation, dehydration and wax embedding
Mouse embryos were dissected at different embryonic time points, washed twice
with PBS for 2 min and fixed overnight in 4% paraformaldehyde in PBS at 4ºC
with rocking. The next day, embryos were washed twice in PBS for 30 min and
dehydrated through graded ethanol series (25%, 50%, 70%, 85% and 95%) for 1
hour each, then 100% overnight. Dehydrated embryos were processed for wax
embedding starting with tissue clearing in Histoclear twice for 40 min at room
temperature, 1:1 = histoclear:wax for 30 min at 60ºC followed by three times in
wax for 40 min at 60ºC. Then embryos were transferred to embedding moulds and
left at 60ºC for further 30 min, then appropriately orientated. Blocks were left to
cool at room temperature until they solidified.
2.2.9.2 Non-radioactive riboprobe synthesis
Typically, 10 µg of plasmid DNA which contained in situ riboprobe insert was
digested with 50 units of restriction enzymes in a 200 µl reaction volume for 3
hours. Digested DNA was incubated with 2 µl of 0.5 M EDTA, 10 µl of 20% SDS
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and 4 µl of proteinase K (10 mg/ml) for 30 min at 37ºC, and purified by phenol
chloroform extraction. In vitro transcription was performed using DIG RNA
Labelling Kit (SP6/T7) (Roche Applied Science) with the following components: 1
µg of digested DNA, 2 µl of 10X DIG RNA labelling mix, 2 µl of 10X transcription
buffer, 0.5 µl of Recombinant RNasin® Ribonuclease Inhibitor (Promega), 1 µl of
SP6 or T7 RNA polymerase and appropriate volume of DEPC treated water to a
total volume of 20 µl. Reaction mixture was incubated for 3 hours at 37ºC for T7
and 40ºC for SP6. Efficiency of transcription was determined by analysing the
riboprobe on a 1% agarose gel and visualising under UV. Good probes usually
showed a 10 fold brighter band than the plasmid DNA band. Finally, the riboprobe
was cleaned by passing through a CHROMA SPIN-100 DEPC-H2O column
(Clontech) according to the manufacturer’s instruction.
2.2.9.3 Section in situ hybridisation
Wax embedded embryos were sectioned at 8 µm thickness using microtome,
mounted onto glass slides and dried in a 37ºC oven overnight. Non-radioactive
RNA in situ hybridisation was performed as previously described (Wilkinson,
1998) with some modifications. The process can be divided into pre-hybridisation
treatment, post-hybridisation washing and antibody detection.
Pre-hybridisation treatment; wax sections were deparaffinised by placing into
Histoclear twice for 10 min, rehydrated through graded ethanol series (100% twice
for 1 min, 70% for 1 min, 50% for 1 min, 25% for 1 min), then placed into 1X PBS
for 2 min, 4% paraformaldehyde in 1X PBS for 20 min, 1X PBS twice for 2 min,
proteinase K (20 µg/ml) in 1X PBS for 8 min, 4% paraformaldehyde in 1X PBS for
5 min, 1X PBS twice for 2 min, 0.1 M triethanolamine with 1 ml acetic anhydride
for 10 min, 1X PBS twice for 2 min and then dehydrated through graded ethanol
series (25% for 1 min, 50% for 1 min, 70% for 1 min, 100% twice for 1 min). After
the slides were air dried, 100 µl of hybridisation mixture was added and cover
slipped. The mixture contained riboprobe at 1:100 dilution, 1 µl/ml of RNase
inhibitor and 0.5 mg/ml of tRNA in Hybmix (50% formamide, 0.3 M sodium
chloride, 20 mM Tris-HCl, 5 mM EDTA, 10% dextran sulphate and 1X Denhardt’s).
The slides were incubated at 65ºC overnight.
97
Post hybridisation washing; All washes were performed at hybridisation
temperature in a glass staining trough in a water bath. The slides were washed in 2X
SSC twice for 30 min, formamide (50% formamide, 10% 20X SSC, 40% H2O)
twice for 30 min, 2X SSC twice for 30 min and 0.2X SSC twice for 30 min. After
the last wash the slides were removed from water bath and allowed to cool to room
temperature.
Antibody detection; the slides were washed in buffer 1 (0.1 M Tris-HCl pH 7.6,
0.15 M sodium chloride) for 2 min at room temperature, then blocked with 10%
foetal calf serum (FCS) in buffer 1 for 1 hour. The slides were incubated with 0.5
ml of antibody solution containing anti-digoxygenin, Fab fragments (1:1000)
(Roche Applied Science) in buffer 1 with 2% FCS at 4ºC overnight. The next day,
slides were washed in buffer 1 three times for 5 min, twice in buffer 2 (0.1 M Tris-
HCl pH 9.5, 0.1 M sodium chloride, 0.05 M magnesium chloride) for 5 min and
developed with 0.5 ml of NBT/BCIP solution (4.5 µl/ml of NBT and 3.5 µl/ml
BCIP in 1:1 = 2X buffer 2:10% PVA) at room temperature. When developed
sufficiently, slides were washed in running tap water for 10 min, dried and mounted
with Vectamount H-5000 (Vector).
2.2.10 Whole mount in situ hybridisation
2.2.10.1Embryo preparation
Mouse embryos were dissected at different embryonic time points, washed twice
with PBS for 2 min and fixed overnight in 4% paraformaldehyde in PBS at 4ºC
with rocking. The next day, embryos were washed twice in PBT (PBS, 0.1%
Tween-20) for 30 min at 4ºC and dehydrated through graded methanol series (25%,
50% and 75%) for 1 hour each, followed by two washes in 100% methanol.
Dehydrated embryos were stored in 100% methanol at -20ºC.
2.2.10.2Whole mount in situ hybridisation
All washes were performed at room temperature for 10 min unless otherwise stated.
Embryos were rehydrated by washes in 75%, 50% and 25% methanol in PBT
followed by two washes in PBT. Then the embryos were bleached in 6% hydrogen
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peroxide in PBT for 1 hour, washed three times in PBT, and treated with 10 µg/ml
proteinase K for 10 min to 30 min depending on embryonic stage. The reaction was
stopped by washing in 2 mg/ml glycine in PBT followed by two washes in PBT.
Next, embryos were refixed in 0.2% glutaraldehyde in 4% paraformaldehyde for 20
min and washed twice in PBT which was then replaced by 2 ml of prehybridisation
mix (50% formamide, 5x SSC pH 4.5, 50 µg/ml yeast RNA, 1% SDS, 50 µg/ml
heparin). Once the embryos had sunk, the prehybridisation mix was replaced with 5
ml of fresh mix and incubated for 3 hours at 70ºC. Then, the embryos were
incubated in fresh 1 ml prehybridisation mix containing 10 µl of digoxigenin-
labelled probe at 70ºC overnight. The next day, the hybridisation mix was removed
and embryos were washed in solution 1 (50% formamide, 5x SSC pH 4.5, 1% SDS)
for 15 min, followed by two more washes in solution 1 for 30 min at 70ºC, and then
two washes in solution 2 (50% formamide, 2x SSC pH 4.5, 1% SDS) for 30 min at
65ºC. Then embryos were washed three times in TBST (8 mg/ml NaCl, 0.2 mg/ml
KCl, 25 mM Tris pH 7.5, 1% Tween-20, 0.48 mg/ml levamisole) before preblocked
for 90 min in TBST containing 10% sheep serum. The 10% sheep serum was then
replaced with 2 ml of antibody solution containing anti-digoxygenin, Fab fragments
(1:2000) (Roche Applied Science) in TBST with 1% sheep serum and incubated
overnight at 4ºC with rocking. The next day, antibody solution was removed and
embryos were washed three times in TBST for 5 min and the washes in TBST were
repeated hourly for six times at room temperature and overnight at 4ºC. The next
day, embryos were washed three times in NTMT (100 mM NaCl, 100 mM Tris pH
9.5, 50 mM MgCl2, 0.1% Tween-20) and developed in 1 ml NTMT containing 4.5
µl NBT and 3.5 µl BCIP with rocking until the colour developed, and stopped by
washing in PBT and stored in PBT at 4ºC.
2.2.11 Immunohistochemistry
For immunohistochemistry, wax sections were deparaffinised by placing into
Histoclear twice for 10 min, rehydrated through graded ethanol series (100% for 2
min, 95% for 2 min, 75% for 2 min), then washed three times in PBS-0.1% Triton
X-100 for 10 min each. The slides were blocked in blocking buffer (5% goat serum
in PBS-0.1% Triton X-100, 0.15% glycine, 2 mg/ml BSA) for 30 min at room
temperature, and incubated with primary antibody (phospho-Histone H3 (1:200);
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cleaved caspase-3 (1:200)) in blocking buffer overnight at 4ºC. The next day the
slides were washed three times in PBS-0.1% Triton X-100, and incubated with
polyclonal goat anti-rabbit immunoglobulins biotinylated (1:250) in blocking buffer
for 1 hour at room temperature. After three time washes in PBS-0.1% Triton X-100,
the slides were incubated with streptavidin, Alexa Fluor® 555 conjugate (1:300) in
PBS-0.1% Triton X-100 for 2 hours at room temperature, washed three times in
PBS-0.1% Triton X-100, and mounted in VECTASHIELD mounting medium with
DAPI.
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3 RESULTS
3.1 Expression pattern of Tbx22 in mice
Loss of function mutations in TBX22 have been shown to be the molecular basis of
X-linked cleft palate with or without ankyloglossia, in both human (Braybrook et al.,
2001; Braybrook et al., 2002; Chaabouni et al., 2005; Marcano et al., 2004) and
mouse (Pauws et al., 2009a). The phenotype has been shown to be closely allied to
the spatiotemporal expression pattern that is conserved in several different species
including mouse, chick and zebrafish (Braybrook et al., 2002; Bush et al., 2002;
Haenig et al., 2002; Herr et al., 2003; Jezewski et al., 2009). Though several groups
have shown Tbx22 expression using both section and whole mount in situ
hybridisation especially at around E13.5 prior to palatal shelf elevation, it was
decided to perform whole mount and/or section in situ hybridisation from E9.5 to
E15.5 to provide a reference for the experimental data presented in the rest of this
thesis.
3.1.1 Expression of Tbx22 from E9.5 to E15.5
In order to investigate the expression of Tbx22 in the early stages of lip and palate
morphogenesis, it was decided to start with E9.5 mouse embryos (Figure 3.1, A and
B). At this developmental stage, the mandibular processes of the first branchial arch
were already visible while the maxillary processes were not established until about
a day later. Although expression of the gene was observed at this stage by RT-PCR
(Braybrook et al., 2002), no obvious expression was detected in the first branchial
arch from which the future maxillary processes arise, or in fact any other parts of
the embryos by the whole mount in situ hybridisation method used. It is possible
that at this stage, the gene may be expressed at a very low level that it was under the
detection limit by whole mount in situ hybridisation method used, whereas it was
detectable by RT-PCR which in theory is sensitive enough to detect very low copy
numbers of mRNA.
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By E10.5, the first branchial arch was divided into maxillary and mandibular
processes. As shown in Figure 3.1 (C-F), expression of Tbx22 was observed in the
maxillary and mandibular processes, in the medial nasal processes and also in the
nasal fin area where the medial and lateral nasal processes meet. At this stage,
expression was especially strong in the top half of the mandibular prominences that
were fusing to form the mandible, and around the nasal fins, which in the wt
gradually degrade by the end of E11.5 to E12.0. This could indicate that TBX22
may be having an important role in these tissues at or around this developmental
time point. In addition, the expression was also detected in the somites and otic
vesicles (Figure 3.1, C and D).
The swelling of palatal shelves were first observed from the maxillary prominences
at around E11.5. The frontal view of whole mount in situ hybridisation showed a
defined and specific expression of Tbx22 in the anterior tip of the mandible
indicated by an arrow in Figure 3.1, H. The tongue extends from the tuberculum
impar, which appears on the lower edge of the mandible and further two swellings
called the lateral lingual prominences that extend to form the anterior two thirds of
the tongue. Expression at the anterior tip observed at this stage is of particular
interest because this anterior region corresponds to the future frenulum region
which in the null mice attached more anteriorly to the mandible than wt
(ankyloglossia phenotype) (Pauws et al., 2009a). By removing the mandible,
expression was also visible in almost the entire swelling of the palatal shelves as
well as around the fused medial and lateral nasal processes (Figure 3.1, I and J).
Expression was also noted in the otic vesicles as well as in the periocular
mesenchyme around the eyes which was not detectable at earlier stages (Figure 3.1,
K and L).
By E12.5, the growing palatal shelves started to become more apparent. A specific
expression of Tbx22 was observed in the middle region of the palatal shelves, and in
the medial and lateral nasal mesenchyme (Figure3.1, M and N). Also, section in situ
hybridisation showed expression of the gene at the base of the tongue anteriorly
around the frenulum, in the medial and lateral nasal mesenchyme where there were
nasal fins up until E11.5 in the wt, and in the periocular mesenchyme around the
eyes (Figure 3.2, A and C). Higher magnification of the palatal shelf indicated its
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expression in the mesenchyme but not in the epithelium (Figure 3.2, E). These
observations are in agreement with previous studies (Braybrook et al., 2002; Bush
et al., 2002; Herr et al., 2003).
The embryos became generally bigger in size at E13.5. The expression pattern of
Tbx22 was similar to that seen at E12.5 while the expression in the growing palatal
shelves was slightly shifted posteriorly compared to E12.5 embryos (Figure 3.1, O-
R). However, this was somewhat variable between embryos where some had
stronger expression in the middle region and others had more intense staining in
posterior regions. Again, section in situ hybridisation showed expression at the base
of the tongue anteriorly around the frenulum, in the medial and lateral nasal
mesenchyme and in the periocular mesenchyme around the eyes (Figure 3.2, B and
D). Also, the expression was more prominent in the palatal mesenchyme but not in
the epithelium, although less obvious than at E12.5 (Figure 3.2, F).
The elevation of downward growing palatal shelves to the horizontal position
seemed to occur in a rather short time window between E14.0-E15.0. Therefore
dissecting embryos at E14.5 often resulted in harvesting morphologically mixed
samples as far as the palatal shelves were concerned. These included embryos in
which the palatal shelves had still not elevated to the horizontal position, palatal
shelves in the middle of the elevation process and even those that were already
elevated and beginning to fuse in the middle region of the horizontally oriented
shelves (Figure 3.1, S-V). Expression of Tbx22 at this stage seemed shifted further
towards more posterior parts of the palatal shelves. Interestingly, there was no
expression detected around the middle region of the fusing palatal shelves, whereas
expression persisted in the posterior region while the palatal shelves extended
towards each other in a horizontal direction. This may suggest a specific role for
TBX22 in posterior palatal shelf growth at around this developmental stage.
Craniofacial expression of Tbx22 was detected up until E16.5 by RT-PCR
(Braybrook et al., 2002). However, no obvious expression was observed in the
palate post-fusion at E15.5 using the whole mount in situ hybridisation method
(Figure 3.1, W and X). Again, it is possible that at this stage the gene may not have
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been expressed strongly enough to be detected by this method, with RT-PCR being
considerably more sensitive.
105
E10.5
max
man
ba2
e
fnp
lnp
mnp
man
max
max
man
lnp
mnp
ps
C
E
G
I
A
E9.5
ba1
fnp
Tbx22
E11.5
K
B
H
J
F
L
D
e
f
ov
ov
106
E12.5
E14.5
ps ps
pp
M
S
U
Q
E15.5
W
E13.5
O
N
T
V
R
X
P
Tbx22
Tbx22
Sense control
107
Figure 3.1 Expression pattern of Tbx22 from E11.5 to E15.5
Expression pattern of Tbx22 was detected by whole mount in situ hybridisation
from E9.5 to E15.5 using Tbx22 antisense probe (A-X). The sense probe control did
not give signals. Arrow in H indicates the anterior tip of mandible. ba1, first
branchial arch; ba2, second branchial arch; e, eye; f, nasal fin; lnp, lateral nasal
process; man, mandibular process; max, maxillary process; mnp, medial nasal
process; ov, otic vesicle; p, palate; pp, primary palate; ps, palatal shelf. Scale bar =
250 µm (A, E and I), 320 µm (C, K and M), 100 µm (B, F and J), 128 µm (D, L and
N), 200 µm (G, T, V and X), 80 µm (H), 400 µm (O and Q), 160 µm (P and R), 500
µm (S, U and W).
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Figure 3.2 Expression pattern of Tbx22 at E12.5 and E13.5
Expression pattern of Tbx22 was detected by section in situ hybridisation at E12.5
and E13.5 using Tbx22 antisense probe (A-F). High magnification views of the
palatal shelves show that Tbx22 expression is most intense in the mesenchyme but
undetectable in the epithelium (E and F). e, eye; ns, nasal septum; ps, palatal shelf;
t, tongue. Scale bar = 125µm (A-D), 50µm (E and F).
A B
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E12.5 E13.5Tbx22
ps pst
e e ns
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3.1.2 Summary
Using whole mount and section in situ hybridisation, the spatial and temporal
expression patterns of Tbx22 between E9.5 to E15.5 were determined. The gene
was expressed at easily detectable levels from E10.5 to E14.5. In the maxillary
processes and palatal shelves, expression was first observed at E10.5 and persisted
throughout the period of palatogenesis until E14.5. The expression was rather broad
at E10.5 and E11.5 in the maxillary processes, becoming restricted to the middle
portion of the palatal shelves at E12.5, then shifting towards more posterior regions
of the palatal shelves at E13.5 and E14.5. Expression in the periocular mesenchyme
around the eyes appeared at around E11.5 and persisted into later stages. Expression
around the nasal fins where the medial and lateral nasal processes first meet became
evident at E10.5 and then persisted in the medial and lateral nasal mesenchyme at
least up until E13.5. Similarly, expression in the mandibular processes started at
around E10.5, at which time the processes were not yet fused. It persisted after the
mandibular processes were fused to form the intact mandible at around E11.5, and
continued to be expressed at the anterior base of the tongue around the site of the
future frenulum. Staining in the otic vesicles at E10.5 and E11.5 has not been
reported previously. This could be purely due to trapping of the probe in the vesicle
or might be a true staining which requires further analysis. At this point, no ear
defects have been demonstrated in Tbx22 null mice. Expression patterns observed at
E13.5, prior to shelf elevation, were in good agreement with other previously
published studies (Braybrook et al., 2002; Bush et al., 2002; Herr et al., 2003).
Overall, a good match with the tissues affected by pathological phenotypes in
Tbx22 null mice was observed. These include expression in the middle to posterior
palatal shelves at the site of submucous cleft palate, while expression in the medial
and lateral mesenchyme as well as the frenulum correlate with the appearance of
choanal atresia and ankyloglossia respectively (Pauws et al., 2009a). No obvious
eye phenotype in Tbx22 null mice has been observed and no eye-related defects
have been reported in human CPX patients either.
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3.2 Microarray and real-time PCR analyses show increased
expression of muscle genes in Tbx22 null mice
Tbx22 null mice were developed using the conditional LoxP/Cre method, and were
recently reported by our group (Pauws et al., 2009a). In this mouse line, the first
three exons were removed by crossing floxed animals with β-actin-Cre deleter mice.
The neoR cassette was retained on the Tbx22null allele and also in all the relevant
embryos described in this thesis. In other experiments not described here, removal
of the neoR cassette did not change the phenotype.
Tbx22 null mouse phenotype was investigated by a number of methods including
visual inspection, histology, skeletal preparation and microCT analysis. The next
objective was to investigate the mechanism behind the phenotype, first by looking
at a number of key genes that are expressed in the craniofacial region known to be
required for normal palate development. These included Pax9, Snail, Msx1, Msx2,
Bmp4, Osr1 and Tgfβ3 (Peters et al., 1998; Proetzel et al., 1995; Satokata and Maas,
1994; Murray et al., 2007; Winograd et al., 1997; Zhang et al., 2002; Lu et al.,
2000; Nie, 2005). Cleft palate has not been observed in Osr1 homozygous mutant
mice because they die with severe cardiac and urogenital defects before palate
development is complete (Wang et al., 2005), but an Osr1 knockin has been shown
to rescue the developmental defects of the Osr2 mutant mouse including cleft palate
(Gao et al., 2009; Lan et al., 2004). In addition, previous observation by luciferase
reporter assays suggested an interaction between TBX22 and the OSR1 putative
promoter, making OSR1 a candidate target gene for TBX22 (Dr. A. Andreou
unpublished observation). Expression of these genes was investigated by comparing
wild type and null mice at E13.5 (or E14.5 for Tgfβ3), using section in situ
hybridisation (Figure 3.3). In general, no specific differences were detected, except
for a modest increase in Msx2 in the posterior tongue (Figure 3.3, D) and Pax9
which appeared to be upregulated in the mesenchyme at the base of the nasal
septum through the oronasal membranes in the null embyros, at the site of rupture
in the wild type (Figure 3.3, A). The latter could reflect a primary role of the gene
in cell survival (Robson et al., 2006), but this seemed to be more of a secondary to
the persistence of the oronasal membranes. Although a small proportion of Tbx22
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null mice exhibit an overt cleft palate at later stages (>E15.5), no differences to the
gross morphology of the palatal shelves was noted at E13.5 and the expression
pattern of these genes did not differ significantly (Pauws et al., 2009a).
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Figure 3.3 Expression patterns of Pax9, Snail, Msx1, Msx2, Bmp4, Osr1 and
Tgfβ3
Expression patterns of Pax9 (A), Snail (B), Msx1 (C), Msx2 (D), Bmp4 (E), Osr1
(F) and Tgfβ3 (G) were examined by in situ hybridision at E13.5 (E14.5 for Tgfβ3).
A, anterior; P, posterior (Pauws et al., 2009a).
G
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Since TBX22 is a transcription factor, and likely to be a transcriptional repressor
(Andreou et al., 2007) it was expected that its loss would result in significant
expression changes to one or more of the known or unknown genes active in the
developing palate. It was therefore decided to perform a global comparative
expression analysis using a method that does not introduce biases based on
preconception. One of the most powerful tools for this is microarray analysis, which
can be used to compare the expression of thousands of genes between samples. The
array consists of spots of oligonucleotides, each corresponding to a short section of
a specific gene to which target cDNA or cRNA can be hybridised. The abundance
of each transcript in the target sample is normally detected by fluorophore labelling.
In the experiments described below, comparative gene expression profiles were
generated for developing palatal shelves at E13.5 in the presence and absence of
functional Tbx22. E13.5 embryos were used because the gross morphology of the
wt and null palatal shelves was similar and Tbx22 was detected specifically in the
palatal shelves at this stage (Figure 3.1, O-R). RNA samples were collected from
the dissected palatal shelves of three wt and three null littermates and converted into
cDNA. Integrity and concentration of these samples were determined according to
standard methods before hybridisation to Affymetrix GeneChip® Mouse Gene 1.0
ST Arrays (which contained probes representing for ~29,000 genes) was performed
by Dr Tony Brooks in the UCL Genomics facility. The quality control of the array
data was also carried out by Dr Tony Brooks and indicated a good reproducibility
of biological replicates and detected no outliers (Appendix Figure 1.1). Thus all six
arrays performed were included in the data analysis.
3.2.1 Dysregulated gene expression in Tbx22 null mice
The resulting array data was then returned for analysis with GeneSpring GX 10
(Agilent) software. The programme processes raw array data through background
correction and normalisation between samples (or arrays) to allow identification of
differentially expressed genes. A user can set parameters for selection criteria. For
example, the programme will display genes (or probes, in more precise term, as
some of the probes spotted on array chips do not encode or correlate to known
genes) that changed above the fold change threshold set by a user. In this study, a
threshold of 1.2 fold was chosen in order to incorporate a modest number of
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differentially expressed genes (Figure 3.4 and Table 3.1). The majority of the genes
fall within the blank area between the black lines, while those plotted outside the
lines represent genes that were up or downregulated by 1.2 fold or more (Figure
3.4). Similarly, a statistical test can also be carried out to generate p-values for each
gene.
The MicroArray Quality Control (MAQC) consortium and other groups have
suggested that differentially expressed genes are better identified and results are
more reproducible when selected by fold change rather than statistical t-tests,
pointing out that the impact of normalisation and background correction become
minimal when the fold change is used instead of p-values (Shi et al., 2005; Guo et
al., 2006; Shi et al., 2006). Therefore, initial selection of differentially expressed
genes was made on this basis. Commonly used thresholds are in the region of 2 to 3
fold (Mariani et al., 2003). However, due to the small number of genes that changed
more than 2 fold, the threshold was arbitrarily set to 1.2 fold in order to include a
manageable number of genes for initial target discovary (Table 3.1). Probes that
represented for either predicted or hypothetical proteins for which no gene
information was available, were excluded from the study hereafter (the number of
total probes before removing unknown genes is shown in brackets in Table 3.1). In
the palatal shelves of E13.5 Tbx22 null mice, 85 genes were changed (apart from
Tbx22 itself) at FC >1.2. Of those, 43 genes showed an increase in the null palatal
shelves compared to the wt palatal shelves, while 42 showed a decrease in the null
palatal shelves compared to the wt palatal shelves. The number of genes that were
up and downregulated at this threshold level did not greatly reflect the idea that
Tbx22 mainly acts as a transcriptional repressor (Andreou et al., 2007). However, it
is difficult to judge at this stage, as the biological significance of the 1.2 fold
threshold has not yet been investigated. It may reflect the fact that TBX22 acts only
on a small number of target genes or because of the heterogeneous nature of the
dissected tissue samples used and that only a limited number of the total cell
population from the middle to posterior regions may be Tbx22 positive cells.
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Figure 3.4 Scatter plot graph generated by GeneSpring showing genes that are
changed more than 1.2 fold
The majority of the genes fall in the blank area between the black lines, while the
dots plotted above and below the black lines represent genes that were up or
downregulated by 1.2 fold or more in the Tbx22 null palatal shelves compared to
the wt palatal shelves, respectively.
FC Up Down
> 2.0 0 (2) 1 (8)
> 1.9 0 (2) 1 (9)
> 1.8 1 (3) 1 (10)
> 1.7 1 (3) 1 (10)
> 1.6 2 (5) 1 (10)
> 1.5 5 (8) 1 (10)
> 1.4 9 (40) 2 (11)
> 1.3 19 (85) 9 (24)
> 1.2 43 (154) 42 (90)
> 1.1 (888) (1076)
Table 3.1 Fold change and the number of genes up and down regulated in the
Tbx22 null palatal shelves compared to the wt palatal shelves
The number of genes that changed more than the given thresholds is tabulated. The
number of total probes before removing those represented for predicted genes and
hypothetical proteins where no gene information was available is shown in brackets.
For FC >1.1, the probes that encode known genes were not manually screened for
but is also expected to be lower than the number shown in brackets.
Downregulated
Upregulated
Tbx22
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Next, the genes that increased or decreased more than 1.2 fold were tabulated with
the Affymetrix Transcripts Cluster ID, gene symbol, gene description, gene
function, fold change and p-value (Table 3.2 and 3.3). The fold change values in
general were modest and the p-values for the majority of genes were above 0.05.
The fold change for Tbx22 itself was 2.88 (p=0.0087).
Those that had FC >1.2 and p<0.05 in the upregulated list included carbonic
anhydrase 10 (FC=1.39 p=0.025), troponin T3, skeletal, fast (FC=1.32, p=0.027),
myosin, heavy polypeptide 7, cardiac muscle, beta (FC=1.25, p=0.022), cholinergic
receptor, nicotinic, beta polypeptide 1 (muscle) (FC=1.22, p=0.0068),
DENN/MADD domain containing 4A (FC=1.22, p=0.032), X-linked lymphocyte-
regulated 5B | 5C | 5A (FC=1.21, p=0.028), alkaline phosphatase 3, intestine, not
Mn requiring (FC=1.21, p=0.00048) and collectin sub-family member 10 (FC=1.21,
p=0.0084).
Those that had FC >1.2 and p<0.05 in the downregulated list included cytochrome c
oxidase subunit VIIb (FC=2.01, p=0.0047), magnesium transporter 1 (FC=1.33,
p=0.0019), zinc finger protein 294 (FC=1.28, p=0.026), gamma-aminobutyric acid
(GABA-A) receptor, subunit beta 2 (FC=1.24, p=0.000024), multiple inositol
polyphosphate histidine phosphatase 1 (FC=1.23, p=0.030), coiled-coil domain
containing 46 (FC=1.23, p=0.0031), angiotensin II, type I receptor-associated
protein (FC=1.22, p=0.025) and a disintegrin-like and metallopeptidase with
thrombospondin type 1 motif, 17 (FC=1.20, p=0.028).
However, none of these were obvious candidate genes known to be important for
normal palate development, with the possible exception of gamma-aminobutyric
acid (GABA-A) receptor, subunit beta 2 (Gabrb2). Downregulation of Gabrb2 as
well as gamma-aminobutyric acid (GABA-A) receptor, subunit alpha 1 (Gabra1)
(FC=1.22, p=0.15) and glutamate receptor, ionotropic AMPA4 (alpha 4) (Gria4)
(FC=1.21, p=0.13) is potentially interesting considering the importance of
GABAergic inhibitory neurotransmission in normal palate development. This is
demonstrated by cleft palate mice that lack gamma-aminobutyric acid (GABA-A)
receptor, beta 3 subunit (Gabrb3) (Hagiwara et al., 2003; Homanics et al., 1997) or
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the glutamic acid decarboxylase (Gad1 also known as Gad67) that synthesise
GABA from glutamate (Asada et al., 1997; Condie et al., 1997).
Next, the up or downregulated genes above FC >1.2 were looked at regardless of
their p-values. The array data showed an increase in Keratin 5 (Krt5) in the null
palatal shelves (FC=1.27, p=0.097). It is known that the palatal epithelium is
orthokeratinised following fusion of the palatal shelves (Gibbs and Ponec, 2000).
Upregulation of loricrin which encodes for a predominant protein Loricrin found in
keratinocytes, as well as type I and II keratin are reported to be increased between
E14.5 and E15.5 (Brown et al., 2003). However, it is not straightforward to put this
into the biological context of Tbx22 null mice as there is no obvious defect found in
the palatal epithelium or palatal fusion. Paired box gene 3 (Pax3) was
downregulated in the null palatal shelves (FC=1.21, p=0.40). This is potentially
interesting since persistent expression of Pax3 in the neural crest is known to cause
cleft palate (Wu et al., 2008). Alcohol dehydrogenase 1 (Adh1) was also
downregulated (FC=1.27, p=0.27). Dehydrogenase enzymes are required in retinoid
metabolism, and cleft palate can be induced by retinoic acid in mice (Padmanabhan
and Ahmed, 1997; Degitz et al., 1998). Therefore this could also be interesting to
follow up in the future.
Despite the fact that we observed an ossification defect in the null mice at later
stages, other than cathepsin K (Ctsk) which increased by 1.62 fold (p=0.074), no
obvious gene markers of osteogenesis were detected at FC >1.2 at the stage
examined. Some of the cleft palate candidate genes and genes related to ossification
described in the Introduction were then individually checked for their FC, but the
values for many of those were between 1.0 to 1.1 (Appendix Table 1.1). There is a
possibility that expression of these genes might be slightly altered, in which case it
is unlikely to be detected especially because the palatal shelves contained both
Tbx22 expressing and non-expressing cells.
Interestingly, there was a noticeable general increase in muscle related genes in the
null palatal shelves compared to the wt palatal shelves. There were 20 muscle
related genes in the upregulated list at FC >1.2, including members of the myosin,
actin, actinin, titin, troponin, tropomyosin and calsequestrin gene families
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(highlighted in yellow in Table 3.2). In contrast, no muscle genes were represented
in the downregulated list. This prompted an investigation of some of these muscle
genes for validation by real-time PCR since Tbx22 mainly acts as a transcriptional
repressor (Andreou et al., 2007) and thus the potential downstream target genes
were expected to be upregulated. Of those upregulated, myosin, heavy polypeptide
3, skeletal muscle, embryonic (Myh3) (FC=1.57, p=0.061), actin, alpha 1, skeletal
muscle (Acta1) (FC=1.35, p=0.12) and calsequestrin 2 (Casq2) (FC=1.30, p=0.21)
were initially chosen as representatives to be examined by real-time PCR.
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3.2.2 Validation of results
Since the results obtained from microarray studies can contain false positives,
several upregulated genes of interest were investigated by the commonly used
validation procedure of real-time PCR. Initially, gene expression of Ctsk and three
different muscle genes Myh3, Acta1 and Casq2 were compared between the wt and
null mice at E13.5. At least three biological triplicates (littermates of the same
genotype but from a different litter to the original microarray analysed samples)
were performed for each gene and both Gapdh and 18S rRNA (data not shown for
18S rRNA since no significant differences between the two housekeeping genes
were detected) were used as endogenous controls.
Ctsk encodes for a lysosomal cysteine protease expressed in osteoclasts that are
involved in bone resorption. Despite the fact that the obvious phenotype in the null
palate is a defective ossification which becomes apparent from E15.5, this was the
only gene related to osteogenesis at E13.5. The microarray data showed that Ctsk
was upregulated in the null palatal shelves compared to those from the wt (FC=1.62,
p=0.074). However, expression of Ctsk examined by real-time PCR showed only a
slight increase by 1.13 fold which was not significantly different (p=0.54) (Figure
3.5) and thus was not investigated further. Runx2 and Osterix, key osteogenic
markers, were also examined by real-time PCR, but no differences were detected at
this stage (Figure 3.5). Since the microarray data indicated a general upregulation of
muscle related transcripts in the null palatal shelves, several of these genes were
investigated by real-time PCR. For this purpose, Myh3, Acta1 and Casq2 were
chosen as representatives from different muscle gene families. Myh3 encodes for
heavy chain of myosin which is a major muscle contractile protein. Acta1 encodes
for alpha actin which is also a major constituent of the muscle contractile protein
found in skeletal muscle. Casq2 encodes for a cardiac calsequestrin which is a
calcium binding protein found in the sarcoplasmic reticulum. Though it is termed
‘cardiac’ and its expression is exclusively found in the heart primordium during
early development (E8-E9), later it is known to be highly expressed in the fetal
skeletal muscles including those of the soft palate (Park et al., 1998). Using real-
time PCR, expression of these muscle related genes, Myh3, Acta1 and Casq2, were
increased by 2.44 (p=0.030), 2.16 (p=0.030) and 2.32 (p=0.035) fold respectively in
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the palatal shelves of the null compared to the wt (Figure 3.5). Though the fold
change values calculated by real-time PCR were higher than those from the
microarray data, the two assays indicated consistent trends of upregulation for these
three muscle genes. Thus far, the microarray results for other genes have not been
validated by real-time PCR.
3.2.3 Myogenic regulatory factors
In the microarray analysis, the threshold was arbitrarily set to 1.2 fold change so
that the list included a manageable number of genes for initial screening. Although
no obvious early muscle markers or markers of muscle differentiation were detected
above the 1.2 fold threshold, it was decided to investigate several such genes to try
to explain the global upregulation of late structural muscle genes such as myosin
and muscle actin. Myogenesis is the formation of muscular tissue, involving the
determination of mesodermal precursor cells, myoblast proliferation, fusion and
differentiation into myotubes. These steps are regulated by the MyoD family of
bHLH transcription factors including MyoD, Myf5, myogenin and Mrf4. Of these,
MyoD and Myf5 are known to have a role in initiation of myogenic differentiation
while myogenin is critical for terminal differentiation of myoblasts (Hasty et al.,
1993; Nabeshima et al., 1993). Interestingly Mrf4 does not direct skeletal muscle
identity in the developing head (Kassar-Duchossoy et al., 2004), suggesting that the
myogenesis pathway operates differently in the head and trunk. This may be due to
the fact that the majority of craniofacial muscles, except the tongue and laryngeal
muscles, arise from anterior paraxial and prechordal mesoderm whereas skeletal
muscles in the trunk are derived from somitic mesoderm.
The fold changes for the myogenic regulatory factors were individually examined
as none of them appeared in the list at FC >1.2. The microarray data indicated a
general trend towards increased expression for MyoD (FC=1.17, p=0.27), myogenin
(FC=1.09, p=0.70) and Myf5 (FC=1.19, p=0.13) as well as p21 (FC=1.09, p=0.53),
a known target of MyoD (Table 3.4). Next, the array data was confirmed by real-
time PCR. Expressions of MyoD (FC=1.73, p=0.017), myogenin (FC=1.69,
p=0.038) and p21 (FC=1.62, p=0.031) were increased in the null palatal shelves
compared to the wt (Figure 3.5). Myf5 also showed a tendency towards increased
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expression but did not achieve a statistical significance (FC=1.75, p=0.10) (Figure
3.5).
ID Gene symbol Gene description Regulation FC p-value
10553256 MyoD Myogenic differentiation 1 up 1.17 0.27
10349993 Myog Myogenin up 1.09 0.70
10372226 Myf5 Myogenic factor 5 up 1.19 0.13
10443463 Cdkn1a (p21) Cyclin-dependent kinase inhibitor 1A (P21) up 1.09 0.53
Table 3.4 The microarray data show a trend towards increased expression of
MRFs and p21 in the Tbx22 null palatal shelves
Microarray data for MyoD, Myf5, myogenin and p21 comparing between the wt and
Tbx22 null palatal shelves at E13.5 are tabulated with the Affymetrix Transcripts
Cluster ID, gene symbol, gene description, regulation, fold change and p-values.
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3.2.4 Summary
Initially, several well-known cleft palate candidate genes (Pax9, Snail, Msx1, Msx2,
Bmp4, Osr1 and Tgfβ3) were investigated for their expression pattern in wt and
Tbx22 null mice. However, no obvious or significant differences were detected.
Therefore, in order to obtain a global picture of differentially expressed genes in the
absence of Tbx22, we performed a microarray on E13.5 palatal shelves. Though the
fold changes were generally modest, possibly due to the heterogeneous nature of the
samples, the assay data revealed several interesting genes above the set threshold.
These include Gabrb2, Gabra1, Gria4, Adh1 and Pax3 that were all downregulated.
These were not followed up in this particular project because the primary aim was
to look at upregulated genes, based on the hypothesis that TBX22 mainly acts as a
transcriptional repressor. In the list of upregulated genes, many genes relating to
muscle development were identified. This was unlikely to have been a random
occurrence especially because no similar genes were present in the downregulated
list. Increased expression of some of these genes including the key myogenic
regulatory factors MyoD and myogenin were confirmed by real-time PCR. There
were no obvious changes in several osteogenic genes tested in the Tbx22 null
palatal shelves at E13.5.
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3.3 TBX22 is capable of regulating MyoD in vitro
3.3.1 Putative promoters of MRFs contain TBEs
As Tbx22 has been shown to preferentially interact with a conserved T-box binding
element (TBE) (Andreou et al., 2007), genomic sequences up to 2 kb upstream of
the transcription start site to the first exon of several genes were scanned for the
presence of possible TBEs using the JASPAR database (http://jaspar.cgb.ki.se/)
(Table 3.5). Of those analysed, the putative promoters for MyoD, myogenin, Myf5
and Acta1 all contained one or more TBE. The presence of a TBE in the putative
promoter suggested that Tbx22 could potentially bind or indeed regulate the
expression of this gene in vivo. However, this was a very inexact determination and
required testing by functional assays. For this analysis, Myf5 was excluded because
it was not significantly changed in the Tbx22 null palatal sheves as measured by
real-time PCR. Myogenin and muscle specific genes including myosin and actin are
known to be regulated by MyoD (Asakura et al., 1993; Deato et al., 2008; Sartorelli
and Caretti, 2005; Shklover et al., 2007; Wheeler et al., 1999). In addition, No tail, a
zebrafish ortholog of Brachyury, has previously been shown to interact with the
upstream region of the MyoD gene (Morley et al., 2009). Therefore it was decided
to follow up the potential interaction between TBX22 and MyoD.
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Gene Position relative to TSS Strand Predicted site sequence
MyoD -515 bp to -505 bp -1 5’-TGCTCACCTAG-3’
3’-ACGAGTGGATC-5’
Myf5 -699 bp to -689 bp 1 5’-CTAGGTCTGAT-3’
3’-GATCCAGACTA-5’
“ -1316 bp to -1306 bp 1 5’-CCAAGTGTGAA-3’
3’GGTTCACACTT-5’
myogenin -813 bp to -803 bp 1 5’-CTAGGGGAGAA-3’
3’-GATCCCCTCTT-5’
“ -1810 bp to -1800 bp -1 5’-CTAGGTGTGAT-3’
3’-GATCCACACTA-5’
Myh3 - - -
Acta1 -938 bp to -928 bp -1 5’-CTGGGTCTGAA-3’
3’-GACCCAGACTT-5’
Casq2 - - -
p21 - - -
Table 3.5 MRF putative promoters contain one or more TBEs
Genomic sequences extending 2 kb upstream of the transcription start site to the
first exon were scanned for the presence of putative TBEs. For each gene, predicted
site sequence and its position relative to the transcription start site is shown. Strand
1 and strand -1 refer to positive and negative strands, respectively.
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3.3.2 TBX22 is expressed in HEK 293T cells
Initially, it was decided to investigate whether TBX22 can regulate or interact with
the MyoD promoter using in vitro reporter assays and chromatin
immunoprecipitation in HEK 293T cells. These experiments used V5-tagged human
TBX22 constructs, including the wt sequence (pcDNA3.1.TBX22.V5/His) and a
mutant containing a missense asparagine to a tyrosine substitution at position 264
(pcDNA3.1.TBX22(N264Y).V5/His). This N264Y mutation was identified in one
of the classic CPX families (Marcano et al., 2004), and has previously been shown
to abolish TBX22 function, as assessed by DNA binding and repression of the
TBX22 P0 promoter (Andreou et al., 2007). Therefore the mutant N264Y was used
as a control alongside the wtTBX22 sequence in the following experiments. It was
first necessary to confirm that both constructs were correctly expressed following
transfection. Figure 3.6 shows that the wtTBX22 and N264Y proteins were
successfully detected, while no band was observed in the mock (pcDNA3.1.V5/His)
transfected lane. β-actin was used as a loading control, which showed a similar level
of expression in all samples.
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Figure 3.6 Immunoblot analysis of HEK 293T cells transfected with mock,
wtTBX22 or N264Y
HEK 293T cells were transfected with mock, wtTBX22 or N264Y, and subjected to
immunoblot analysis using anti-V5 antibody. β-actin was used as a loading control.
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3.3.3 TBX22 can repress the MyoD promoter activity in vitro
In silico analysis revealed a TBE upstream of MyoD transcription start site (-515
bp/-505 bp). To assess the transcriptional activity of TBX22 on the MyoD putative
promoter, HEK 293T cells were transfected with MyoD promoter-luciferase
construct (pGL3-MyoD) which included the TBE (Figure 3.7, A) and vectors
constitutively expressing either the wtTBX22 or the mutant N264Y. Luciferase is
an enzyme that produces light upon oxidising its substrate luciferin and is
commonly used as a reporter gene to assess the transcriptional activity of a gene of
interest on a putative promoter. pGL3-Basic vector contains firefly luciferase gene
(luc+) but lacks eukaryotic promoter or enhancer sequences. Thus successful
expression of luciferase depends on a functional promoter being placed upstream
from the luc gene. The basal promoter activity of pGL3-MyoD in HEK 293T cells
was 23.7 fold higher than that of empty pGL3 (p=0.00010) (Figure 3.7, B). A dose-
dependent repression of MyoD promoter activity down to 46.2% was observed with
addition of wtTBX22 (down to 67.0% by 2.5 ng wtTBX22 (p=0.0060) and 46.2%
by 10 ng wt TBX22 (p=0.0015)) but not by the addition of a control construct
expressing GFP (Figure 3.7, B). This effect was largely abrogated in the N264Y
mutant. The data presented is a representative of three independent experimental
repeats and the average values were calculated based on four replicates.
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Figure 3.7 TBX22 represses the MyoD promoter activity
Schematic showing pGL3 and pGL3-MyoD constructs (A). TBX22 repressed the
MyoD promoter activity in luciferase assay (B). 50 ng of pGL3 vector containing
the MyoD putative promoter region (-683 bp/+115 bp) was cotransfected with 10 ng
of pcDNA3.1 empty vector, 2.5 and 10 ng of wtTBX22, N264Y or GFP in HEK
293T cells. Bars represent relative promoter activity after normalising firefly
luciferase light unit to Renilla luciferase light unit. Relative promoter activity of
pGL3-MyoD cotransfected with 10 ng of pcDNA3.1 empty vector was arbitrarily
set at 100. The graph is a representative of three independent experimental repeats
and the values shown are the average of four replicates. The error bars represent
standard deviation. *p<0.05, paired Student’s t test.
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3.3.4 Abolition of the putative TBE sequence in the MyoD promoter
does not affect TBX22 dependant repression
To investigate a direct effect of TBX22 on the putative MyoD TBE, two invariant
bases of the consensus sequence (TGCTCACCTAG) were substituted using in vitro
mutagenesis. This resulted in substitutions of the C to A at -511 bp relative to TSS
and C to A at -509 bp relative to TSS (TGCTAAACTAG), known as pGL3-mut
MyoD hereafter. Using pGL3-mut MyoD, the transcriptional activity of TBX22 on
the mutated MyoD putative promoter in HEK 293T cells was assessed. Cells were
transfected with pGL3-mut MyoD which included the mutated TBE, and expression
vector that constitutively expressed the wtTBX22. The basal promoter activity of
pGL3-mut MyoD in HEK 293T cells was 24.6 fold higher than that of pGL3
(p=0.00027) (Figure 3.8). Similarly to the results obtained from pGL3-MyoD, a
dose-dependent repression of the mutated MyoD promoter activity down to 36.8%
was observed with the wtTBX22 (down to 65.6% by 2.5 ng wtTBX22 (p=0.0045)
and 36.8% by 10 ng wt TBX22 (p=0.00037)) but not by the addition of a GFP
control construct (Figure 3.8). The data presented is a representative of three
independent experimental repeats and the average values were calculated based on
four replicates. This experiment indicates that the inhibition detected does not occur
through specific interaction with the predicted TBE.
138
0
20
40
60
80
100
120
pGL3 empty pGL3-mut MyoD
wtTBX22
pGL3-mut MyoD
GFP
Re
la
tiv
e
M
yo
D
pr
om
ot
er

ac
tiv
ity
-
2.5ng
10ng
*
*
Re
la
tiv
e
M
yo
D
pr
om
ot
er

ac
tiv
ity
Figure 3.8 Change in the putative TBE sequence in MyoD promoter region
does not alter repressive effect of TBX22
50 ng of pGL3 vector containing the mutated MyoD putative promoter region (-683
bp/+115 bp) was cotransfected with 10 ng of pcDNA3.1 empty vector, 2.5 and 10
ng of wtTBX22, or GFP in HEK 293T cells. Bars represent relative promoter
activity after normalising firefly luciferase light unit to Renilla luciferase light unit.
Relative promoter activity of pGL3-MyoD cotransfected with 10 ng of pcDNA3.1
empty vector was arbitrarily set at 100. The graph is a representative of three
independent experimental repeats and the values shown are the average of four
replicates. The error bars represent standard deviation. *p<0.05, paired Student’s t
test.
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3.3.5 TBX22 can interact with MyoD promoter region
Although TBX22 had a specific repressive effect on the MyoD promoter in vitro, it
appeared to be independent of the putative TBE. In order to investigate if a physical
interaction exists between TBX22 and the MyoD promoter region, the technique of
chromatin immunoprecipitation was used. The assay however, does not distinguish
if the interaction is direct or indirect (i.e. via co-factors or other accessory proteins
that may exist). As above, the expression vectors used were V5-tagged so that they
could be immunoprecipitated with anti-V5 antibody and protein G. Following
transient transfection into HEK 293T cells, the MyoD promoter region was detected
by PCR amplification from total inputs as expected, and from the wtTBX22
immunoprecipitated with anti-V5 antibody but not from the N264Y mutant (Figure
3.9). This suggested either direct or indirect interaction did specifically occurred
between the wtTBX22 and the MyoD promoter region but was abolished by the
N264Y mutation. No amplification was observed from mock transfected samples,
or samples immunoprecipitated without anti-V5 antibody (Data published in
Kantaputra et al., J. Dent. Res. 2011 – in press).
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Figure 3.9 ChIP-PCR MyoD
HEK 293T cells were transfected with mock, wtTBX22 and N264 expression
vectors prior to chromatin immunoprecipitation. PCR amplification of the MyoD
promoter region was detected from total inputs as expected, and from the wtTBX22
immunoprecipitated with anti-V5 antibody but not from N264Y. No amplification
was observed from mock transfected samples, or samples immunoprecipitated
without anti-V5 antibody.
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3.3.6 Endogenous MyoD is not repressed by overexpression of
TBX22 in C2C12 cells
Next, C2C12 cells were used to examine if overexpression of TBX22 has any effect
on the endogenous level of MyoD expression. C2C12 is a mouse myoblast cell line
which was originally obtained by Yaffe and Saxel (1977) through selective serial
passage of myoblasts cultured from the thigh muscle of C3H mice 70 hours after a
crush injury (Yaffe and Saxel, 1977), and have been shown to express muscle
proteins including MyoD. The C2C12 cells differentiate when they become
confluent, forming myotubes. This eventually depletes the myoblastic population.
In the experiment, the undifferentiated cells were transfected with mock, wtTBX22,
N264Y or GFP. 1 µg of each DNA plasmid was used for cells in 6 well plate. Then
mRNA was collected from the transfected cells after 48 hours of incubation, and
subjected to real-time PCR for quantitative assay. A high transfection efficiency
was reflected in the huge increase in Tbx22 expression (Figure 3.10). However,
overexpression of the wtTBX22 did not alter the level of endogenous MyoD
expression in C2C12 cells (Figure 3.10). The endogenous MyoD expression level in
cells transfected with N264Y and GFP constructs were also similar to that of the
mock transfected cells.
141
Tbx22
0
500
1000
1500
2000
2500
3000
Mock (1µg) wtTBX22 (1µg)Tb
x2
2

re
la
tiv
e

e
xp
re
ss
io
n

n
o
rm
a
lis
e
d
to

G
ap
dh




.
MyoD
0
0.4
0.8
1.2
Mock (1µg) wtTBX22 (1µg) N264Y (1ug) GFP (1µg)En
do
ge
n
o
u
s
M
yo
D

re
la
tiv
e

e
xp
re
ss
io
n

n
o
rm
a
lis
e
d
to

G
a
pd
h
Figure 3.10 Overexpression of TBX22 does not alter endogenous MyoD
expression in C2C12 cells
Effect of Tbx22 overexpression on endogenous MyoD in C2C12 cells was
quantified by real-time PCR and normalised against Gapdh. Relative expression of
mock transfected sample was arbitrarily set at 1. The error bars represent standard
deviation. The graph is a representative of four independent experimental repeats.
*p<0.05, paired Student’s t test.
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3.3.7 Summary
Real-time PCR revealed increased expression of MyoD and myogenin in the palatal
shelves of Tbx22 null mice. Another key transcription factor of myogenesis Myf5
also showed a trend towards increased expression in the null palatal shelves but
failed to achieve a statistical significance. These MRFs form heterodimers with
ubiquitously expressed E proteins which bind to a specific DNA sequence called E-
box (consensus sequence CANNTG) found in many muscle gene promoters to
activate gene expression (Lassar et al., 1991). It is possible that a number of late
muscle structural genes were found upregulated in microarray analysis as a
consequence of increased MRFs. Luciferase assay showed TBX22 can regulate
MyoD promoter activity in HEK 293T cells which provides a link between lack of
functional TBX22 and increased MyoD expression followed by increased late
muscle markers in Tbx22 null mice. Substitution of two bases in the TBE sequence
in MyoD promoter region, however, did not affect TBX22 dependent repression.
This suggests possibilities that the protein may act on sequence other than the TBE
or involves co-factors (Pauws et al., 2009b). ChIP-PCR demonstrated that TBX22
is capable of interacting with the MyoD promoter region in HEK293T cells. Taken
together, these assays indicate TBX22 can regulate MyoD expression in vitro.
However, endogenous MyoD was not repressed by overexpression of TBX22. This
was performed in C2C12 cell line because HEK 293T cells do not express
endogenous MyoD. Thus, this could be due to context differences between these
cell lines, where C2C12 cells may not express, for example, the necessary co-
factors or other accessory proteins.
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3.4 Molecular mechanisms underlying the submucous cleft
palate phenotype in Tbx22 null mice
Concurrent with the efforts to identify downstream target genes of TBX22, an
important focus of this project was also to elucidate a possible molecular
mechanism underlying the pathology of the submucous cleft palate phenotype
observed in Tbx22 null mice.
In Tbx22 null mice, the majority of null animals exhibit submucous cleft palate
rather than a complete cleft of the secondary palate. It is estimated that ossification
of the palatine bone in the secondary palate is severely reduced by 68% compared
to the wt (Pauws et al., 2009a). Detailed analysis of the null palate at E15.5 revealed
a lack of mineralized bone and reduced osteoblastic activity measured by alkaline
phosphatase, an osteoblast marker, in the null palatine bone. In addition, the area of
Runx2 expression was smaller in the null posterior palate, indicating a reduced
number of osteoblasts (Pauws et al., 2009a). However, it was not entirely clear if
the severe palatine bone reduction in the null posterior palate was primarily caused
by a reduction in osteoblast proliferation or delayed differentiation and/or
maturation, or another mechanism.
Unlike overt cleft palate, only a couple of animal models of submucous cleft palate
have been described including Tshz1 and Tgfbr2 deficient mice (Core et al., 2007;
Xu et al., 2006). These, however, exhibit a cleft or premature truncation of the soft
palate and might be considered a partial overt cleft rather than a true submucous
cleft. There are several mouse models with overt cleft palate where Tbx22
expression analyses have been performed, including Mn1-/- mutant mice (Liu et al.,
2008; Meester-Smoor et al., 2005) and 36Pub mutant mice deficient for Spry2
(Welsh et al., 2007). Meningioma 1 (MN1) was first described as the gene disrupted
by balanced chromosomal translocation in meningioma (Lekanne Deprez et al.,
1995), although mice with a targeted deletion in Mn1 did not lead to increased
incidence of tumour formation but instead they developed severe craniofacial bone
defects including cleft palate (Meester-Smoor et al., 2005). This mouse model is of
particular interest because a recent study which used these mice showed that the
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transcription factor acts upstream of Tbx22 by demonstrating a downregulated
expression of the gene in the null palatal shelves at E13.5. They also noted a
reduced expression of Cyclin D2 accompanied by reductions in cell proliferation in
the middle and posterior regions of the null palatal shelves at E13.5 (Liu et al.,
2008). More recently, another group showed an essential role of MN1 in osteoblast
proliferation, differentiation and maturation (Zhang et al., 2009). The altered
expression of Tbx22 was also shown in the 36Pub mutant mice that essentially
lacked the FGF signalling antagonist Spry2 which resulted in palate and facial
clefting due to excessive cell proliferation, revealing importance of growth signal
dosage (Welsh et al., 2007). In these mice, expression of Tbx22 did not expand to
the posterior end of the palatal shelves as it did in the wt at E14.5.
These studies prompted the investigation of cell proliferation rates in Tbx22 null
mice, since an altered cell cycle rate could also explain the submucous cleft palate
phenotype, possibly in combination with defects in osteoblast differentiation and/or
maturation. In addition to cell proliferation, cellular apoptosis in the Tbx22 null
palatal shelves was also examined although there are only a couple of animal
models where altered apoptosis is thought to be responsible for a cleft palate
phenotype (Dudas et al., 2006; Rice et al., 2004).
3.4.1 Cell proliferation measured by phospho-Histone H3 in the
palatal shelves at E13.5
It was decided to investigate E13.5 embryos as Tbx22 is expressed specifically and
at relatively high levels in the growing palatal shelves at this time. This is also the
developmental stage just prior to palatal shelf elevation when some other mouse
models with cleft palate such as Osr2, Msx1, Fgf10 and Fgfr2b mutant mice exhibit
defects in cell proliferation (Ito et al., 2003; Lan et al., 2004; Rice et al., 2004;
Satokata and Maas, 1994).
Cell proliferation was measured by immunohistochemical assay using phospho-
Histone H3 (Ser10) as a primary antibody. Histone H3 is specifically
phosphorylated on serine 10 during late S or G2 cell cycle phases and is a
convenient way to assess the mitotic index. For analysis, the palatal shelves were
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categorised into the anterior, middle and posterior regions. The number of cells
stained with DAPI and the number of phospho-Histone H3 positive cells on six
serial sections per region from four wt and four null littermates were then counted
in the palatal epithelium and mesenchyme.
In the palatal epithelium at E13.5, the percentage of the phospho-Histone H3
positive cells in the anterior (2.47±1.34% in the wt, 2.69±0.89% in the null, p=0.84),
middle (3.34±0.57% in the wt, 3.30±1.09% in the null, p=0.95) or posterior
(2.55±0.67% in the wt, 2.78±1.10% in the null, p=0.77) regions did not differ
significantly between the wt and null mice (Figure 3.11, A-F, G). In the palatal
mesenchyme, the percentage of phospho-Histone H3 positive cells was significantly
reduced by 53.9% in the middle region of the null palatal shelves compared to the
wt (4.25±1.15% in the wt, 1.96±0.19% in the null, p=0.03) (Figure 3.11, B, E and
H). In the posterior region, a 42.7% reduction was observed in the null palatal
mesenchyme on average but was not statistically significant (2.93±1.25% in the wt,
1.68±0.27% in the null, p=0.20) (Figure 3.11, C, F and H), whereas no alteration in
cell proliferation was detected in the anterior palatal mesenchyme where there is no
expression of Tbx22 (2.03±0.20% in the wt, 1.94±0.27% in the null, p=0.41)
(Figure 3.11, A, D and H).
The results suggest that loss of Tbx22 leads to reduced cell proliferation rates
especially in the middle to posterior palatal mesenchyme where the gene is
expressed (Figure 3.2), but not in the anterior region at E13.5. There was no
significant difference in the proliferation rate in the palatal epithelium along the
anterior to posterior regions. This was expected as Tbx22 is known to be expressed
almost exclusively in the palatal mesenchyme but not in the epithelium (Braybrook
et al., 2002; Bush et al., 2002). Therefore, it seems like TBX22 has a role in cell
proliferation in the palatal mesenchyme at E13.5, in addition to previously
suggested roles in osteoblast differentiation and maturation at later stages. It could
also be that, in the growing palatal shelves, those cells actively proliferating more in
the wt might be the ones that become osteoblasts later in palate development.
146
wt
Anterior Middle Posterior
E
C
D
BA
F
null
147
Figure 3.11 Analysis of cell proliferation in the wt and Tbx22 null mouse
palatal shelves at E13.5
Cell proliferation in the palatal shelves at E13.5 was measured by
immunohistochemical assay using phospho-Histone H3 antibody. For analysis, the
palatal shelves were categorised into the anterior (A and D), middle (B and E) and
posterior (C and F) regions. The area of tissue counted for positive cells was
restricted to the approximate area of each palatal shelf as shown in panels A-H. The
percentage of phospho-Histone H3 positive cells was seperately analysed for the
epithelium (G) and mesenchyme (H) in each region. In comparison with the wt, the
number of phospho-Histone H3 positive cells in the null palatal mesenchyme was
significantly reduced in the middle region (H). The error bars represent standard
deviation. *p<0.05, paired Student’s t test. Scale bar = 50 µm.
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3.4.2 Apoptosis measured by cleaved Caspase-3 in the palatal
shelves at E13.5
Apoptosis was measured by immunohistochemical assay using cleaved Caspase-3
as a primary antibody. Inactive full length Caspase-3 zymogen is activated during
apoptosis, by cleavage into p17 and p12 fragments. The p17 fragment is then
recognised by the primary antibody. For analysis, the palatal shelves were
categorised into the anterior, middle and posterior regions as described above. The
total number of cells stained with DAPI and the number of Caspase-3 positive cells
on six serial sections from four wt and four null littermates were then counted.
At E13.5, only very few cells were positive for cleaved Caspase-3 in the palatal
shelves (Figure 3.12, A-F), and no significant difference in terms of percentage of
cleaved Caspase-3 positive cells was detected in the anterior (0.05±0.02% in the wt,
0.04±0.01% in the null, p=0.23), middle (0.11±0.04% in the wt, 0.09±0.04% in the
null, p=0.49) or posterior (0.08±0.02% in the wt, 0.08±0.01% in the null, p=0.97)
regions of the wt and null palatal shelves (Figure 3.12, G). The results suggest that
Tbx22 does not seem to have an obvious role in apoptosis in the growing palatal
shelves at this developmental stage.
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Figure 3.12 Analysis of cell apoptosis in the wt and Tbx22 null mouse palatal
shelves at E13.5
Cell apoptosis in the palatal shelves at E13.5 was measured by
immunohistochemical assay using cleaved Caspase-3 antibody. For analysis, the
palatal shelves were categorised into the anterior (A and D), middle (B and E) and
posterior (C and F) regions, and the percentage of Caspase-3 positive cells were
analysed (G) in each region. The area of tissue counted for positive cells was
restricted to the approximate area of each palatal shelf as shown in panels A-H. The
number of cleaved Caspase-3 positive cells did not differ significantly between the
wt and null palatal shelves (G). The error bars represent standard deviation. *p<0.05,
paired Student’s t test. Scale bar = 50 µm.
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3.4.3 Reduced cell proliferation in the null palatal shelves is
accompanied by a decreased Cyclin D2 expression
The process of cell cycle regulation is mainly controlled by two key factors, cyclins
and cyclin-dependent kinases (CDKs) that are well conserved among all eukaryotes.
Of these, CDKs are expressed constitutively whereas cyclins are produced in
response to various signals. Of particular note, Cyclin D is the first to be
synthesised in response to growth factors stimulating the cell cycle.
It was interesting to note that the expression level of Cyclin D2 was shown to be
reduced in Mn1-/- mice where cell proliferation was also decreased (Liu et al., 2008).
Moreover, it was also reported that the expression level of Tbx22 in Mn1-/- mice
was dramatically reduced in the palatal shelves at E13.5. Therefore, to examine if
the reduced cell proliferation in Tbx22 null mice is accompanied by a decreased
Cyclin D2 expression, expression levels of this gene were examined by whole
mount in situ hybridisation.
Although Cyclin D2 was expressed globally, expression in the anterior to middle
regions of the growing palatal shelves in the null compared to the wt at E12.5 and
E13.5 was specifically downregulated (Figure 3.13). Tbx22 expression in the palatal
shelves partially overlapped with Cyclin D2 expression. However this seemed
ambiguous especially at E13.5 because Tbx22 expression in some embryos was
found in the middle regions but in other embryos it was detected in more posterior
regions of the palatal shelves. It is therefore possible that TBX22 plays a role in
regulating cell proliferation rates, which may or may not be via modulating the
level of Cyclin D2 expression in the palatal shelves at these developmental stages.
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3.4.4 Summary
To summarise, cell proliferation seemed to have been compromised in the middle
regions of the palatal shelves in Tbx22 null mice compared to the wt littermates,
whereas no obvious difference in apoptosis was observed at E13.5. The reduced
proliferation in the Tbx22 null palatal shelves was specific to the palatal
mesenchyme. Tbx22 is almost exclusively expressed in the mesenchyme but not in
the epithelium, suggesting a cell autonomous effect in the regulation of cell
proliferation. Examination of Cyclin D2 expression revealed a reduction in the null
palatal shelves at E12.5 and E13.5 which may help to explain the reduced cell
proliferation although Tbx22 and Cyclin D2 only partially overlapped. Cyclin D2
expression in the anterior region seemed to have decreased but cell proliferation
rate was unaffected anteriorly. This aspect needs more careful examination by
techniques such as section in situ hybridisation, nevertheless Tbx22 seems to
regulate cell proliferation whether it is through cyclin D2 expression or not.
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3.5 Expression analyses of growth factor genes in wt and
Tbx22 null mouse palatal shelves
The most common cause of cleft palate found in mouse models is defective palatal
shelf growth often caused by altered cell proliferation. This has been the case for
Tbx22 null mice that also display delayed ossification of the posterior hard palate
(Pauws et al., 2009a). Palatal growth is a complex process and many factors are
involved throughout. These include transcription factors such as Msx1, Osr2 and
Shox2 as well as signalling molecules and growth factors such as Shh, Tgfβs, Bmps
and Fgfs (Gritli-Linde, 2007; Wilkie and Morriss-Kay, 2001). These are potentially
worth investigating in Tbx22 null mice in relation to the cell proliferation defects
observed. In particular, the level of Cyclins is essentially determined by
extracellular growth factors (Sherr, 1995) and it would be interesting to investigate
if expression of these are altered in the Tbx22 null palatal shelves. In the scope of
this project, it was intended to examine some of the BMP and FGF signalling
components.
3.5.1 Expression of growth factor genes is not significantly altered in
Tbx22 null mice
Expression analyses of Bmp2, Bmp3, Bmp4, Fgf10, Fgfr2b and Spry2 genes which
are all implicated in palatal shelf growth were examined by whole mount in situ
hybridisation. The experiments were carried out on E13.5 embryos in order to
investigate if any of these growth factors were responsible for the reduced cell
proliferation in Tbx22 null mice detected at this developmental stage.
In the developing palate, expression of Bmps is regulated in a spatiotemporal
manner. Before shelf elevation, at E13.0, Bmp4 is reported to be expressed in both
epithelial and mesenchymal cells, whereas Bmp2 expression only appears in
mesenchymal cells (Lu et al., 2000). In this study, Bmp2 was expressed anteriorly
but absent in the posterior region of the palatal shelves at E13.5 both in the wt and
null palatal shelves (Figure 3.14, B, C, E and F). Bmp4 expression, albeit very weak,
was detected in the posterior end of the shelves both in the wt and null mice (Figure
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3.14, I, J, M and N). The pattern and intensity of expression of Bmp2 and Bmp4 are
reported to be dynamic, and both become more intensely expressed in the
condensed mesenchyme as the palate develops from E13.0 to E16.0, indicating their
roles for palatal bone formation as well as mesenchymal proliferation before fusion
(Liu et al., 2005). Though Bmp3 was almost negative throughout the course of
palatogenesis in one study (Lu et al., 2000), its expression has been reported in the
posterior palate during palatal fusion in another study (Nie, 2005). Here, a specific
and intense expression of Bmp3 was observed in the posterior palatal shelves before
fusion at E13.5, although the expression pattern was similar between wt and null
mice (Figure 3.14, G, H, K and L). It has been reported that BMP3 acts as a
negative regulator of osteogenesis by antagonising osteogenic BMPs such as BMP2
(Daluiski et al., 2001). In fact, Bmp2 and Bmp3 display a reciprocal expression
pattern along the anterior to posterior palatal shelves. These findings suggest that
posterior expression of Bmp3 may contribute to the development of soft palate to
some extent by suppressing the Bmp2 which can act as a potent inducer of
osteoblast differentiation (Lian et al., 2006; Ryoo et al., 2006).
Expression of Fgf10 during palatogenesis has been detected in the palatal
mesenchyme from E11.5 to E13.5 (Alappat et al., 2005). The expression was
reported in the anterior to middle shelves throughout this period although
expression within the mesenchyme was shifted from close apposition to the palatal
epithelium to more ventrolaterally away from the MEE as shelf growth progressed.
In agreement with the previous study, Fgf10 was expressed in the anterior to middle
regions of the palatal shelves but posteriorly it was undetectable (Figure 3.15, B, C,
E and F). The pattern of expression in the wt and null palatal shelves was similar.
For Fgfr2b, expression has been reported in the developing oral epithelium
particularly in the palatal epithelium from E12 to E14, as well as in the palatal
mesenchyme of the nasal side at E13 (Rice et al., 2004). Here, expression of Fgfr2b
was found in the anterior to middle regions of the palatal shelves that overlapped
with Fgf10 expression (Figure 3.15, G, H, K and L), which was expected
considering that FGFR2b is a receptor for FGF10. However, no significant
difference was detected between the wt and null palatal shelves. Spry2 expression is
reported in the epithelium and mesenchyme of anterior palatal shelves at E12.5
which becomes more restricted to the epithelium of the middle shelves by E14.5
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(Welsh et al., 2007). Similarly in this study, expression was detected in the anterior
to middle shelves which was particulary intense in the growing tip of palatal shelves
and in the developing rugae at E13.5 (Figure 3.15, I, J, M and N). This expression
pattern was similar in both the wt and null palatal shelves. Submucous cleft palate
in Tbx22 null mice is translated into an aberrant pattern of the rugae in the posterior
half of the hard palate (Pauws et al., 2009a), but the rugae irregularity was not
apparent at E13.5. This may not be surprising since palatal bone formation starts
from E15.0 onwards and probably aberrant rugae in the null mice may be a
reflection of having poorly developed palatine bones.
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3.5.2 Summary
Although Tbx22 seems to be involved in the regulation of cell proliferation, none of
the growth signalling components tested by whole mount in situ hybridisation were
altered in the palatal shelves of Tbx22 null mice at E13.5. However, more precise
comparisons of expression patterns within the palatal shelves can be made by
section in situ hybridisation. In terms of a regulatory relationship, there is now
mounting evidence that Tbx22 may be downstream of FGF and BMP signalling
pathways. For instance, FGFs were found to positively regulate Tbx22 in early
facial morphogenesis whereas BMPs could repress expression of the gene at later
stage in the chick and mouse frontonasal mass (Higashihori et al., 2010; Fuchs et al.,
2010). The results presented here indicate that there may be no feedback from
TBX22 to BMP or FGF signalling components investigated, in the palatal shelves at
E13.5.
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3.6 Characterisation of ankyloglossia and choanal atresia
In addition to submucous cleft palate, Tbx22 null mice display ankyloglossia and
choanal atresia (Pauws et al., 2009a). Ankyloglossia, also called tongue-tie, is
defined as having a shortened frenulum attachment near the tip of the tongue which
can restrict movement of the tongue. In the null mice, the tongue attaches more
anteriorly to the floor of the mouth (Figure 1.15). This resembles ankyloglossia
frequently seen in human CPX patients.
Another defect found in the null mice was choanal atresia, which is characterised by
a persistent oronasal membrane in the choanae (Figure 1.15). The severity of atresia
varies from mild cases where only the posterior part of the choanae is obstructed to
more severe cases where the entire length of choanae are blocked from anterior to
posterior. Also, it can manifest as unilateral or bilateral. This phenotype, rather than
submucous cleft palate or ankyloglossia, is suggested to be the main cause of the
post-natal lethality because it was absent in the surviving pups but present in pups
that died after birth. Unlike submucous or overt cleft palate and ankyloglossia, this
has not until now been a feature synonymous with CPX.
3.6.1 Morphological analysis of facial regions in early development
Previously, the detailed analysis of craniofacial structures revealed that
ankyloglossia and choanal atresia phenotypes in Tbx22 null mice were evident at
E15.5 (Pauws et al., 2009a). At this developmental time point, the tongue in the null
mice is attached as anteriorly as the incisive foramen while it is free at this position
in the wt mice. Similarly at this stage, oronasal membranes persist with variable
severity in the null mice whereas they are already disappeared in the wt. In order to
examine the morphology of relevant tissues at earlier developmental stages, H&E
staining was carried out on embryos at E12.5 and E11.5. H&E staining allows easy
visualisation of histological sections whereby nuclei are stained dark blue by
hematoxylin and cytoplasm is stained pink by eosin.
With regard to the ankyloglossia phenotype, the coronal sections of wt at E12.5
indicated that the anterior tip of the tongue was freed from the floor of the mouth
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and the frenulum was beginning to be established (Figure 3.16, A and C). In
contrast, in the null mice the tip of the tongue was still attached to the floor of the
mouth and no obvious frenulum was detected (Figure 3.16, B and D). This suggests
that formation of the frenulum in the null mice occurs later than in the wt, starting at
or after this time point. Eventually, the frenulum in the null mice becomes visible
by E15.5 although located more anteriorly compared to the wt (Figure 1.15).
The developing choanae can be observed in coronal sections of wt embryos at
E12.5, which showed the appropriate degradation of the oronasal membranes
(Figure 3.16, A and C). In contrast, oronasal membranes in the null mice persisted
in the choanae between the oral and nasal cavities (Figure 3.16, B and D). This
particular embryo displayed bilateral choanal atresia although we have also
observed unilateral atresia while in a small percentage of null mice the phenotype
was completely absent (Pauws et al., 2009a). Since the various facial prominences
undergo complex fusion events between E10.5 to E12.5, the general facial structure
at E11.5 differs dramatically to that of E12.5. At E11.5, the posterior nasal fins
seemed to have degenerated in the wt choanae, leaving what looked like a
disappearing oronasal membrane behind (Figure 3.17, A). This is consistent with
the findings that, in the wt, the posterior nasal fins persist until E11.0, which usually
undergo degeneration by E11.5 (Dupe et al., 2003; Tamarin, 1982). This leaves
oronasal membranes in the choanae that disappear by E12.5 in the wt. In contrast,
the nasal fins failed to undergo cleavage and the fins persisted in many of the null
choanae at the equivalent stage (Figure 3.17, C). On occasions, the choanae from
null mice resembled those of the wt whereby the nasal fins did degenerate (Figure
3.17, B). In this case, the morphology was very similar to that of the wt where there
were still oronasal membranes in the choanae at this stage, but they were likely to
disappear soon after. This finding was most likely because some null mice have
unilateral atresia or do not display the phenotype (Pauws et al., 2009a).
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Figure 3.16 Histological analyses of Tbx22 null mouse craniofacial regions at
E12.5
H&E staining was carried out on embryos at E12.5. At this developmental stage,
the anterior tip of the tongue was freed from the floor of the mouth and oronasal
membrane had disappeared in the wt (A and C). In the null mice, the tip of the
tongue was attached to the floor of the mouth and oronasal membranes persisted in
the choanae (B and D). ns, nasal septum; om, oronasal membrane; ps, palatal
shelves; t, tongue. Scale bar = 250 µm.
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Figure 3.17 Histological analyses of Tbx22 null mouse choanal regions at E11.5
H&E staining of coronal sections of E11.5 wt and null mice through the posterior
portions of nasal fins. The nasal fins degenerated in the wt, leaving oronasal
membrane behind (A). The nasal fins persisted in many of the choanae in the null
mice (C). On occasions, the nasal fin did degenerate in the null mice giving rise to
the oronasal membrane (B). f, nasal fin; lnp, lateral nasal process; max, maxillary
process; mnp, medial nasal process; om, oronasal membrane. Scale bar = 50 µm.
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3.6.2 Expression pattern of Fgf8 during degeneration of the nasal fins
is not significantly altered in Tbx22 null mice
Genetic pathways underlying the development of choanae have not been subjected
to intense research in the past. This is probably because the occurrence of choanal
atresia is relatively rare in the human, and as a consequence there are only a limited
number of animal models available to study the phenotype. Nevertheless, as
described above, Raldh3 null mice provide an interesting insight into the occurrence
of choanal atresia. In the absence of Raldh3, Fgf8 expression persists in the nasal
fins at E11.0, suggesting that expression of Fgf8 needs to be inhibited for normal
choanae development. Therefore, we next investigated Fgf8 expression in the nasal
fins in the wt and Tbx22 null mice at E10.5 and E11.0 at which time the nasal fins
are still present in the wt (Dupe et al., 2003).
The medial and lateral nasal processes are formed by the mesenchyme surrounding
the nasal placodes by E10.5. This defines the nasal pits. At this stage, Tbx22 was
expressed in the medial nasal processes as well as around the presumptive nasal fins
where medial and lateral nasal processes merge that were found ventrally to the
nasal pits (Figure 3.18, A and D). The expression was also detected in the maxillary
and mandibular processes. At the same stage, in the wt, Fgf8 was expressed in the
medial and lateral nasal processes forming a horseshoe pattern around the nasal pits
which extended ventrally in nascent fins (Figure 3.18, B and E). The expression
was also detected at the oral edge of the medial nasal process. In addition, the
expression was observed in the maxillary processes and in the mandibular processes
as well as in the medial anterior forebrain between the two medial nasal processes.
In the null mice, the pattern of Fgf8 expression and intensity appeared very similar
to the wt (Figure 3.18, C and F).
At E11.0, Tbx22 expression was not detected in the nasal fins anteriorly as shown
by the frontal view (Figure 3.18, G and J). However, its expression was evident
around the fused medial and lateral nasal processes on the stomodeum side around
the posterior end of nasal fins between the future primary and secondary palate
which corresponded to where the choanae would form (Figure 3.18, M and P). At
the equivalent stage, Fgf8 continued to be strongly expressed in the epithelium of
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the nasal processes surrounding the nasal pits both in the wt and null mice (Figure
3.18, H, I, K and L). Expression was also visible at the posterior end of the nasal
fins partially overlapping with Tbx22 expression and in the maxillary processes.
This was similar between the wt and null mice (Figure 3.18, N, O, Q and R). Thus,
a lack of Tbx22 does not seem to affect Fgf8 expression in the craniofacial regions
at E10.5 and E11.0.
169
A wt
D
CB
G H
E F
LK
I
J
M
P
ON
Q R
nullwt
wt nullwt
Tbx22 Fgf8 Fgf8E10.5
Tbx22 Fgf8 Fgf8E11.0
mnp
lnp
mnp
lnp
man
max
max
f
f
maxf
170
Figure 3.18 Expression pattern of Fgf8 at E10.5 and E11.0
Expression pattern of Tbx22 and Fgf8 was detected by whole mount in situ
hybridisation at E10.5 (A-F) and E11.0 (G-R). The arrows indicate nasal fins. f,
nasal fin; lnp, lateral nasal process; man, mandibular process; max, maxillary
process; mnp, medial nasal process. Scale bar = 250 µm (A-C, G-I and M-O), 100
µm (D-F, J-L and P-R).
3.6.3 Summary
H&E staining showed that the ankyloglossia phenotype in Tbx22 null mice was
visible at the base of the tongue at E12.5. At this stage, the frenulum was not
established in the null mice but it was formed in the wt. Choanal atresia was also
evident in the null mice at E12.5 characterised by the persisted oronasal membranes
in the choanae. Slightly earlier at E11.5, nasal fins almost disappeared in the wt
choanae, leaving oronasal membranes that were going to rupture soon after. In the
null choanae, the nasal fins persisted at the equivalent stage. As Fgf8 is one of only
a few genes known to be important for the choana development, its expression
pattern was examined at E10.5 and E11.0 before the choanal atresia defect becomes
apparent in the null mice. However, the expression pattern was very similar
between the wt and null mice, suggesting Tbx22 does not regulate Fgf8 during nasal
development.
Sense control
Fgf8
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CHAPTER 4: DISCUSSION
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4 DISCUSSION
Clefts of the lip and palate are a heterogeneous group of disorders that rank among
the commonest birth defects known, affecting 1 in 700 births worldwide (Murray,
2002; Vanderas, 1987; Wyszynski et al., 1996). The underlying cause is poorly
understood, with a complex interaction of genes and environmental factors being
implicated. Nevertheless, several important genetic factors have been identified,
including mutations in the T-box transcription factor TBX22 that cause X-linked
cleft palate and ankyloglossia (CPX) (Braybrook et al., 2001). CPX is characterised
by cleft palate phenotypes ranging from a complete cleft of the secondary palate,
submucous cleft palate, cleft of the soft palate, bifid uvula or absent tonsils, which
are all frequently but not exclusively associated with ankyloglossia (Stanier and
Moore, 2004). The expression of TBX22/Tbx22 is detected in both human and
mouse developing palatal shelves as well as at the base of the tongue, medial and
lateral nasal prominences and periocular mesenchyme correlating well with the
various CPX phenotypes (Braybrook et al., 2002; Bush et al., 2002; Herr et al.,
2003). Similar expression in the facial mesenchyme is also observed in other
species including chick and zebrafish (Haenig et al., 2002; Jezewski et al., 2009),
indicating a conserved role for TBX22 in craniofacial development. Recent studies
have shed light on the regulation of Tbx22 by BMP and FGF signalling during
mouse and chick frontonasal morphogenesis (Fuchs et al., 2010; Higashihori et al.,
2010), although little is known about molecular pathways that lead to the disease
phenotype in CPX. Thus, this project aimed to better understand the functional role
of TBX22 by characterising and investigating the recently described Tbx22 null
mouse (Pauws et al., 2009a).
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4.1 Tbx22 expression during craniofacial development
The pathogenic phenotypes found in CPX patients include cleft palate with a
varying spectrum from submucous to overt cleft palate which are frequently
associated with ankyloglossia (Braybrook et al., 2001; Stanier and Moore, 2004). A
detailed spatial analysis of Tbx22 expression has been described, especially at
around E13.5 prior to palatal shelf elevation. Not surprisingly, expression of TBX22
has been reported in the developing palatal shelves, at the base of the tongue and
around the nasal septum (Braybrook et al., 2002). This pattern of expression in
craniofacial region is generally conserved in other species including mouse, chick
and zebrafish (Braybrook et al., 2002; Bush et al., 2002; Haenig et al., 2002; Herr et
al., 2003; Jezewski et al., 2009).
At E9.5, no significant Tbx22 expression was detected. Some of the previous
studies have reported Tbx22 expression at E9.5, especially using RT-PCR
(Braybrook et al., 2002) but also in the somite and craniofacial regions (Farin et al.,
2008). Meanwhile, other studies concentrating on the craniofacial region reported
no expression at this stage with transcripts becoming detectable from E10.5
onwards (Bush et al., 2002; Fuchs et al., 2010). This suggests that expression first
appears between E9.5 and E10.5 in facial region. Differences between studies might
reflect the specific probes used, the different mouse strains employed, or difference
in timing or staging of embryos, even within litters. For this latter point, it is known
that mouse staging based on copulatory plug for E9.5 can range from E9.0 to
E10.25. This range in embryonic days converts to 21 to 29 somite stages, and
therefore more accurate and consistent observation would be achieved by matching
embryos by the number of somites at early stages. Tbx22 expression in the
maxillary and mandibular processes only became detectable at E10.5 along with
expression in the medial nasal processes and in the nasal fins found in between the
fusing medial and lateral nasal processes. Expression in the medial nasal processes
ceased by E11.5 but persisted around the presumptive choanae where the maxillary,
the medial and lateral nasal processes merge in between the future primary and
secondary palates. Expression was also noted at the anterior tip of the mandible.
This would probably correspond to the expression domain observed later at the
anterior base of the tongue, around the frenulum which becomes obvious from
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E12.5 onwards. From E12.5 onwards, expression has been well described in several
studies (Braybrook et al., 2002; Bush et al., 2002; Herr et al., 2003) continuing up
until shelf fusion, where Tbx22 expression becomes undetectable or at least
significantly reduced in the palate.
Although the expression pattern of Tbx22 generally correlates well with where the
clinical features of CPX are found (Stanier and Moore, 2004), the choanal atresia
phenotype in Tbx22 null mice is novel (Pauws et al., 2009a). This has not been a
recognised feature in human CPX patients, which may be due to a selection bias,
where patients with choanal atresia are simply not screened for mutations in TBX22.
Similarly, although there is significant Tbx22 expression in the somites, neither
human CPX patients nor the null mice show any obvious somitic defect. However,
a combined loss of Tbx18 and Tbx22, that are expressed in an overlapping manner
in the early somites, has been suggested to lead to posteriorisation of the somites
(Farin et al., 2008 and Andreas Kispert personal communication). This suggests that
these closely related T-box genes may be functionally redundant in the somites.
Overall, it can be seen that Tbx22 expression is detected in a very temporal and
tissue specific pattern between E9.5 and E15.5 in the craniofacial region, which
explains its requirement in normal craniofacial development. Tbx22 null mouse
should therefore provide a good model to study the CPX phenotypes.
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4.2 Microarray analysis of the wt and Tbx22 null palatal
shelves
Earlier data for T-box genes in general and TBX22 in particular (Andreou et al.,
2007) show that their major cellular function is in transcriptional regulation.
Therefore, one of the principle aims of this project was to identify putative
downstream targets under the transcriptional control of TBX22. For this purpose, it
was decided to employ a global approach of microarray expression analysis.
Comparative gene expression profiling is a powerful technique with the potential to
reveal the gene networks that TBX22 is involved in during normal palatogenesis
and provide tools for the further study of cleft palate. For the microarray analysis,
the palatal shelves from the transgenic mouse model which lacked functional Tbx22
(Pauws et al., 2009a) were appropriate to use because they recapitulated the cleft
palate phenotypes observed in human CPX patients, namely an overt cleft of the
secondary palate and submucous cleft palate characterised by delayed ossification
of the palatine bone.
Affymetrix GeneChip® Mouse Gene 1.0 ST Arrays were used to compare the
expression of ~29,000 gene transcripts in the presence and absence of Tbx22. To do
this, expression profiles of dissected E13.5 palatal shelves from three wt and null
littermates were examined. This time point was chosen because maximal and
specific Tbx22 expression is observed in the palatal shelves just prior to elevation
(Braybrook et al., 2002; Bush et al., 2002; Herr et al., 2003). Also, it seemed
reasonable to compare the wt and null palatal shelves when they are most similar in
their gross morphology and just prior to developing phenotypic differences. At the
slightly later stage of E14.5, the palatal shelves are in any case quite variable in
shape between normal littermates, due to variability in the timing of elevation. Later
still (>E15.5), when the ossification defects become obvious, expression differences
could easily be attributed as secondary effects to the more severe morphological
differences, while Tbx22 expression is by now greatly reduced (This thesis and
Braybrook et al., 2002).
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There are several methods that exist for the identification of differentially expressed
genes between samples in the microarray data analysis (Allison et al., 2006).
GeneSpring GX 10 programme, for instance, provides an array of statistical tools
that can be applied to the dataset. Two of the most commonly employed methods to
identify such genes are fold change and the t-statistic, owing to their relative
simplicity and interpretability. Here, we used two experimental groups (the wt and
Tbx22 null palatal shelves) with three biological replicates each, and then looked at
fold change and p-values based on unpaired t-test. Since it has been suggested that
differentially expressed genes are best identified and more reproducible using fold
change rather than t-statistic (Guo et al., 2006; Shi et al., 2005; Shi et al., 2006), we
decided to rank the differentially expressed genes according to their fold changes
and then calculate p-values alongside. In such a situation, it would be ideal to
follow up genes with large fold change and low p-value. Setting a threshold at 2 to
3 fold is generally considered to be a good starting point for identification of
significantly changed genes. However, none of the probes encoding for known
genes, apart from Tbx22 and Cox7b, had a fold change above 2. In this experiment,
whole palatal shelves were used for the analysis, which in wt contained cells
positive and negative for Tbx22. This could well have diluted or contributed to the
relatively low fold changes generally. This includes those found for Tbx22 itself
because the expression of Tbx22 is specifically restricted to the middle and
posterior regions of the palatal shelves but not in other areas. For that reason, it
seemed sensible to set a threshold at level that would include a modest number of
genes that could be validated by other methods. Ideally, it may have been more
appropriate to perform analysis that involved some sort of cell-type specific
selection before the microarray. For instance, isolation of specific cell population in
targeted gene knockout mice by fluorescence-activated cell sorting for GFP positive
cells has been coupled with microarrays to circumvent this problem (Bouchard et al.,
2005).
Tbx22 itself had a fold change of only 2.88 (p=0.0087). This may seem very low
considering that the knockout gene is theoretically absent from the null mice. For
example, in a different study of wild type mice at different developmental stages, a
fold change of 43 was described for loricrin in the developing palate simply
between E14.5 and E15.5 (Brown et al., 2003). However, this might at least in part
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be explained by the mutant cells containing a low level of non-protein coding RNA
from the Tbx22 null allele that does not involve the first three exons (Dr. E. Pauws
unpublished observation). Although the relative level of gene expression between
samples would also be optimised if the samples were specifically sorted for Tbx22
expressing cells, it was not practical to achieve this at the time when the
experiments were carried out.
Under the 1.2 fold threshold model, 43 genes were upregulated while 42 genes were
downregulated in the E13.5 palatal shelves of Tbx22 null mice compared to the wt.
However, of these, only 8 genes each in the up and downregulated lists had p-
values less than 0.05. Moreover, most of these did not seem to be of obvious
relevance to palate development. In general, the recommended number of replicates
for microarray analysis to obtain reliable estimates of true differences between
conditions is six (i.e. twelve for 2 conditions). An increased number of replicates
would therefore have been very likely to improve the p-values for many of the
genes listed. However, since the current study was aimed at finding a small number
of important differences between conditions, it was decided to validate selected
candidates by other methods such as quantitative real-time PCR and functional
analysis rather than repeat expression arrays that already showed relatively few
major differences.
4.2.1 Downregulated genes
Though the downregulated genes were not followed up in this project, a selection of
genes that may be related to cleft palate are discussed below.
The importance of GABAergic inhibitory neurotransmission in the normal palate
development is demonstrated by mice with cleft palate that lack Gabrb3 or Gad1
(Asada et al., 1997; Condie et al., 1997; Hagiwara et al., 2003; Homanics et al.,
1997). In humans, associations between non-syndromic CL/P and GABRB3 (Inoue
et al., 2008; Scapoli et al., 2002) and GAD1 (Kanno et al., 2004) have been reported.
The fold changes for Gabrb3 (FC=+1.04, p=0.54) and Gad1 (FC=+1.03, p=0.48) in
the Tbx22 null palatal shelves were close to 1.0 (Appendix Table 1.1). Still,
downregulation of Gabrb2 by 1.24 fold (p=0.000024) may be worth noting. In
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addition, the microarray data showed a downregulation of another subunit for
GABA type A receptor (Gabra1) (FC=1.22, p=0.15) as well as glutamate receptor
alpha 4 (Gria4) (FC=1.21, p=0.13) although they were not significant in terms of p-
values. There are two types of GABA receptors, type A and B, and both Gabrb2
and Gabrb3 encode for a beta subunit of type A receptor. Besides their expression
in the central and peripheral nervous system, GABRB3, GAD1 and GABA are all
detected in the developing palatal shelves implying a potential role of GABA
neurotransmission for normal palate development (Brown et al., 2003). In fact,
various neurotransmitters including GABA are thought to be involved in the shelf
reorientation process (Babiarz et al., 1979; Zimmerman, 1985). In this particular
respect however, GABAergic neurotransmission could be less relevant to Tbx22
null mice since the elevation process proceed normally in the vast majority of null
mice. These genes may not be directly regulated by TBX22 considering the finding
that it mainly acts as a transcriptional repressor (Andreou et al., 2007), but the
possible decrease in expression in the null palatal shelves is potentially interesting
to follow up in the future.
Pax3 is normally expressed in the neural crest precursors and is required for
development of neural crest cell lineages. Its expression, however, is generally
much reduced after migration of the cells from the neural tube and this
downregulation is crucial for differentiation to proceed. In the wt palatal shelves,
endogenous expression of Pax3 is detected medially at E12.5 and E13.5 which is
abated at birth, and the mice develop cleft palate when the expression persists (Wu
et al., 2008). In contrast, palatal morphology is unaffected by reduced Pax3
expression level (Zhou et al., 2008). Therefore, downregulation of Pax3 (FC=1.21,
p=0.40) in the null palatal shelves may not be directly related to the pathlogical
phenotype in Tbx22 null mice. It is also possible that the fluctuation indicated by
the microarray data could be a false positive and thus this aspect requires further
investigation.
Retinoic acid (RA) has been associated with the development of cleft palate. RA is
synthesised from retinol (vitamin A) via retinal as the intermediate (Duester, 2000).
The first step involves oxidation of retinol to retinal and the second step involves
oxidation of retinal to RA. The first enzymatic reaction can be catalysed by several
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alcohol dehydrogenases, one of which is alcohol dehydrogenase of class I (ADH1).
In vivo gene disruption of Adh1 in mice leads to a reduction in retinoid metabolism
(Deltour et al., 1999), and the physiological role of ADH1 has been suggested in
minimising retinol toxicity (Molotkov et al., 2002). The next step of oxidation from
retinal to RA is carried out by retinaldehyde dehydrogenases (Raldh) 1 to 3 whose
enzymatic activities in retinoid metabolism have been demonstrated by in vivo
studies (Duester, 2001). The microarray data revealed a reduced expression of Adh1
(FC=1.27, p=0.27) in the Tbx22 null palatal shelves. This could be interesting to
follow up in the future considering the importance of dehydrogenase enzymes
implicated in retinoid metabolism as has been shown by cleft palate induced by
retinoic acid in mice (Padmanabhan and Ahmed, 1997; Degitz et al., 1998).
Aldh1a7 is shown not to be involved in the biosynthesis of retinoic acid although it
is closely related to Aldh1 (Raldh1) (Hsu et al., 1999). Thus, its downregulation
(FC=1.21, p=0.47) may be less relevant with regard to the cleft phenotype in Tbx22
null mice.
4.2.2 Upregulated genes
Since TBX22 has been shown to act as a transcriptional repressor in vitro (Andreou
et al., 2007), we focused on genes that were upregulated in the absence of Tbx22
and decided to follow up some of them by real-time PCR. Verification of
microarray results by an alternative method is necessary because of their inherent
problems with inconsistent quantification and false positive results (Chagovetz and
Blair, 2009). Real-time PCR is the most commonly used method for this purpose.
At the 1.2 fold change threshold, Ctsk (FC=1.62, p=0.074) was the only known
gene related to osteogenesis. It is involved in bone resorption and is expressed
exclusively in osteoclasts during mouse embryonic development (Dodds et al.,
1998). In the normal mouse palatal shelves, genes involved in ossification process
are generally increased as the palatal bone forms. For instance, the Ctsk precursor
expression is increased between E13.5 to E14.5, and osteopontin, one of the organic
components of bone, is also upregulated between E14.5 to E15.5 (Brown et al.,
2003). However, the microarray data for Ctsk was not verified by real-time PCR,
suggesting that it was a false positive. Several other genes related to osteogenesis or
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ossification including Runx2, Osterix, Osteopontin, Alkaline phosphatase, type I
collagen and others were checked for their fold changes in the array data but those
were in the range of 1.0 to 1.1 fold increase or decrease. Taken together, the results
indicated that there was no obvious change in bone markers between the wt and null
palatal shelves at E13.5. In fact, this stage probably is slightly too early to look for
any major changes in bone markers considering the fact that palatal bone formation
does not start until around E15.5, after the palatal shelves have fused. Thus, with
regard to the ossification defect, it would be more interesting to carry out
experiments just before the defect in the null palate becomes obvious, which would
be around E15.0.
Interestingly, there was a general upregulation of muscle related genes in the Tbx22
null palatal shelves. In fact, 20 out of 43 upregulated genes were muscle related
while no such genes came up in the downregulated list at 1.2 fold change threshold.
The upregulated muscle genes belong to members of the myosin, actin, actinin, titin,
troponin and calsequestrin gene families. Their main functions include muscle
metabolism, contraction and filament assembly. Of those upregulated in the
microarray data, three muscle genes Myh3, Acta1, Casq2 were chosen as
representatives from different gene families to examine by real-time PCR while the
other muscle genes were not investigated by this technology. The microarray data
showed increased expression of Myh3 (FC=1.57, p=0.061), Acta1 (FC=1.35,
p=0.12) and Casq2 (FC=1.30, p=0.21). The real-time PCR results also indicated
upregulation for Myh3 (FC=2.44, p=0.030), Acta1 (FC=2.16, p=0.030) and Casq2
(FC=2.32, p=0.035) confirming the direction of the change in gene expression
detected by microarrays. However, the magnitude of fold change was larger in real-
time PCR. This is largely down to the fact that real-time PCR detects the amount of
product as the reaction progresses so that it allows quantitative measurements in a
wider dynamic range relative to microarrays. Similarly, p-values were improved in
real-time PCR probably because of the larger difference in the average fold change.
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4.3 Myogenic regulatory factors
The global upregulation of muscle genes suggested an increase in muscle
differentiation or myogenesis, perhaps triggered through deregulation of some of
the key myogenic regulatory factors. Myogenesis refers to the formation of muscles
during embryonic development in particular. The initial process involves the
determination of mesodermal cells to myoblasts that are embryonic progenitor cells
of myocytes. These myoblasts proliferate in the presence of growth factors such as
FGF2 (Kelvin et al., 1989). Eventually, the mononucleated myoblasts align and fuse
with each other to form multinucleated myotubes or skeletal muscles. These steps
are largely controlled by four myogenic regulatory factors, MyoD, Myf5, myogenin
and Mrf4 (Arnold and Braun, 1996). The functional roles for each of these factors
have been defined by targeting inactivation studies of single or multiple genes in
mice. Surprisingly, null mutation for MyoD in mice results in normal muscle
development (Rudnicki et al., 1992). In these mice, expression of Myf5 is
upregulated instead. Similarly, skeletal muscle morphology is normal in Myf5
mutant mice (Braun et al., 1992). These results have indicated that individually,
neither gene is critical for normal myogenesis. However, the mice that are double
mutant for MyoD and Myf5 are devoid of skeletal muscles and myoblasts (Rudnicki
et al., 1993), suggesting that they compensate for each other and are functionally
redundant. The double null mutant mice develop cleft palate but it has not been
determined if the defect is intrinsic to the palate or caused as a secondary effect by a
lack of mechanical help from the facial musculature (Rot-Nikcevic et al., 2006). In
terms of hierarchical relationships, MyoD is genetically downstream of Myf5
because its expression is delayed in Myf5 null mice (Tajbakhsh et al., 1997).
Similarly, Mrf4 acts upstream of MyoD as has been demonstrated by delayed MyoD
expression when Mrf4 is inactivated (Kassar-Duchossoy et al., 2004). Mouse
mutants for myogenin show reduced skeletal muscle mass but normal myoblasts,
indicating its role in terminal differentiation (Hasty et al., 1993; Nabeshima et al.,
1993). It is also known that MyoD activates myogenin (Deato et al., 2008). As
myogenesis proceeds, other muscle specific marker genes for differentiated cells
such as myosin heavy chain and actin start to be expressed (Arnold and Braun,
1996). Therefore, it was reasonable to assume that expression of the myogenic
regulatory factors might also have been affected in the Tbx22 null palatal shelves.
182
Of the four myogenic regulatory factors described, MyoD, Myf5 and myogenin were
further investigated while Mrf4 was not followed up as it was suggested not to be
involved in the developmpent of head muscles (Kassar-Duchossoy et al., 2004).
However, none of these were detected above the 1.2 fold threshold in microarray
analysis although there was a general trend towards upregulation for MyoD
(FC=1.17, p=0.27), myogenin (FC=1.09, p=0.70) and Myf5 (FC=1.19, p=0.13) in
the Tbx22 null palatal shelves. Nevertheless, a statistically significant increase in
the palatal shelves of Tbx22 null mice was detected by real-time PCR for both
MyoD (FC=1.73, p=0.017) and myogenin (FC=1.69, p=0.038). In addition, p21, the
known target of MyoD, was also increased as measured by real-time PCR (FC=1.62,
p=0.031). Again, the magnitude of fold change was larger when expression was
examined by real-time PCR compared to the microarray. Myf5 expression detected
by real-time PCR was also increased on average although it was not statistically
significant (FC=1.75, p=0.10). Therefore, the results indicate that upregulation of
some of the myogenic regulatory factors may explain, at least in part, the global
upregulation of muscle specific genes detected by microarray analysis.
It has not yet been determined whether the upregulation of muscle specific genes
reflect an increased number of myoblasts within the null palatal shelves or result
from a specific increase of expression within each cell. To address this, it is
necessary to understand the normal pattern of expression for these muscle genes
during normal palate development. In the presumptive mouse soft palate in the
posterior region, muscles first emerge as mesenchymal condensation at around
E13.5 (Zhang et al., 1999). At this stage, both MyoD and myogenin are detected in
the condensed mesenchyme using immunohistochemistry. Moreover, the
myofilaments start to appear in the condensed mesenchymal cells or myoblasts,
indicating muscle differentiation. These myoblastic cells follow myogenic
differentiation and muscle fibers begin to appear by E18.5. Accordingly, a general
rise in muscle markers such as myosin heavy and light chains and actin have been
reported throughout palate development from E13.5 to E15.5, which may be
important for shelf reorientation (Brown et al., 2003).
To answer the question as to where the differential expression of muscle genes
originate in the Tbx22 null palatal shelves, we attempted to localise the MyoD
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mRNA by in situ hybridisation in the wt and null palatal shelves. However, no
obvious staining was visible within the palatal shelves (data not shown). This could
be due to its relatively low expression level compared to some other genes (Figure
3.5). In order to locate the origin of differential expression, the experiment may
need optimisation (e.g. by using alternative in situ probes) or alternatively
immunohistochemistry should be performed since the method has been shown to
work efficiently to mark MyoD and myogenin (Zhang et al., 1999).
It is also possible that the fluctuations of muscle gene expression are secondary to
what is happening in non-myoblastic cells and irrelevant to soft palate muscles. In
relation to this issue, what is still not clear is whether Tbx22 is expressed in palatal
mesenchymal cells of mesodermal origin. The role of TBX22 in cranial paraxial
mesoderm in particular has not been reported, but studies have shown that Tbx22 is
expressed in the cranial paraxial mesoderm at primitive streak stages which lasts at
least until E3 in chick embryos (approximately equivalent to E11.5 in mouse)
(Haenig et al., 2002). However, whether it is expressed in palatal mesenchymal
cells specifically of mesodermal origin at E13.5 has not been examined although we
know that the vast majority of palatal mesenchyme is of CNC origin (Ito et al.,
2003) and some of which is Tbx22 positive. For those reasons, it is difficult at the
moment to speculate precisely where the differential MyoD expression as well as
other muscle related gene expression come from. Nevertheless, it is a reasonable
assumption that the difference in MyoD expression would have been mainly
contributed by CNC-derived palatal mesenchyme, based on the fact that the
majority of mesenchymal cells originate from the CNC (Ito et al., 2003).
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4.4 MyoD is regulated by TBX22 in vitro
T-box binding element (TBE) consists of one or more copies of the minimal
AGGTGTGA sequence (Naiche et al., 2005). It was first demonstrated by the high
affinity of Brachyury to a 20 base pair palindromic sequence
T(G/C)ACACCTAGGTGTGAAATT (Kispert and Herrmann, 1993). Later, it was
shown that not only Brachyury but other T-box proteins were capable of binding to
the TBE or half of the sequence called a T-half site which is thought to be mediated
via the highly conserved T-box DNA binding domain (Ghosh et al., 2001; Lingbeek
et al., 2002; Tada and Smith, 2001). TBX22 itself has been demonstrated to have
the potential to autoregulate its own P0 promoter which contains several putative
TBEs (Andreou et al., 2007). Therefore, it was next intended to search the promoter
regions of muscle related genes for a putative TBE in silico.
Scanning the genomic sequences spanning 2 kb upstream of the transcription start
site found TBEs in some of the genes. Among the muscle specific genes, MyoD and
Acta1 had one TBE each whereas Myf5 and myogenin had two TBEs. Myh3 and
Casq2 did not have any TBE. Apart from muscle specific genes, p21 whose
expression was significantly altered was also examined but no TBE was detected
within the region scanned. Though in silico analysis can give an indication that a
gene could be regulated by TBX22 or perhaps another T-box protein, a
demonstration of relevance using alternative functional assays is necessary. Myf5
was excluded because the gene was not confirmed as differentially expressed by
real-time PCR. Myogenin is known to be activated by MyoD via binding to its E-
box in the promoter region (Sartorelli and Caretti, 2005; Deato et al., 2008). This
may suggest that myogenin expression in the null palatal shelves may have been
increased due to the higher level of MyoD rather than itself being a direct target of
TBX22. Similarly, MyoD is capable of regulating expression of muscle specific
genes such as myosin and actin (Asakura et al., 1993; Shklover et al., 2007;
Wheeler et al., 1999), which could explain the global upregulation of those genes.
Likewise, p21 is also a well known target of MyoD (Guo et al., 1995; Halevy et al.,
1995; Peschiaroli et al., 2002).
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Some key evidence that links T-box genes to MyoD regulation has been reported
recently by Morley et al (2009). These authors combined chromatin
immunoprecipitation with zebrafish genomic microarrays (called ChIP-chip) to
investigate the binding capacity to promoter sequences of No tail (Ntl), a
transcription factor, which is a zebrafish ortholog of Brachyury. An interaction
between Ntl and the upstream region of the zebrafish myod was among those
identified in this study (Morley et al., 2009). Tbx6 has been shown to be involved in
regulation of MyoD expression and is able to bind to the T half-site found in its
promoter (Fang et al., 2004; Goering et al., 2003). Another example is the
regulation of branchiomeric myogenesis by Tbx1 (Kelly et al., 2004). In the absence
of Tbx1, both Myod and Myf5 failed to be activated in the pharyngeal mesoderm,
suggesting a direct or indirect role of Tbx1 in the regulation of these myogenic
factors (Kelly et al., 2004). Thus, it may be possible that other T-box family
members could have a similar role in myogenesis. The microarray data and a
finding that MyoD contained a predicted TBE in its proximal promoter region
prompted a more detailed investigation of the effect of TBX22 on MyoD promoter
activity in vitro.
Luciferase reporter assay and chromatin immunoprecipitation were both used to
follow up on the possibility that TBX22 may have a regulatory role in MyoD
expression in the palatal shelves. Using luciferase reporter assay, overexpression of
TBX22 in HEK 293T cells were found to result in a dose-dependent repression of
MyoD promoter activity, down to ~50%, whereas the TBX22 N264 mutant was
ineffective in its ability to repress. However, contradicting the original premise,
base substitutions in the TBE within the MyoD promoter did not affect repressor
activity. It could be that there are other sequences in the MyoD proximal promoter
region that can interact with TBX22, other than the putative TBE described, that are
yet to be determined. It is also possible that some interaction between TBX22 and
its target genes may involve co-factors rather than direct DNA binding. As
described in the Introduction, some T-box proteins are known to regulate
transcription cooperatively with other factors including homeodomain, GATA zinc
finger and LIM domain proteins that may mediate their selectivity for target genes
rather than by DNA sequence recognition alone (Bruneau et al., 2001; Hiroi et al.,
2001; Krause et al., 2004; Lamolet et al., 2001; Stennard et al., 2003). This is also
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true for other transcription factors such as homeobox proteins that display DNA
binding specificity (Laughon, 1991; Scott et al., 1989).
Chromatin immunoprecipitation was performed to investigate if there was any
physical interaction between TBX22 protein and the MyoD promoter region. The
positive results of this assay suggested that there is a specific interaction since not
only did TBX22 pull down the MyoD promoter sequence, but this interaction was
abolished for the TBX22 N264Y mutant. However, this assay does not distinguish
direct or indirect interaction between TBX22 and the MyoD promoter region tested
because the technique involves cross-linking or fixation with formaldehyde which
inevitably cross-links both DNA-protein and protein-protein interactions in live
cells.
Finally, in order to try to investigate the effect of TBX22 on MyoD in a more in
vivo fashion, levels of endogenous MyoD in C2C12 myoblastic cells were measured
in the presence and absence of overexpressed TBX22. In this experiment, MyoD
levels were not found to be repressed in the presence of TBX22. At face value, these
results are contradictory and confusing. It could simply be due to cellular context
differences where C2C12 cells used may not have expressed the relevant co-factors
or accessory proteins that were present in HEK 293T cells. HEK 293T cells do not
express MyoD at a detectable level and hence was not suitable to look at effects on
endogenous expression levels. We anticipate that further investigation of MyoD
regulation by TBX22 will be performed in the future studies, initially analysing
different cell lines that express endogenous MyoD.
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4.5 TBX22 and myogenesis
Thus far, our studies have failed to confirm a direct role for TBX22 in myogenesis.
Nevertheless, it is interesting to note that in addition to its prominent expression in
the craniofacial region, it also has a distinct, transient expression profile in the
developing somites and myotome, detected between E9.5 and E11.5 (Farin et al.,
2008; Andreas Kispert personal communication). In the early somites, Tbx22 and its
closely related paralog Tbx18 are co-expressed with both proteins being shown to
interact with PAX3, which at this stage is associated with myogenic cell
specification. These factors are suggested to act cooperatively in maintaining
anterior-posterior somite polarity, indicating their roles in the somitic paraxial
mesoderm (Farin et al., 2008 and Andreas Kispert personal communication). Tbx18
is expressed in the craniofacial region including otic mesenchyme and smooth
muscle cells surroung vessels in the head (Haenig and Kispert, 2004; Trowe et al.,
2008) but so far not implicated in the occurrence of cleft palate. In addition, Pax3 is
not expressed in the muscle primordium of the branchial arch (Horst et al., 2006).
Thus, it seems unlikely that these three factors act in a similar cooperative manner
in the cranial region as they do in the somites with regard to myogenesis.
Research concerning structural abnormalities of the palatal muscles during
embryonic development is scarce, although a few studies have suggested prenatal
abnormal muscle morphology in clefts of the soft palate. In prenatal periods, palatal
muscles emerge from condensed mesenchyme within the soft palate during the sixth
to ninth weeks in human. In terms of sequence of appearance, the tensor veli
palatini muscle appears first followed by the levator veli palatini, palatopharyngeus,
palatoglossus and the uvula last which is absent in mice (Cohen et al., 1993).
Comparison of soft palate morphogenesis between fetuses with cleft palate and
control specimens demonstrated a similar muscular morphology of the tensor veli
palatini, levator veli palatini, palatopharyngeus and palatoglossus in both
experimental groups (Cohen et al., 1994). However, muscle fiber directions were
found to be disoriented and disorganised in fetuses with cleft palate especially near
the medial edge epithelia. Despite the small number of samples, this study has to
some extent demonstrated abnormal myogenesis in cleft palate.
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The importance of normal muscle function is clear, especially in patients with
submucous cleft of the soft palate which features muscle defects as described in the
Introduction. In fact, this remains one of the more complicated challenges to repair
for cleft palate surgeons who aim to close off the oral from nasal passages to
improve speech and other side effects of a submucous cleft. In terms of a
developmental model, it is still not clear if the lack of functional Tbx22 in the
mouse leads to an intrinsic defect of muscle development or if this is secondary to
the bone defect. It is possible that a general increase in muscle gene expression
might be a common feature in other models of cleft palate. However, studies using
model organisms that feature an involvement of muscles in the occurrence of clefts
are also limited. One example where soft palate morphologies have been
investigated in cleft-induced and normal A/Jax mice, indicated no discernible
differences of the soft palate muscles between the cleft and non-cleft mice (Trotman
et al., 1995). However, mice that are double mutant for Myf5 and MyoD completely
lack striated muscle and display a cleft of the seconday palate as well as a cleft
between the primary and secondary palates (Rot-Nikcevic et al., 2006). In this case,
the authors suggested that the clefts seemed to be caused by an absence of any
mechanical help from the facial musculature during palate development as well as
by micrognathia, an undersized mandible rather than by intrinsic defects in the
palate. To date, only a cursory examination of palatal muscles in Tbx22 null mice
has been undertaken and no muscle defects have been found by dissection and
visual inspection under light microscope (unpublished data). This work requires a
more detailed study starting with histological examination at different stages and
may be aided by more accurate measures such as MRI scanning. It is hoped that this
type of study will be of great benefit to bring about future improvements of patient
treatment, particularly in the more complicated but esoteric submucous clefts.
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4.6 The role of TBX22 in palate development
Concurrent with the efforts to identify downstream target genes of TBX22, an
important focus of this project was also to investigate the molecular network and
mechanisms underlying pathogenic phenotypes observed in Tbx22 null mice. Thus
far, an obvious and clearly demonstratable defect in the Tbx22 null palate is the
delayed ossification of the palatine bone which is classified as submucous cleft
palate (Pauws et al., 2009a). In the wt palate, mineralisation of the palatine bone
becomes visible by E15.5. In contrast, it is almost completely absent in the null
palate although the mesenchymal condensation is observed. Interestingly, only a
few days later at E18.5, mineralisation becomes detectable in the null palate but is
severely reduced in size compared to the wt palate of equivalent stage. It is
interesting that there is very little or any Tbx22 expression in the post fusion palate
(Braybrook et al., 2002; Bush et al., 2002) yet the ossification defect in the hard
palate becomes obvious from around this stage onwards. Further analysis of bone
maturation using alkaline phosphatase histochemistry at E15.5 detected strong
staining in the condensed osteoblasts surrounding the mineralised bone matrix,
whereas it was much weaker in the condensed mesenchyme of the null palate
(Pauws et al., 2009a). Alkaline phosphatase activity and mineralised bone matrix
indicated that mature bone forming osteoblasts were produced by E15.5 in wt.
However in the null palate it seemed that the mineralisation defect resulted as a
consequence of defective osteoblastogenesis either through a lack of osteoblast
differentiation and/or maturation. However, it was not yet clear how, or which steps
of osteogenesis were affected by a lack of functional Tbx22.
Osteogenesis is a multi-step process. Initially, the palatal mesenchymal cells are
undifferentiated that proliferate and eventually form mesenchymal condensation.
Then they start to differentiate into osteoprogenitor cells marked by expression of
Runx2 (Ducy et al., 1997; Ducy et al., 2000; Komori et al., 1997). These immature
progenitor cells further differentiate into mature bone forming osteoblasts, aided by
key transcription factors of osteogenesis including Runx2 and Osterix (Nakashima
et al., 2002) as well as various growth factors such as BMP2 in particular (Ryoo et
al., 2006). Runx2 is a key regulator of osteoblast differentiation and a lack of Runx2
blocks maturation of osteoblast progenitor cells into mature osteoblasts leading to a
190
complete lack of both intramembranous and endochondral ossification in mouse
(Komori et al., 1997). Therefore, we initially investigated Runx2 expression, which
was detected in the condensed mesenchyme in the null palate at a similar level to
that observed in the osteoblasts in the wt palate, although the area was smaller
indicating a reduced number of differentiated osteoblasts (Pauws et al., 2009a). In
Tbx22 null mice, ossification of the palatine bone was not completely lost but took
place instead to a much lesser extent. This was interpreted as there being a delay in
the ossification process, since at least some osteoblast progenitors did mature to
become bone forming osteoblasts. Taken together, it seemed that the differentiation
and/or maturation process was partially but not completely blocked and the
ossification defect was independent of Runx2. It is a possibility that other key
osteogenic factors such as Osterix may have been affected but this still remains to
be tested.
4.6.1 Cell proliferation and apoptosis analysis in the wt and Tbx22
null palatal shelves
Next, it was intended to investigate other possible functions or indeed consequences
of a lack of TBX22, apart from its putative roles in myogenesis or osteoblast
differentiation and/or maturation. Cell proliferation is a key process in normal
palatal growth. In particular, a decrease in cell proliferation in the palatal shelves is
one of the most common features found in mice with cleft palate. For instance, mice
mutant for Msx1, Fgf10, Fgfr2b, Tgfβr2, Shox2 and Osr2 all display reduced cell
proliferation (Alappat et al., 2005; Ito et al., 2003; Lan et al., 2004; Rice et al.,
2004; Satokata and Maas, 1994; Yu et al., 2005). Among these, Fgf10 and Shox2
mutant mice also show increased apoptosis. In contrast, Wnt1-Cre mediated
removal of Tgfβr1 (Alk5) in mice results in an increased cell proliferation and
apoptosis in the palatal shelves (Dudas et al., 2006). With regard to Tbx22,
differential changes in the cell proliferation rate in Mn1-/- mice (MN1 acts upstream
of Tbx22) (Liu et al., 2008) as well as in chick with overexpressed human TBX22
(Higashihori et al., 2010) have been reported. In addition, in vitro experiments have
suggested an important role for MN1 in osteoblast proliferation and maturation
(Zhang et al., 2009). These studies implicate a possible role for TBX22 in cell
proliferation as well as differentiation and maturation of osteoblasts in Tbx22 null
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mouse during palatal shelf growth. Therefore, analyses of cell proliferation and
apoptosis were measured using standard techniques involving phospho-Histone H3
and cleaved Caspase-3, respectively.
There were only a few cells positive for Caspase-3 in the E13.5 wt and null palatal
shelves with no significant difference found between them in the anterior, middle or
posterior regions. The cell counting for Caspase-3 was not done separately for the
palatal epithelium or mesenchyme since there were so few positive cells. This
suggested that apoptosis was a relatively rare event in the rapidly growing shelves.
Though increased apoptosis may contribute toward the occurrence of cleft palate in
mice mutant for Fgf10 (Alappat et al., 2005; Rice et al., 2004), Shox2 (Yu et al.,
2005) or Alk5 (Dudas et al., 2006), it seemed unlikely that Tbx22 has a major role in
this process at E13.5. This may agree with the finding that apoptosis rate in Mn1
null mice at the equivalent stage was not affected either (Liu et al., 2008). However,
in this mouse model, apoptosis was increased in the palatal mesenchyme later at
E15.5. Therefore, it is still possible that the process might be affected in Tbx22 null
mice at different stages.
For cell proliferation analysis, the cells positive for phospho-Histone H3 were
counted separately in the palatal mesenchyme and epithelium since Tbx22 is known
to be expressed in the palatal mesenchyme but not in the epithelium (Braybrook et
al., 2002; Bush et al., 2002). In the palatal mesenchyme at E13.5, no reduction was
detected in the anterior region of the null palatal shelves compared to those of wt
while a statistically significant 53.9% reduction was found in the null palatal
shelves in the middle region (p=0.03). In the posterior region, the percentage of
positive cells was reduced by 42.7% on average in the null palatal shelves but this
was not statistically significant (p=0.20). Overall, the reduction in proliferation
coincided with the region normally expressing Tbx22. In the palatal epithelium at
the same stage, no significant difference was detected in the anterior, middle or
posterior regions between the wt and Tbx22 null palatal shelves. The results
therefore indicate that Tbx22 regulates cell proliferation in a cell autonomous
manner whereby the differential rate is only detected in the palatal mesenchyme but
not in the epithelium. In Mn1 null mice, cell proliferation is reduced in both middle
and posterior palatal mesenchyme and epithelium where Mn1 is expressed (Liu et
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al., 2008). These observations imply that cell proliferation in the palatal
mesenchyme may be regulated, at least in part, through the MN1-TBX22 pathway
but MN1 acts independent of TBX22 in the palatal epithelium in the regulation of
cell proliferation.
4.6.2 Cyclin D2 is reduced in the Tbx22 null palatal shelves
We next tested Cyclin D2 expression in the wt and Tbx22 null mice since
downregulation of the gene has been reported in Mn1-/- mice, which probably
explained the reduced cell proliferation in the null palatal shelves (Liu et al., 2008).
Regulation of cell proliferation through the level of cyclins has also been
demonstrated by other genes such as Gli2 during embryonic lung development
(Rutter et al., 2010). Cyclin D2 and other members of the cyclin family have
characteristic periodicity in abundance through the cell cycle. Cyclin D2 functions
as a regulator of cyclin-dependent kinases (CDK) 4 and 6 that are required for
progression through G1 to S phase. In the murine and human embryonic palatal
mesenchymal cells, the blockage of G1 to S phase by mycotoxin secalonic acid D
(SAD) leads to inhibition of cell proliferation (Hanumegowda et al., 2002;
Dhulipala et al., 2004). This outcome is explained by the reduced levels of CDKs
and cyclins D, E and A as well as an increased level of p21 in the palatal
mesenchymal cells in vitro and murine embryonic palates in vivo (Dhulipala et al.,
2005). These studies clearly demonstrate the importance of an appropriate level of
cell-cycle related proteins for normal cell proliferation during palatal growth. In the
Tbx22 null palatal shelves, decreased Cyclin D2 expression was observed compared
to the wt in the anterior to middle regions of the palatal shelves at E12.5 and E13.5.
However, Cyclin D2 expression only partially overlapped with that of Tbx22 in both
the E12.5 and E13.5 wt palatal shelves, which at these stages shifts from the middle
to more posterior regions as detected by whole mount in situ hybridisation.
Therefore it may be necessary to perform a more detailed study using sections to
better correlate the expression of Tbx22 and Cyclin D2 with the proliferation index
along the anterior to posterior axis within each region. Nevertheless, Tbx22 is likely
to play a role in the regulation of palatal mesenchymal cell proliferation, whether it
is through Cyclin D2 expression or not. On a similar note, the increased expression
of p21 in the Tbx22 null palatal shelves detected by real-time PCR may also explain
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the reduced cell proliferation as its main role is to inhibit the activity of cyclin-
CDK2 and 4 in the G1 phase. It is well known that the expression of p21 is tightly
controlled by the tumor suppressor protein P53 but can also be induced by factors
such as MyoD in a P53 independent manner during differentiation (Guo et al.,
1995). Currently, it still remains to be answered if the upregulation of p21 was
primarily caused by increased MyoD or by other factors.
4.6.3 Regulation of cell proliferation by Tbx22/TBX22
A recent study has shown that overexpression of human TBX22 resulted in
decreased cell proliferation in the frontonasal mass in chick leading to cleft beak
(Higashihori et al., 2010). In this case it is not clear if the human TBX22 is
equivalent to the chick TBX22, so it is not known whether it is acting by simple
overexpression or instead downregulating by competing out the endogenous protein.
If the former is the case, this implies a negative role of TBX22 in cell proliferation.
However, it is not known if the same mechanism operates later during development
of palate, which in any case differs between chick and mammals. It appears that the
chick study contradicts the results obtained in this study in terms of the direction of
cell proliferation rate controlled by TBX22. In the case of Tbx1, gene dosage is
known to be critical in the manifestation of cleft palate, as well as other pathogenic
phenotypes implicated in DiGeorge syndrome which is caused by
haploinsufficiency in humans. This is clearly illustrated by the occurrence of cleft
palate in both Tbx1-/- mice and transgenic mice overexpressing TBX1 (Liao et al.,
2004). Therefore either too little or too much expression of the gene caused the
same cleft phenotype, underscoring the importance of appropriate expression level
for normal palate development. This could also be the case for Tbx22 because a
complete lack of functional Tbx22 in mouse (Pauws et al., 2009a) and
overexpression of TBX22 in chick (Higashihori et al., 2010) both result in a cleft
phenotype in the form of overt or submucous cleft palate and cleft lip, respectively.
Indeed, a gene dosage probably is important for TBX22 as it is thought to be
capable of autoregulating its own promoter, suggesting a negative feedback loop to
fine tune the level of expression (Andreou et al., 2007). Still, direct comparison
between species in these experiments has to be tempered by the apparent
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differences in the facial structures between the two species (i.e. chick not only has a
beak but also has a natural cleft palate).
4.6.4 Expression pattern of BMP and FGF signalling components
Defective cell proliferation is a common cause of cleft palate in mice and there have
been many genetic factors implicated for normal palatal growth. These include
transcription factors such as Msx1, Osr2 and Shox2 as well as signalling molecules
and growth factors such as Shh, Tgfβs, Bmps and Fgfs (Gritli-Linde, 2007; Wilkie
and Morriss-Kay, 2001). In the scope of this project, it was intended to examine
some of the BMP and FGF signalling components in relation to the cell
proliferation defect observed in the Tbx22 null palatal shelves.
The importance of BMP signalling in lip and palate development has been implied
in human and mouse. In human, mutations in BMP4 have been associated with
subepithelial, microform and over cleft lip (Suzuki et al., 2009). Mutations in the
BMP target gene MSX1 are also associated with cleft lip and palate (Jezewski et al.,
2003; van den Boogaard et al., 2000). In line with this, Msx1 deletion in mice leads
to a cleft of the secondary palate (Satokata and Maas, 1994). Convincing evidence
regarding the role of BMP signalling is provided by several mouse studies. Bmp2,
Bmp3, Bmp4 and Bmp5 are all expressed in the palatal shelves prior to, during and
after fusion (Lu et al., 2000; Nie, 2005). Among these, expression of Bmp2, Bmp4
and Bmp5 are decreased when cleft palate is induced by retinoic acid, suggesting
that they are required during normal palatogenesis (Lu et al., 2000). Conditional
inactivation of the type 1 Bmp receptor Alk2 in neural crest cells, that contribute to
various craniofacial structures including palate, leads to multiple craniofacial
defects including cleft palate (Dudas et al., 2004). Similarly, conditional
inactivation of the type 1 Bmp receptor Bmpr1a (Alk3) in the facial primordia
results in reduced cell proliferation in the maxillary process and palatal cleft (Liu et
al., 2005). Though with some contradictory results, several studies have shown the
regulatory role of BMP signalling in facial mesenchymal cell proliferation. One
study reported that application of BMP2 soaked beads to the chick maxillary
primordia resulted in elevated proliferation (Barlow and Francis-West, 1997).
Another study found that implantation of BMP2 beads in chick frontonasal mass
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did not affect cell proliferation although Noggin (a BMP antagonist) treatment
resulted in reduced proliferation of the maxillary prominences and frontonasal mass
ultimately leading to the deletion of the maxillary and palatine bones (Ashique et al.,
2002). These studies clearly indicate the importance of BMP signalling for palatal
growth. Using whole mount in situ hybridisation, expression patterns of Bmp2,
Bmp3 and Bmp4 were determined. As described in the results, these genes were
expressed in specific domains along the anterior to posterior axis of the developing
shelves. However, little difference was determined between the wt and Tbx22 null
mice at E13.5. Recent studies indicate BMP signalling pathway in the regulation of
Tbx22 expression in stage and tissue specific manner in chick and mouse facial
mesenchyme (Fuchs et al., 2010; Higashihori et al., 2010). In palatal shelf explants
taken from chick (HH26) and mouse (E12.5), BMP4 repressed Tbx22 (Fuchs et al.,
2010). Given the findings of Fuchs et al. (2010) and Higashihori et al. (2010), it is
reasonable to assume that TBX22 is likely to be placed downstream of BMP
signalling but there may be no feedback from TBX22 to BMPs investigated in this
thesis.
Fgf signalling is another key factor during palatogenesis, and it has been reported
that up to 5% of non-syndromic cleft lip and palate in human could be caused by
mutations in FGF components including FGFR1, FGFR2 and FGF8 (Pauws and
Stanier, 2007; Riley et al., 2007). In the developing palate, Fgfr2b and Fgf10
mediate epithelial-mesenchymal signalling to regulate cellular functions such as cell
proliferation and cell survival. The importance of FGF signalling in palate
development is highlighted with Fgf10 and Fgfr2b null mice that develop cleft
palate (Rice et al., 2004; Alappat et al., 2005). In the Fgfr2b null mice, cell
proliferation was found to be decreased in both the palatal epithelium and in the
mesenchyme which probably explains the cleft phenotype. In contrast, cell
proliferation was not altered in Fgf10 null mice but apoptosis within the anterior
MEE was significantly increased, leading to cleft secondary palate. Interestingly,
recent findings indicated that a gain-of-function mutation in FGFR2 resembled loss
of FGF function in palatal mesenchymes (Snyder-Warwick et al., 2010). It was
shown that mesenchymal cell proliferation was increased at E13.5 but decreased
significantly by E14.5 leading to the cleft palate phenotype. Also, the 36Pub mice
which lacked Spry2, an antagonist of FGF signalling, showed increased cell
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proliferation at E14.5 which resulted in cleft palate phenotype (Welsh et al., 2007).
In this mouse model, Tbx22 expression was unchanged at E13.5 but reduced at the
posterior end of palatal sheves at E14.5. These findings indicate that both
augmentation and inhibition of FGF-FGFR signalling could result in the identical
cleft phenotype due to increased or decreased cell proliferation, suggesting that an
adequate dose is essential for normal palatogenesis. These studies imply the
importance of FGF signalling pathway for palatal growth, particularly in cell
proliferation. However, expression of Fgf10, Fgfr2 and Spry2 detected by whole
mount in situ hybridisation did not differ significantly between the wt and Tbx22
null mice at E13.5. Both studies by Fuchs et al. (2010) and Higashihori et al. (2010)
suggested that FGF signalling is necessary for the induction of Tbx22 expression in
early facial mesenchyme. However, Tbx22 expression became independent of FGF
signalling at later stages in palatal shelf explants taken from chick (HH26) and
mouse (E12.5) (Fuchs et al., 2010). These results suggest that in the palatal shelves,
FGF and TBX22 may operate independently and there is no feedback between these
two pathways. However, regulation of Tbx22 by FGF signalling in the developing
palatal shelves may be stage specific since its expression is altered in the 36Pub
mice which lacked Spry2 at E14.5 but not at E13.5 (Welsh et al., 2007).
Overall, one might speculate that in the null palatal shelves, muscle related genes
(expressed normally in the palatal mesenchyme) have increased as a consequence of
there being fewer osteoblastic cells. This is probably a more reasonable assumption
than Tbx22 having a direct effect on soft palate muscle development, especially as
no obvious muscle defects have been observed so far. There are few links between
myogenic and osteogenic markers. For instance, C2C12 cells normally follow
myogenic differentiation but BMP2 is capable of suppressing the expression of
MyoD and myogenin to induce osteoblastic differentiation (Katagiri et al., 1994).
This suggests that the level or balance between myogenic and osteogenic marker
expression can determine cell fate. Tbx22 is likely to be downstream of BMP and
FGF pathways. Thus, it could be that BMP or FGF signallings may be affected by a
lack of Tbx22 and the myogenic markers appeared altered as a consequence.
Interestingly, MyoD has recently been shown to be able to stimulate the Osterix
promoter in C3H/10T1/2 mesenchymal cells and C2C12 cells (Hewitt et al., 2008).
Osterix is one of the key factors for bone development as has been shown by lack of
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mineralisation in null mouse (Nakashima et al., 2002). This may seem
counterintuitive considering the general role of MyoD in myogenesis, but the
authors have shown that suppression of MyoD in C2C12 cells led to reduction of
Osterix expression and also prevented the expected rise in alkaline phosphatase
stimulated by BMP2. However, the level of Osterix expression was not altered by
the increased MyoD in the Tbx22 null palatal shelves. In fact, it would be surprising
if Osterix was increased in the null palatal shelves. These clearly indicate that
observations made by in vitro manipulations do not always reflect in vivo situations.
Nevertheless, the relationship between these factors and how they regulate each
other during palate development are areas of considerable interest. Alternatively, it
is also possible that the defective osteogenesis and altered myogenic genes are
entirely independent of each other.
4.6.5 The regulation and regulatory role of Tbx22
The regulation and regulatory role of Tbx22 based on previous studies and this
study are summarised in Figure 4.1. In early face, Tbx22 is regulated by FGF and
BMP signalling (Fuchs et al., 2010; Higashihori et al., 2010). Implantation of FGF2
and FGF8 soaked beads upregulated its expression while BMP4 and BMP7
downregulated the expression. Also, antagonists of FGF and BMP signalling
resulted in downregulation and upregulation of Tbx22, respectively. Msx2 and Dlx5
were suggested to be downstream of Tbx22 as their expression was repressed by
TBX22 overexpression (Higashihori et al., 2010). In the palatal shelf, Tbx22
expression was unaltered by FGF signalling but was repressed by addition of BMP4
soaked beads (Fuchs et al., 2010). A lack of Mn1 (Liu et al., 2008) or Spry2 (Welsh
et al., 2007) in mice resulted in downregulation of Tbx22 in the palatal shelves,
placing these genes upstream of Tbx22. This study has demonstrated a
downregulation of MyoD in the Tbx22 null palatal shelves and the functional assays
have shown that it can be regulated by TBX22 in vitro. In addition, Cyclin D2 was
reduced in the Tbx22 null palatal shelves. Cell proliferation assay performed in this
study suggested a role of TBX22 in proliferation in addition to the previously
reported role in differentiation and maturation of osteoblasts during palate
development.
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Figure 4.1 The regulation and role of Tbx22 in the early face and palatal shelf
In the early facial mesenchyme, Tbx22 can be upregulated by the addition of
exogenous FGF2 and FGF8, but downregulated by BMP4 and BMP7. In addition,
Msx2 and Dlx5 are reduced by overexpression of TBX22. In the palatal shelf, Mn1
and Spry2 are both upstream of Tbx22 whereas MyoD and Cyclin D2 are
downstream. Exogenous BMP4 is capable of downregulating Tbx22 in the shelf.
TBX22 is involved in cell proliferation, osteoblast differentiation and maturation.
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4.7 Characterisation of other craniofacial anomalies in
Tbx22 null mice
Tbx22 null mice show ankyloglossia and choanal atresia phenotypes in addition to
the submucous and overt cleft palate. These pathogenic phenotypes have been well
characterised at E15.5 but less is known at earlier stages. In this part of the project,
it was intended to investigate the morphology of relevant tissues by H&E staining,
and in particular the involvement of Fgf8 in choanae formation at E10.5 and E11.0
by whole mount in situ hybridisation.
4.7.1 Ankyloglossia
Under normal circumstances, a selective degeneration occurs at the tip of the tongue
by E13 due to cellular apoptosis and resorption process, leaving a frenulum as the
only attachment (Paulson et al., 1985; Morita et al., 2004). Although the exact
pathogenesis of ankyloglossia is not clear (Klockars, 2007), the failure of cellular
degeneration is suggested to lead to a much longer anchor between the anterior
tongue and the floor of the mouth (Morowati et al., 2010). The histological sections
of wt showed that the formation of frenulum was evident at E12.5. This freed the
anterior tip of the tongue from the floor of the mouth. In contrast, the frenulum was
not visible in Tbx22 null mice at the equivalent stage. In the null mice, it clearly
seemed that there were excess tissues at the anterior base of the tongue.
Interestingly, the difference between the wt and null mice seems more obvious at
earlier stages compared to E15.5 at which time the phenotype is considered to be
mild. In human, the frenulum recedes naturally in some ankyloglossia cases while
children grow (Ruffoli et al., 2005). This might as well be the case for mice. At this
time, it is not clear if the ankyloglossia phenotype in Tbx22 null mice results from a
lack of cell death, excess proliferation, a combination of both or other mechanisms.
A recent study has suggested a negative role of TBX22 in cell proliferation in early
facial mesenchyme (Higashihori et al., 2010). If this was the case at the anterior
base of the tongue, the lack of Tbx22 would increase proliferation. However, the
present study suggests that a lack of Tbx22 results in decreased cell proliferation at
least in the palatal shelves. In either way, this needs further testing in the relevant
tissue to understand molecular basis of the defect.
200
4.7.2 Choanal atresia
The choanae are the passageways at the back of the nose between the nasal cavity
and the pharynx that originates at the junction between the primordia of the primary
and secondary palates. In normal choanae development, epithelial cells of medial
and lateral nasal processes initially merge to form nasal fins at E10.5 (Tamarin,
1982; Diewert and Wang, 1992). By late E11, the fins undergo cleavage which
results in the formation of oronasal membranes, and they begin to involute with the
formation of interstitial gaps that enlarge and eventually rupture so that complete
opening between nasal and oral cavities is achieved by E13. Apoptosis plays an
important role in degeneration of nasal fins anteriorly upon lip fusion (Jiang et al.,
2006), but the exact molecular mechanism for choanae formation is not known. The
H&E staining of the wt showed that the posterior nasal fins underwent cleavage
process by E11.5 but the oronasal membranes were still existed in the choanae. By
E12.5, the choanae were open, indicating that the oronasal membranes in the wt
rupture between E11.5 and E12.5. This is consistent with the previous findings. In
contrast, the nasal fins persisted in many of the null mice at E11.5 and the oronasal
membranes were evident at E12.5 (if not ruptured by this stage, are likely to persist
into later embryonic stages).
Apart from Tbx22 null mice, choanal atresia is also seen in the mutant mouse
models of Chd7 (Bosman et al., 2005) and Raldh3 (Dupe et al., 2003). Chd7 mutant
mice closely resemble human CHARGE syndrome which is predominantly caused
by mutations in CHD7 (Vissers et al., 2004). The mutant mice develop a range of
defects such as eye and genital abnormalities and cardiac defects as well as cleft
palate and choanal atresia. To the latter point, oronasal membranes in some mutant
mice persist which could explain the postnatal lethality. However, to date, the cause
of choanal atresia in Chd7 mutant mice has not been defined. Raldh3 knockout in
mice impairs retinoic acid synthesis during nasal development, leading to choanal
atresia. In this case, the phenotype is believed to result from persistence of Fgf8
expression in the mutant nasal fins at E11.0. FGF signalling is considered essential
in the midfacial development and a range of Fgfs including Fgf8 and their receptors
are expressed in spatially restricted manners in the early facial prominences
(Bachler and Neubuser, 2001). In this study, whole mount in situ hybridisation
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indicated similar Fgf8 expression in the wt and Tbx22 null mice in the epithelial
layers of the medial and lateral nasal processes around the nasal pits as well as in
the nascent fins at E10.5. At E11.0, Fgf8 was not detected in the nasal fins
anteriorly in both the wt and Tbx22 null mice, whereas the expression was evident
at the posterior end of the nasal fins. However, this was similar between the wt and
null mice suggesting that Fgf8 is not altered in Tbx22 null mice during choanae
development. Recent findings indicate that FGF signalling regulates Tbx22
expression in early facial mesenchyme (Fuchs et al., 2010; Higashihori et al., 2010),
but the results presented here suggest no negative feedback loop in the nasal regions.
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4.8 Future studies
As a consequence of this project, there are a number of interesting lines of
investigation that may be followed up. It is hoped that these will continue in the lab
to provide a better understanding of the role of TBX22 in craniofacial development.
4.8.1 Verification of microarray data
The expression microarray experiments provided a list of differentially expressed
genes in the absence of Tbx22 in the palatal shelves. In the scope of this project,
only selected upregulated genes were further investigated and downregulated genes
were not followed up. However, there were few interesting genes including Gabrb2,
Gabra1, Gria4, Adh1 and Pax3. Microarray is a useful tool to obtain a global view
of differentially expressed genes but it can easily contain false positives. These
genes in particular will first need verification by another method such as real-time
PCR. Although they may not be directly regulated by TBX22, it would be of
considerable interest if their differential expressions are confirmed because of the
potential implication in the occurrence of cleft palate.
Importantly, Tbx22 positive cells around the nasal septum and at the base of the
tongue were not included in the microarray experiments and expression profiles
from these tissues would be somewhat different from the data obtained from E13.5
palatal shelves. Thus, it would also be interesting to examine gene expression
profiles of these tissues.
4.8.2 Further testing of the effect of Tbx22 overexpression
Functional analysis including luciferase reporter assays and chromatin
immunoprecipitation indicated the regulation of MyoD by TBX22 in HEK 293T
cells. However, the overexpression study has failed to show the effect of TBX22 on
the level of endogenous MyoD expression in C2C12 cells. This could be due to the
difference in cellular contexts, and will be investigated further. Though it is known
to be difficult to achieve high transfection efficiency in murine or human embryonic
palatal mesenchymal cells, it would be interesting to look for endogenous MyoD
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expression because these cells are more likely to accurately reflect the in vivo
situation.
4.8.3 Determining the origin of differentially expressed muscle genes
The study indicated the global upregulation of muscle related genes in the Tbx22
null palatal shelves. However, where the differences come from in the palatal
shelves is not clear. This needs more examination at both mRNA and protein levels.
It is not known which cells are specifically affected by the lack of Tbx22 because of
the heterogeneous nature of palatal mesenchyme. One way in which this issue could
be resolved would be to perform double labelling experiments on palatal
mesenchymal cells using antibodies specific for TBX22 as well as a marker for
CNC-derived cells or mesoderm derived cells. Another useful experiment would be
to cross the floxed Tbx22 mice to Wnt1-Cre/R26R (Chai et al., 2000) or Mesp1-
Cre/R26R (Yoshida et al., 2008) in order to indelibly mark the progeny of the CNC
or mesoderm, respectively, during embryogenesis. This will allow a specific
knockdown of Tbx22 in CNC-derived or paraxial mesoderm derived cell lineages,
and would clarify specific phenotypic effects that Tbx22 has on each cell type.
4.8.4 Further investingation of the ankyloglossia and choanal atresia
phenotypes
In this project, there was insufficient time to adequately analyse the ankyloglossia
and choanal atresia phenotypes in Tbx22 null mice. Firstly, a more comprehensive
histological analysis from E10.5 to E12.5 is required to better understand the
relevant morphology during early tongue and choanae development. At a
developmental level, there is still very little known about the precise origins and
occurrence of these features. Apoptosis and/or cell proliferation may be of
particular interest because persistence of the oronasal membrane and having excess
tissue at the base of the tongue could well be caused by a failure in one or a
combination of these mechanisms.
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Appendix Figure 1.1 Affymetrix quality control analysis
Boxplots are used to identify any outliers (A). All the boxes looked similar
indicating all the samples used had the same median and similar intensity range.
The density plot shows any differences in the distributions of the density of the
probe intensities (B). Here, all intensity distributions representing each array (or
sample) overlap well.
MvA plots allow a graphical view to see fold changes and fluorescence intensity,
and are used to check the reproducibility of biological replicates (C). The x-axis is
the average intensity of each probeset and the y-axis is the log2 fold change
between the intensity value of each probeset. The graphs indicate good agreement
between biological replicates.
Control probesets are used to identify problems with hybridisation and/or chip
(Bac) and target preparation (PolyA+). Both Bac (D) and PolyA+ (E) probesets
displayed the expected rank order of log2 intensity values for the six arrays. Also,
signal value comparison between positive and negative controls as indicated by
AUC (values between 0.8 and 0.9 are considered typical) showed good separation
between positive and negative controls (F).
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HEK 293T Well
Firefly
luciferase
Renilla
luciferase Firefly/Renilla
pGL3 A01 726 3036 0.24
pGL3-MyoD A02 10972 2452 4.47
pGL3-MyoD/pcDNA3.1(-) 2.5 ng A03 16036 3466 4.63
pGL3-MyoD/pcDNA3.1 (-) 10 ng A04 15640 2938 5.32
pGL3-MyoD/wtTBX22 2.5 ng A05 18822 5504 3.42
pGL3-MyoD/wtTBX22 10 ng A06 10648 4564 2.33
pGL3-MyoD/GFP 2.5 ng A07 15500 3146 4.93
pGL3-MyoD/GFP 10 ng A08 7682 1588 4.84
pGL3 B01 466 2364 0.20
pGL3-MyoD B02 9740 2396 4.07
pGL3-MyoD/pcDNA3.1(-) 2.5 ng B03 9354 2382 3.93
pGL3-MyoD/pcDNA3.1 (-) 10 ng B04 9660 2030 4.76
pGL3-MyoD/wtTBX22 2.5 ng B05 10298 3916 2.63
pGL3-MyoD/wtTBX22 10 ng B06 5564 2574 2.16
pGL3-MyoD/GFP 2.5 ng B07 12308 2844 4.33
pGL3-MyoD/GFP 10 ng B08 8512 1662 5.12
pGL3 C01 528 2544 0.21
pGL3-MyoD C02 8122 2040 3.98
pGL3-MyoD/pcDNA3.1(-) 2.5 ng C03 11486 2628 4.37
pGL3-MyoD/pcDNA3.1 (-) 10 ng C04 11864 2326 5.10
pGL3-MyoD/wtTBX22 2.5 ng C05 14650 3688 3.97
pGL3-MyoD/wtTBX22 10 ng C06 5956 2858 2.08
pGL3-MyoD/GFP 2.5 ng C07 9248 2352 3.93
pGL3-MyoD/GFP 10 ng C08 7020 1488 4.72
pGL3 D01 538 2882 0.19
pGL3-MyoD D02 6494 1414 4.59
pGL3-MyoD/pcDNA3.1(-) 2.5 ng D03 7710 2076 3.71
pGL3-MyoD/pcDNA3.1 (-) 10 ng D04 6176 1364 4.53
pGL3-MyoD/wtTBX22 2.5 ng D05 10740 3382 3.18
pGL3-MyoD/wtTBX22 10 ng D06 7540 2992 2.52
pGL3-MyoD/GFP 2.5 ng D07 10070 2248 4.48
pGL3-MyoD/GFP 10 ng D08 6646 1354 4.91
Appendix Table 1.2 Sample luciferase reporter assay (raw data)
The luciferase/Renilla ratio was calculated from the Firefly and Renilla luciferase
raw values.
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